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ABSTRACT 
 
 
In multicellular organisms, cells ensure the simultaneous availability of growth factors and 
nutrients before they invest in cellular processes that lead to growth. The TOR kinase is a master 
regulator of cellular growth and nucleates two distinct protein complexes known as TOR 
complex 1 and 2 (TORC1 and 2). The activity of TORC2 is mainly regulated by growth factors, 
whereas TORC1 activity is responsive to both growth factors and nutrients, and thus acts as a 
detector of favorable growth conditions. The consequence of TORC1 activation is increased 
protein translation through its substrates S6K and 4E-BP1. Many of the upstream signals that 
lead to activation of TOR pathway are tumor suppressors and deregulation of the pathway leads 
to disease. We aim to better understand the regulation of mammalian TORC1 (mTORC1) by 
upstream signals. In the work described here, we identified PRAS40 as a new component of 
mTORC1. PRAS40 is phosphorylated in response to growth factors and this phosphorylation 
event leads to mTORC1 activation. We also showed that the small GTPase Rheb, a major 
upstream activator of mTORC1, activates it by directly interacting with mTORC1. Both PRAS40 
and Rheb relay information from growth factors to mTORC1, and do not seem to be regulated by 
nutrients, particularly amino acids. In this work, we also investigated how amino acids lead to 
mTORC1 activation. We showed that amino acids activate mTORC1 by recruiting the complex 
to lysosomal surface through the action of evolutionarily conserved Rag GTPases. We also 
indentified a complex of three proteins (p14, p18 and MP1), that we call the “Ragulator” 
complex, as Rag GTPase interacting proteins. The Ragulator itself localizes to lysosomes 
through lipid modifications on p18, and tethers the Rag GTPases on the lysosomal surface. We 
speculate that amino acid-induced lysosomal localization of mTORC1 enables its encounter with 
Rheb. Through this work, we propose a model for growth factor and amino acid-induced 
mTORC1 activation. 
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Overview of TOR Signaling Pathway 
Proliferation (increase in cell number) and growth (increase in cell mass) are usually 
tightly coupled, yet independent processes. Often, a cell doubles its mass before it divides so as 
to maintain a certain size, and inhibition of cellular growth stops the cell cycle. However, growth 
can take place without cell division, as happens in nerve cells that exit the cell cycle but continue 
to grow. Similarly, cells can divide without growing, as happens in the first few divisions of the 
fertilized embryo. The identification of signaling pathways that promote cellular growth 
independently of proliferation, and the elucidation of the important roles these pathways play in 
homeostasis and disease have stimulated research on size control. 
Over the years, the evolutionarily conserved TOR (Target of Rapamycin) kinase has 
emerged as a central regulator of cellular and organismal growth whose activity is sensitive to 
both cell autonomous and extrinsic factors. Although loss of TOR function is lethal in all 
organisms studied so far, reduced TOR signaling results in reduced cell size and hyper-activation 
of the kinase promotes cellular growth, establishing the necessity and sufficiency of the kinase 
for growth (reviewed in (Fingar and Blenis, 2004)). 
TOR participates in two mutually exclusive protein complexes known as TOR Complex 
(TORC) 1 and 2. Mammalian TORC1 (mTORC1) integrates information on the availability of 
growth factors and nutrients (amino acids and glucose), energy status and cellular stress and 
regulates mRNA translation and energy homeostasis through its downstream targets. S6K 
(ribosomal protein S6 kinase) and 4E-BP1 (eukaryotic translation initiation factor 4E binding 
protein 1) are the best characterized mTORC1 targets due to historical reasons, although more 
mTORC1 targets are being identified. mTORC2 is sensitive to growth factors only, and increases 
nutrient uptake and suppresses apoptosis by the phosphorylation and activation of its major 
substrate Akt. Thus, the two TOR-containing protein complexes work together to ensure that 
cells grow only when growth is needed and when conditions are favorable in multicellular 
organisms. In unicellular organisms like yeast, although growth factors are not present, the 
function of the TOR kinase as a sensor of favorable growth conditions is conserved, and changes 
in TOR activity manifests itself as changes in cell smass similar to multicellular organisms.  
Given that cellular growth is often a prerequisite for cell division, it is not surprising that 
accelerated growth is a hallmark of tumorigenesis. Rapidly dividing cancer cells also have to 
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rapidly increase their size before they divide, otherwise each daughter cell will be smaller than 
the mother cell, leading to a reduction in cell size in every generation and eventual death. 
Consistent with this, many proteins upstream of the TOR kinase are tumor suppressors and 
proto-oncogenes whose mutations contribute to cancer (Table 1). Consequently, mTOR has been 
a therapeutic target for the treatment of various cancers with some success in clinical trials, and 
the TORC1 inhibitor rapamycin has been approved for the treatment of renal cell carcinoma 
(reviewed in (Lane and Breuleux, 2009)). New and more effective mTOR-targeting strategies in 
cancer are underway.  
Although the role of mTOR in regulation of body size, whole body metabolism, and 
cancer are increasingly appreciated, a signaling-centric view of the TOR pathway, especially that 
of mTORC1, will be summarized here due to its relevance to the work presented.  
 
Rapamycin and the Identification of TOR 
 Rapamycin is a macrolide produced by Streptomyces hygroscopicus that was isolated 
from a soil sample obtained from Rapa Nui (Easter Island) (reviewed in (Abraham and 
Wiederrecht, 1996)). Rapamycin was first identified during an antibiotic screen, and was found 
to be a very potent suppressor of fungal growth (Sehgal et al., 1975). Later studies showed that 
the growth suppressive effects of rapamycin on yeast could also be observed in mammalian cells: 
rapamycin showed anti-tumor activity towards some cancers in animal models (reviewed in 
(Abraham and Eng, 2008)), and showed potent immunosuppressive properties (Mita et al., 2003; 
Morris et al., 1991). In 1999, the drug was approved for use as an immunosuppresant in kidney 
transplant patients, and is in clinical trials for use in different autoimmune diseases. Its anti-
growth properties are also exploited for the prevention of restenosis (narrowing of blood vessel) 
after coronary artery interventions with stent implantation (reviewed in (Abraham, 2002)).   
The cellular receptor of rapamycin is FK506 binding protein 12 (FKBP12), a peptidyl-
prolyl isomerase (Koltin et al., 1991). Binding of rapamycin to FKBP12 eliminates its isomerase 
activity, however, deletion of FKBP12 in yeast shows no growth defects similar to rapamycin 
treatment, but instead confers rapamycin resistance, showing that FKBP12 is not the relevant 
cellular rapamycin target (Heitman et al., 1991). Upon entry into the cell, rapamycin binds to 
FKBP12, and this FKBP12-rapamycin complex inhibits growth via a gain of function 
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mechanism. The target of this complex, TOR, was found in yeast genetically by the 
identification of rapamycin-resistant mutants, and in mammalian cells biochemically by finding 
the binding partner of FKBP12-rapamycin, and was named FRAP or RAFT1 (FKBP12-
rapamycin associated protein or rapamycin and FKBP12 target) (Brown et al., 1994; Sabatini et 
al., 1994), but usually is referred to as mammalian TOR (mTOR). 
 TOR is a member of  the phosphoinositide three kinase-related kinase (PIKK) family that 
also includes ATM, ATR, DNA-PK, TRRAP and SMG-1 kinases. All of these kinases share a 
common domain structure with a characteristic C-terminal phosphoinositide three kinase (PI3K)-
like catalytic domain (reviewed in (Lovejoy and Cortez, 2009)). Despite the homology of its 
kinase domain with PI3K, a lipid kinase, TOR is a serine/threonine kinase like other PIKK 
family members. The kinase domain is sequestered between FAT (FRAP, ATM and TRRAP) 
domain at the N-terminus and the FATC (FAT C-terminus) domain at the C-terminus. The 
precise functions of these domains are unknown. Between the FAT domain and the kinase 
domain lies the FRB (FKBP-rapamycin binding) domain, and, as the name implies, it is the 
binding site for FKBP-rapamycin complex. Mutations in this region prevent binding of FKBP-
rapamycin to TOR and confer rapamycin resistance in yeast (Heitman et al., 1991). The N-
terminal half of the protein is composed of HEAT (Huntington, Elongation factor 3, A subunit of 
protein phosphatase 2A, TOR) domains, and is involved in protein-protein interactions (Figure 
1).  
  TOR substrates do not share sequence homology at the site of phosphorylation, making 
it difficult to define a consensus target motif for TOR. TOR phosphorylates both a Ser/Thr-Pro 
motif and Ser/Thr surrounded by hydrophobic amino acids (hydrophobic motif) (Figure 2). It is 
possible that once TOR encounters a substrate, it shows little sequence specificity towards the 
phosphorylation site, or there are unidentified elements in the substrates that determine the site of 
phosphorylation.   
Over the last few years, the TOR signaling pathway has become increasingly complex with 
the identification of new interacting proteins, new upstream regulators and new post-translational 
events that modify the activity of the complexes (Figure 3). This is certainly a consequence of a 
great interest in understanding how TOR is regulated and how knowledge about the kinase can 
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be exploited in medicine. Conservation of the kinase and its basic functions throughout evolution 
facilitated these efforts by combining the strengths of different model organism.  
 
 
TOR Participates in Two Different Complexes: TORC1 and TORC2 
 Raptor (regulatory associated protein of mTOR) was purified from mammalian cells as 
the first mTOR interacting protein and has been the defining member of mTORC1 (Hara et al., 
2002; Kim et al., 2002). Raptor is a 150kDa protein with many domains whose functions remain 
elusive. The N-terminal RNC (raptor N-terminal conserved) domain is followed by three heat 
repeats and seven WD40 repeats at its C-terminus. The RNC domain shows no sequence 
similarity to known proteins, however is conserved in raptor across species, suggesting that it has 
an important yet unidentified function (Kim et al., 2002).  
Soon after identification of raptor in mammalian cells, its yeast homolog KOG1 
(kontroller of growth 1), was also shown to be a TOR interacting protein. Deletion of raptor is 
lethal both in mammals and yeast (Guertin et al., 2006b; Loewith et al., 2002); however, a 
reduction of raptor protein levels by RNAi-mediated knockdown in cultured mammalian cells 
reduces cellular size and decreases phosphorylation of TORC1 substrates. In addition, rapamycin 
treatment of cells disrupts the mTOR-raptor interaction, showing the crucial role of this 
interaction in mTORC1 function (Kim et al., 2002).  
Although raptor was thought to be a structural component of mTORC1 for a long time, 
recent studies point to a more active role of raptor in mTORC1 regulation. Raptor is involved in 
substrate binding through the TOS (TOR signaling) motif found in mTORC1 substrates. In 
addition, phosphorylation of raptor by upstream signals modulates the activity of the complex. 
And finally, raptor is required for the proper cellular localization of mTORC1 in response to 
certain upstream signals, as will be discussed in more detail in the following chapters.  
Other than raptor, PRAS40 (proline rich Akt substrate of 40 kDa) is the only mTORC1-
specific protein. It interacts with the raptor component of the complex through its TOS motif 
similar to mTORC1 substrates. The PRAS40-mTORC1 interaction is regulated by growth factors 
and is weakened by PRAS40 phosphorylation (Fonseca et al., 2007; Oshiro et al., 2007; Sancak 
et al., 2007; Vander Haar et al., 2007; Wang et al., 2007). More specifically, Akt phosphorylates 
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PRAS40 in response to growth factor stimulation at Thr 246, as a result of which the PRAS40-
raptor interaction is weakened, and mTORC1 is activated (Sancak et al., 2007). Thus, PRAS40 is 
an inhibitor of mTORC1 when not phosphorylated and mutation of this residue to alanine 
prevents insulin-induced mTORC1 activation. It was proposed that PRAS40 inhibits mTORC1 
by preventing its interaction with substrates (Wang et al., 2007). However, PRAS40 inhibits 
mTORC1 kinase activity in vitro even when substrate are in excess, and this inhibition can be 
opposed by addition of Rheb GTPase, a potent activator of mTORC1, to the kinase reaction 
(Sancak et al., 2007). PRAS40 is also phosphorylated at Ser183 by active mTORC1, but the 
functional consequence of this phosphorylation is not clear (Oshiro et al., 2007). In addition, 
amino acids do not increase phosphorylation of PRAS40 at Thr 246, but activate mTORC1 
potently (Sancak Y, unpublished results). Whether there are other phosphorylation sites on 
PRAS40 that are important for mTORC1 activation in response to amino acids or amino acids 
circumvent PRAS40 inhibition by another mechanism is not known.  
Yeast protein AVO3 and its mammalian homolog Rictor (rapamycin insensitive 
companion of TOR) are also mTOR-interacting proteins and are the defining members of 
mTORC2 (Loewith et al., 2002; Sarbassov et al., 2004). Like raptor, rictor is conserved 
throughout eukaryotes and is an essential gene in mammals and yeast, but not in Drosophila 
(Guertin et al., 2006b; Hietakangas and Cohen, 2007; Loewith et al., 2002). Unlike the raptor-
mTOR interaction, the rictor-mTOR interaction is not affected by rapamycin and rictor 
knockdown by RNAi does not affect cell size in cultured mammalian cells and mTORC1 
substrate phosphorylation. Rictor is never found to be associated with raptor, but interacts with 
two other mTORC2-specific proteins Sin1 and PPR5 (Frias et al., 2006; Jacinto et al., 2006; 
Woo et al., 2007; Yang et al., 2006). Sin1 is conserved in yeast and is proposed to be involved in 
maintaining mTORC2 integrity. It also has at least three isoforms that define three distinct 
flavors of mTORC2, but it is not clear whether these three complexes are different in any other 
way (Frias et al., 2006). Loss of either Sin1 or PPR5 prevents phosphorylation of mTORC2 
substrate Akt, showing their necessity for proper mTORC2 function.  
mTORC2 is also known as the rapamycin-insensitive complex, and it is true that short- 
term rapamycin treatment (1 hours or less) does not affect mTORC2 subtstrate Akt 
phosphorylation. However, in some cell lines, prolonged rapamycin treatment (24 hours or 
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more), in addition to inhibiting mTORC1, also eliminates Akt phosphorylation by preventing the 
assembly of TORC2 (Sarbassov et al., 2006). In other cell lines, however, long rapamycin 
treatment activates mTORC2 rather than inhibiting it, due to elimination of an inhibitory input 
from mTORC1 to PI3K signaling that is explained below in more detail. The rapamycin 
sensitivity of mTORC2 in certain cell lines does not correlate with tissue of origin or mutation(s) 
that the cell lines carry, and the molecular mechanism of this sensitivity remains elusive.  
A series of elegant experiments by Ali et al.(Ali and Sabatini, 2005) revealed that while 
the TOS motif is necessary for the phosphorylation of S6K1 by mTORC1, the presence of a long 
carboxyl terminal domain prevents its phosphorylation by mTORC2. Surprisingly, the structures 
of S6K1 and Akt are similar, except that Akt lacks the long carboxyl terminal region S6K1 has, 
and deletion of this domain permits phosphorylation of S6K1by mTORC2. This observation 
suggested that other kinases that are in the same family as S6K and Akt (AGC kinases) can also 
be mTORC1 and mTORC2 substrates, based on the presence of a long carboxyl region and the 
TOS motif (Figure 4). Confirming this observation, two other AGC kinase family members 
SGK1 and PKCα were shown to be mTORC2 substrates (Garcia-Martinez and Alessi, 2008; 
Guertin et al., 2006b; Sarbassov et al., 2004). What other structural or non-structural elements 
define the criteria of being an mTOR substrate remains elusive.  
 LST8 (lethal with sect thirteen protein 8) and DEPTOR (DEP domain containing 6 TOR) 
participate in both of the complexes and their functions are somewhat mysterious. LST8 is an 
evolutionarily conserved essential gene and interacts with the kinase domain of TOR (Kim et al., 
2003; Loewith et al., 2002). mTOR signaling in mLST8 knockout cells is interesting since 
mTORC1 seems to be unaffected in these cells, in contrast to inhibition of the mTORC1 pathway 
after mLST8 knockdown  in cultured mammalian cells (Guertin et al., 2006a; Kim et al., 2003). 
mTORC2 integrity and consequently activity is disrupted in mLST8-null cells. Whether another 
protein compensates for the absence of mLST8 in mLST8-null cells to restore mTORC1 activity 
remains to be seen. It is also possible that mLST8 is necessary for phosphorylation of yet 
unidentified mTORC1 substrates.  
 DEPTOR is a metazoan-specific component of mTORC1 and 2. It binds to the FAT 
domain of mTOR and inhibits the kinase activity of both complexes in vivo and in vitro 
(Peterson et al., 2009). However, the relationship of DEPTOR with the two complexes is not 
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simple. Both mTORC1 and mTORC2 down regulate DEPTOR expression at the RNA and 
protein level. In addition, DEPTOR is phosphorylated by mTOR at multiple sites, and these 
phosphorylations seem to reduce the inhibitory effect of DEPTOR on mTOR activity. Although 
counter intuitive, overexpression of DEPTOR can hyper-activate mTORC2, when DEPTOR 
overexpression induced mTORC1 suppression leads to hypersensitivity of cells to growth 
factors. Interestingly, DEPTOR overexpression is necessary for Akt activation and survival of a 
subset of multiple myeloma cells, pointing to a potentially therapeutic benefit of targeting 
DEPTOR in cancer.  
 We do not know what determines the relative amount of mTORC1 or mTORC2 found in 
a cell or a tissue at a given time, whether it is regulated and whether such a regulation will have 
functional consequences. However, it is true that relative abundance of the two complexes differs 
from cell line to cell line. In addition to the abundance, the activities of the complexes seem to 
vary in different cells, and each complex regulates the activity of the other. Activated mTORC1 
down regulates IRS (insulin receptor substrate) and blunts the response of the cell to growth 
factors, which leads to decreased mTORC2 signaling. mTORC2 on the other hand activates 
mTORC1 through inhibition of its negative regulators TSC2 and PRAS40 by Akt. The 
complexes also regulate each other through DEPTOR as explained before. In conclusion, 
although physically separate, the two complexes participate in a convoluted regulatory 
mechanism, which may involve more players than discovered so far. 
 
Signaling Downstream of mTORC2 
The best-characterized downstream target of mTORC2 is Akt (Sarbassov et al., 2005). 
Akt is a member of the AGC kinase family with three isoforms in mammals (Akt1, 2 and 3), and 
affects a variety of processes in the cell, including survival, proliferation, growth and metabolism 
(reviewed in (Manning and Cantley, 2007)). mTORC2 phosphorylates both the hydrophobic 
motif (S473) and the turn motif of Akt (T450). Hydrophobic motif phosphorylation is important 
for full activation of Akt, whereas turn motif phosphorylation is suggested to affect the stability 
of the protein (Facchinetti et al., 2008; Guertin et al., 2006b; Ikenoue et al., 2008). Surprisingly, 
although loss of rictor and mLST8 abolish S473 phosphorylation, Akt can still phosphorylate 
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some of its substrates, suggesting that S473 phosphorylation is required for some Akt-regulated 
processes in the cell and not others (Guertin et al., 2006b).  
Other mTORC2 subtsrates PKCα and SGK1 are phosphorylated at their hydrophobic 
motif by mTORC2 similar to Akt (Garcia-Martinez and Alessi, 2008; Guertin et al., 2006b). 
Phosphorylation of the SGK1 turn motif by mTORC2 has not been shown, but PKCα turn motif 
phosphorylation and protein stability is affected in cells that lack mTORC2 function. Although 
transient knockdown of rictor in mammalian cells affects the cytoskeleton through PKCα 
(Sarbassov et al., 2004), rictor- and mLST8-null cells do not show a defect in maintenance of 
cytoskeleton (Guertin et al., 2006b). The reason for this discrepancy is not clear.  
 
Signaling Upstream of mTORC2 
 It is well appreciated that growth factor signaling activates mTORC2. However the 
mechanism of this activation is not known. The fact that the in vitro kinase activity of mTORC2 
is sensitive to serum starvation and stimulation suggests that post-translational modification(s) of 
complex proteins preserved during mTORC2 immunopurifications for kinase assays plays a role. 
However, there are only few of such modifications of mTORC2 proteins reported so far, and 
although they seem to contribute to the activity of the complex, it is clear that there are other 
unidentified events that must be important for activation of mTORC2 by growth factors.  
 As mentioned before, due to blunting of IRS-mediated signaling by over-activated S6K1, 
mTORC2 is negatively regulated by mTORC1. Recently, the TSC1/2 complex, whose inhibitory 
role as a GAP (GTPase activating protein) is well appreciated in mTORC1 signaling, was shown 
to regulate mTORC2 activity independently of mTORC1 (Huang and Manning, 2008). TSC1/2 
physically interacts with mTORC2 and promotes its activity in response to insulin. The fact that 
a TSC2 mutant that lacks GAP activity can also stimulate mTORC2 suggests a structural role for 
the TSC1/2 complex in mTORC2 activation. 
 The only known phosphorylation that contributes to regulation of mTORC2 so far is 
rictor phosphorylation by S6K1 in response to insulin (Dibble et al., 2009; Julien et al., 2009; 
Treins et al., 2009). Interestingly, this phosphorylation blunts mTORC2 activity towards Akt, but 
not towards other known mTORC2 substrates, SGK1 and PKCα. It is tempting to speculate that 
through mTORC2’s ability to differentially regulate its substrates, mTORC1-mediated amino 
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acid and nutrient signaling can impinge on certain mTORC2 substrates to better coordinate the 
nutrient response of the cell.  
 
Signaling Downstream of mTORC1 
 
Regulation of Translation by mTORC1 
Early studies on the mechanism of growth inhibition and immunosuppression by 
rapamycin focused on the effects of rapamycin on translation after the finding that rapamycin 
inhibits phosphorylation of ribosomal protein S6 in response to growth factors (Gressner and 
Wool, 1974; Price et al., 1989). Rapamycin treatment of cells leads to growth arrest, probably 
due to a global decrease in protein synthesis as a consequence of inhibition of translation 
initiation as well as inhibition of ribosome biogenesis (decreased transcription of ribosomal 
RNA, ribosomal proteins and tRNA genes) (Mahajan, 1994; Wullschleger et al., 2006). How 
mTORC1 inhibition leads to a reduction in ribosome biogenesis is not clear, but regulation of 
translation by mTORC1 is believed to be mediated by the two best-characterized mTORC1 
substrates S6K1 and 4E-BP1. Both of these substrates are phosphorylated by mTORC1 in vitro 
and in vivo in a rapamycin sensitive manner (Beretta et al., 1998; Burnett et al., 1998; Price et al., 
1989; Price et al., 1992) and they remain the substrates of choice for monitoring mTORC1 
activity.  
Remaining S6 phosphorylation in S6K1-null cells led to the identification of a second S6 
kinase, S6K2 (Pende et al., 2004). S6K2 is also phosphorylated by mTORC1; however, the 
functional consequences of this phosphorylation are not well characterized. Because S6K1 and 
4E-BP1 are the most studied substrates of mTORC1, it is worth describing the contribution of 
these substrates to mTOR-related cellular processes, especially translation, in detail. Other TOR-
regulated cellular processes will be described separately.  
 
S6 Kinase  
The translation of ribosomal proteins and elongation factors is repressed upon growth 
factor withdrawal and rapamycin treatment (Terada et al., 1994). One common feature of the 
mRNAs for these proteins is the presence of a 5’ terminal oligopyrimidine tract (5’ TOP) at the 
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5’ UTR of their transcripts, which is required for the proper regulation of their translation in 
response to growth factors (Levy et al., 1991).  Approximately 20% of total cellular mRNAs 
have 5’ TOPs and most of these encode for ribosomal proteins and other components of the 
translational machinery. Given the correlation between a decrease in S6K and S6 
phosphorylation and decreased 5’ TOP containing mRNA translation in response to rapamycin 
treatment, it was believed for a long time that the former regulates the latter.  
Engineering and analysis of mice that lack both S6K genes (S6K1-/-, S6K2 -/-) and mice 
with mutant S6 that cannot be phosphorylated by S6K (S6 knock-in) were instrumental for 
testing some of these assumptions, and gave unexpected results. First of all, neither S6K1 and 2 
nor S6 is required for 5’TOP containing RNA translation and ribosome biogenesis, since both 
processes are regulated equally well in wild type and mutant mice. How rapamycin treatment 
inhibits these processes still remains unknown. Comparison of S6K1-/- and S6K2-/- mice also 
shows that although these two proteins may have overlapping functions, they are not functionally 
redundant. S6K1 contributes to the regulation of cell size more than S6K2, since loss of S6K1 
results in smaller cells. On the other hand, S6 knock-in mice also have significantly smaller cells 
than wild type controls, and these cells do not reduce their size further in response to rapamycin 
treatment, suggesting that S6 is the critical downstream effector of mTOR for cell size 
regulation. In addition, S6 knock-in mice unexpectedly show increased global translation rate, 
due to enhanced translation initiation (Pende et al., 2004; Ruvinsky et al., 2009), and not 
decreased translation rate, as speculated. What other downstream effectors of mTOR are 
important for regulation of rapamycin-sensitive 5’TOP mRNA translation, and if not through 
ribosome biogenesis, how does S6K and S6 regulate cell size? The answers of these questions 
still remain elusive, but it is likely that other mTORC1 and S6K substrates will be involved. For 
example, S6K1 was shown to increase the rate of translation initiation by phosphorylating eIF4B 
(eukaryotic translation initiation factor 4B), and enabling its association with the pre-initiation 
complex (Holz et al., 2005). S6K also affects the elongation step of translation through 
phosphorylation and inhibition eEF2K (eukaryotic elongation factor 2 kinase) (Wang et al., 
2001). Understanding the contribution of these phosphorylation events to cell size regulation by 
S6K awaits further experiments.  
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4E-BP1 
 Most of the eukaryotic mRNAs acquire a 5’ cap that increases the stability of the mRNA, 
facilitates its nuclear export and is required for efficient translation (reviewed in (Cowling, 
2009)). The cap is formed by the addition of 7-methyl guanosine to the first transcribed 
nucleotide of the RNA, and is recognized by eIF4E (eukaryotic translation initiation factor 4E). 
eIF4E recruits eIF4G to the 5’cap and facilitates initiation of translation. The mTORC1 substrate 
4E-BP1 competes with eIF4G for binding to eIF4E, and inhibits translation initiation by 
perturbing the eIF4E-eIF4G interaction. Activation of mTORC1 leads to 4E-BP1 
phosphorylation and its subsequent dissociation from eIF4E, which now can bind to eIF4G and 
promote translation.  
 4E-BP1 knockout mice are viable, have normal growth rates and overall protein 
synthesis, and the only obvious phenotype is the reduced body size of males.  The mild 
phenotype of the 4E-BP1 knockout mice could be due to compensation for 4E-BP function from 
two other related genes, 4E-BP2 and 3 (Blackshear et al., 1997). Recently, a 4E-BP1 and 2 
double knockout mice was engineered. The double knockout mice are also viable, and have 
increased cell size in some tissues, but not others (Le Bacquer et al., 2007). Although it would 
not be surprising to see a cell size increase when 4E-BP function is lost, a clear conclusion is 
impaired by the fact the S6K phosphorylation is increased in the double knockout mice, and may 
be the reason of cell size phenotype observed. As a result, the role of 4E-BP in regulation of cell 
size remains elusive. The other 4E-BP, 4E-BP3, is also a phospho-protein, however, whether its 
phosphorylation is rapamycin sensitive is not known (Poulin et al., 1998).  
In some cell lines, inhibition of 4E-BP1 phosphorylation cannot be sustained with 
prolonged rapamycin treatment (24 hours or more). Although a few hours of rapamycin 
treatment decreases 4E-BP1 phosphorylation and cap-dependent translation, eventually 4E-BP1 
phosphorylation is regained even though rapamycin is still present in the culture media, and cells 
resume cap depedent translation (Choo et al., 2008; Thoreen et al., 2009). This re-
phosphorylation event is dependent on mTORC1, since knockdown of either mTOR or raptor 
eliminates it. There is no correlation between rapamycin-induced mTORC2 activation observed 
in some cell lines and rapamycin insensitivity of 4E-BP1 phosphorylation, and like the former, 
the latter does not correlate with any genotype. Phosphorylation of 4E-BP1 after prolonged 
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rapamycin treatment however is dependent on new protein synthesis, suggesting that yet 
unidentified factors may be playing a role. These results are interesting from an mTOR biology 
perspective: for years, rapamycin treatment was assumed to correspond to complete inhibition of 
mTORC1, but this does not seem to be the case. In addition, it points to the fact the different 
mTORC1 substrates can be regulated differently by unknown mechanisms.  
 
Regulation of Autophagy by mTORC1 
 Autophagy is an evolutionarily conserved process by which proteins, organelles and 
cytoplasm are engulfed within unique vesicles called autophagosomes, which deliver their cargo 
to lysosomes for degradation to amino acids, or other simple molecules (Chang et al., 2009). 
Autophagy, together with protein degradation by the proteasome, is important for the balance 
between catabolic and anabolic processes in cells, and is involved in the starvation response, 
development, cellular differentiation and cell death (reviewed in (Levine and Klionsky, 2004; 
Reggiori and Klionsky, 2002)).  
 Genes involved in regulation of autophagy were first identified in yeast, and named ATG 
(autophagy-related genes). Most of these genes have mammalian counterparts. In most 
eukaryotic cells, autophagy happens at a basal level and functions as a cell-renewal mechanism, 
especially for organelles and long-lived proteins. Induction of autophagy in response to nutrient, 
oxidative and energetic stress plays a key role for cell survival under these conditions. mTORC1 
is a negative regulator of autophagy,  and under conditions of mTORC1 inhibition, like 
rapamycin treatment or starvation, autophagy is induced.  
Although regulation of autophagy by TORC1 is well appreciated, the mechanism of this 
regulation is not well understood. Recently, Kamada et al. showed that yeast TORC1 
phosphorylates Atg13 in a rapamycin-sensitive manner (Kamada et al., 2009). Atg13, together 
with Atg17, binds to the protein kinase Atg1, and regulates its activity. Atg1 is essential for early 
stages of autophagy induction. Accordingly, under favorable growth conditions, TORC1 
phosphorylates Atg13 and inhibits its interaction with Atg1. Inhibition of TORC1 activity leads 
to Atg13 hypophosphorylation, which now can bind to Atg1 to enhance its kinase activity, 
leading to induction of autophagy. A similar mechanism of regulation of autophagy seems to be 
conserved in mammals. Two mammalian proteins with homology to yeast Atg13 and 17 were 
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identified recently. mTORC1 phosphorylates mammalian Atg13, inhibiting its interaction with 
ULK1 and 2, homologs of Atg1 (Ganley et al., 2009; Hosokawa et al., 2009; Jung et al., 2009). 
FIP200 interacts with ULK1 and 2 and mAtg13, and is thought to be the mammalian counterpart 
of Atg17 (Hara and Mizushima, 2009).  
Like other aspects of mTOR biology, the relationship between autophagy and mTORC1 
is complex, with a mechanistically poorly understood crosstalk between the two. First of all, 
although TORC1 suppresses autophagy, its substrate S6K is required for autophagy under 
starvation conditions in D. melanogaster (Scott et al., 2004). In addition, Atg1 negatively 
regulates TORC1 activity as measured by S6K phosphorylation, but autophagy may also activate 
TORC1 by increasing intercellular amino acid concentrations. This convoluted relationship 
between mTORC1 and autophagy may function to establish a balance between the two pathways 
to maximize proper utilization of nutrients under starvation conditions.  
 
Other Processes Regulated by mTORC1 
It is not surprising that as the master regulator of growth, in addition to protein synthesis, 
mTORC1 regulates other anabolic processes that are involved in making of macromolecules 
needed for growth. Lipid biosynthesis was recently shown to be regulated by mTORC1 upstream 
of the transcription factor SREPB-1 (sterol regulatory element binding protein-1). 
SREBP-1 controls the transcription of genes required for fatty acid synthesis in response 
to insulin. Insulin treatment and Akt activation lead to accumulation of SREP-1 in the nucleus in 
a rapamycin-sensitive manner (Porstmann et al., 2008). Because rapamycin treatment can lead to 
mTORC2 and Akt activation in some cells, to determine the contribution of each complex to 
SREBP-1 activation, Porstmann at al.  knocked down raptor or rictor, mTORC1 and mTORC2-
specific proteins, in cultured cells. Reduction of raptor, but not rictor, protein levels prevented 
transcription of SREBP-1 target genes and lipogenesis in response to insulin. In addition, a 
knockdown of SREBP-1 reduced cell size, showing the contribution of mTORC1-mediated 
lipogenesis to cell growth.  
Treatment of pre-adipocytes with rapamycin in vitro prevents their differentiation into 
adipocytes, and affects maintenance of adipogenicity after differentiation (Bell et al., 2000; Cho 
et al., 2004; Gagnon et al., 2001). Inhibition of mTORC1 activity selectively in adipose tissue in 
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mice leads to a reduction in adipose tissue mass, although these mice eat and absorb food as well 
as control mice (Polak et al., 2008). In addition, these mice have normal expression of genes 
required for fat production and storage, but show increased energy expenditure due to increased 
mitochondrial uncoupling. Although the mechanism of reduced adipose tissue under mTORC1 
loss is not clear, S6K1 is likely to be involved since S6K1-null mice also have reduced adipose 
tissue mass (Um et al., 2004).  
S6K1 has also emerged as the main player in down regulation of IRS protein function in 
response to prolonged insulin treatment. There are at least four IRS proteins in mammals, IRS1- 
4, and they act as adaptor proteins between growth factor receptors and downstream effectors. 
Activated insulin receptor/insulin like growth factor receptor phosphorylates IRS proteins on 
multiple tyrosine residues, leading to formation of docking sites for binding of other proteins, 
and subsequent phosphorylation of recruited proteins by the active receptor. Various stimuli have 
been shown to downregulate IRS protein function through its phosphorylation on serine residues 
and subsequent inhibition of its interaction with the insulin receptor or proteasomal degradation 
(Takano et al., 2001; Tremblay and Marette, 2001). Prolonged insulin treatment and amino acids 
leads to a reduction of IRS1 protein levels, and this effect is reversible by rapamycin treatment 
(Greene et al., 2003; Haruta et al., 2000; Li et al., 1999). mTORC1 activation also leads to a 
reduction in IRS1 mRNA levels (Harrington et al., 2004). 
Although the mechanism of transcriptional regulation of IRS1 expression through 
mTORC1 is not known, S6K is the kinase responsible for IRS phosphorylation and 
downregulation downstream of mTOR (Harrington et al., 2004; Tremblay et al., 2007; Zhang et 
al., 2008). These results have important implications for the insulin resistance seen in obesity and 
type-2 diabetes, since nutrient overload leads to mTORC1 activation-induced IRS degradation. 
Consistent with this idea, S6K1 null mice do not downregulate IRS1 in response to a high fat 
diet, and are resistant to diet induced obesity (Um et al., 2004).  
 It has been long known that caloric restriction increases life span in many organisms, 
including mice. Studies in invertebrates showed a clear link between reduced mRNA translation 
and life span: life span-extending mutations are found in many genes that encode translation-
related proteins (reviewed in (Kennedy and Kaeberlein, 2009)). Although the biology of aging is 
a mystery, mTOR seems to be involved in regulation of life span, probably due to its role in 
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translation. Recent studies showed that S6K1-/- mice live longer and have phenotypes and gene 
expression profiles similar calorically restricted mice (Selman et al., 2009). Even more 
interesting is the finding that rapamycin treatment of middle-aged mice is sufficient to extend life 
span by 14% in females and 9% in males (Harrison et al., 2009). Understanding how mTORC1 
contributes to the biology of aging, and whether rapamycin treatment or caloric restriction can 
prolong human life span are still waiting to be seen.  
 
Signaling Upstream of mTORC1 
 mTORC1 is a downstream effector of many tumor suppressors and is activated in many 
cancers, thus understanding how its activity is regulated is of great interest. It integrates signals 
from growth factors and nutrient availability to regulate the cellular processes explained above. 
Given the importance of mTORC1 for health and disease, it is not surprising that cells have 
developed complex systems to regulate its activity. In general, regulators of mTORC1 affect the 
phosphorylation state of proteins in the complex, modulate the interactions of other proteins with 
the complex or alter the intracellular localization of the complex.  
 
Regulation of mTORC1 by Growth Factors  
 Receptors for most growth factors, including insulin, are tyrosine kinases that dimerize 
and autophosphorylate in response to growth factor biding, leading to their activation and the 
recruitment of proteins with PTB (phosphotyrosine binding) domains. One class of such proteins 
that has a pivotal role in mTOR signaling is the IRS family of proteins. Binding of IRS to the 
activated growth factor receptor allows its phosphorylation on tyrosine residues at its N-
terminus, which serve as docking sites for proteins with SH2 (src homology 2) domains. After 
receptor activation, interactions of many downstream effectors with the receptor either directly 
or indirectly through the IRS proteins lead to a plethora of cellular responses.   
One major downstream effector of growth factor signaling is PI3K (phosphoinositide 3-
kinase), which catalyzes the production of PIP3 (phosphatidylinositol-3, 4,5-triphosphate). The 
kinase is a heterodimer composed of a catalytic subunit and a regulatory subunit, each with 
multiple isoforms in mammals. In response to growth factor stimulation, PI3K associates with 
IRS through the SH2 domain of the regulatory subunit, which leads to the activation of the 
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catalytic subunit (reviewed in (White, 1996)). PI3K can also be activated by binding of the small 
GTPase Ras to the catalytic subunit in growth factor-stimulated cells (reviewed in (Cantley, 
2002)). The consequence of PI3K activation is an increase in PIP3 levels, and recruitment of a 
diverse set of proteins with PH (pleckstrin homology) domains to the membrane by direct 
binding to PIP3. Of particular interest for mTORC1 signaling is the recruitment of Akt to the 
plasma membrane, which brings it to close proximity with PDK-1 (phosphoinositide dependent 
kinase-1). PDK-1 phosphorylates Akt (and other AGC kinases) at its T-loop, and activates it. For 
full activation, Akt requires a second phosphorylation event at its hydrophobic motif by 
mTORC2, however this phosphorylation seems to be dispensable for phosphorylation of some of 
Akt substrates (Guertin et al., 2006b).  
Akt activates mTORC1 by phosphorylating two proteins that otherwise inhibit the 
complex: PRAS40 and TSC2 (tuberous sclerosis complex 2). As mentioned before, PRAS40 is a 
component and an inhibitor of mTORC1, and its growth factor-stimulated phosphorylation leads 
to mTORC1 activation with a mechanism that remains elusive (Fonseca et al., 2007; Sancak et 
al., 2007; Vander Haar et al., 2007; Wang et al., 2007). TSC2 is a major hub in mTORC1 
signaling, and is the target of many activating and inhibitory signals. TSC1 and 2 genes were 
identified in genetic studies as the genes mutated in the familial disease tuberous sclerosis 
complex (European Chromosome 16 Tuberous Sclerosis Consortium, 1993; van Slegtenhorst et 
al., 1997). TSC is characterized by benign tumors (hamartomas) in different organs and can lead 
to metal retardation, seizures, renal failure and cancer. Early studies in Drosophila and 
mammalian cells established that TSC1 and 2 are binding partners, and they negatively regulate 
cell size downstream of PI3K signaling and Akt, but upstream of S6K (Gao and Pan, 2001; Gao 
et al., 2002; Nellist et al., 1999; van Slegtenhorst et al., 1998). It soon was shown that TSC2 is an 
Akt target, and phosphorylation of TSC2 by Akt inhibits its function as a growth inhibitor (Dan 
et al., 2002; Inoki et al., 2002; Manning et al., 2002; Potter et al., 2002; Tee et al., 2002), 
possibly by destabilizing the protein, or by promoting its interaction with 14-3-3 proteins which 
subsequently sequester TSC2 in the cytoplasm away from its site of action (Cai et al., 2006; Dan 
et al., 2002; Inoki et al., 2002).  
Although the protein sequence of TSC1 does not reveal much information about its 
potential function, the GAP (GTPase activating protein) domain of TSC2 hinted that it could 
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regulate the activity of a small GTPase. Based on this rationale, many groups started to search 
for the small GTPase downstream of TSC2 and showed that Rheb (ras homolog enriched in 
brain) causes mTORC1 activation in a TSC1/2-sensitive manner, and that TSC2 stimulates the 
GTPase activity of Rheb (Castro et al., 2003; Garami et al., 2003; Inoki et al., 2003a). In 
addition, in a genetic screen for growth regulators, Stocker et al. showed that loss of Rheb 
function causes reduced cell growth upstream of TORC1 (Stocker et al., 2003). 
Rheb is a member of the Ras family of small GTPases and was identified as a GTPase 
that is induced upon seizures in rat brain (Yamagata et al., 1994). There are two Rheb genes, 
Rheb1 and Rheb2, in mammals with 77% sequence similarity at the protein level, and they both 
function upstream of mTORC1. Whether they affect other cellular processes independently of 
mTORC1 is not known. Like most other Ras family members, Rheb undergoes lipid 
modification at its carboxyl terminus, farnesylation in this case (Clark et al., 1997). Mutants of 
Rheb that cannot be farnesylated are less effective in activating mTORC1 than wild type protein, 
suggesting that Rheb membrane localization is critical for its signaling function (Buerger et al., 
2006; Clark et al., 1997). Recently Rheb amplification and overexpression was reported in 
human prostate cancers.  In mice, Rheb amplification cooperates with increased PI3K signaling 
to promote tumorigenesis (Nardella et al., 2008).  
Overexpressed Rheb binds and activates mTORC1 in cultured cells (Long et al., 2005a; 
Long et al., 2005b). Similarly, addition of GTP-loaded Rheb to in vitro kinase assays activates 
mTORC1 but not mTORC2 as explained in more detail Chapter 2 (Sancak et al., 2007). Thus, it 
is clear that Rheb activates mTORC1 by direct interaction in vivo and in vitro. However, what 
happens after Rheb-mTORC1 interaction is a point of controversy.  Rheb was proposed to 
increase the catalytic function of mTORC1 as well as enhancing substrate binding to mTORC1. 
More detailed biochemical analysis of Rheb-induced mTORC1 activation is required to resolve 
this controversy (Avruch et al., 2009a; Sato et al., 2009).  
TSC2 is also phosphorylated by ERK (extracellular regulated kinase) and RSK1 (p90 
ribosomal S6 kinase1) downstream of MAPK (mitogen activated protein kinase) pathway to 
inhibit its activity, and this is additive with Akt-mediated TSC2 phosphorylation and inhibition 
(Ma et al., 2005; Roux et al., 2004). In addition to TSC2 inhibition, the MAPK pathway 
stimulates in vitro mTORC1 kinase activity via RSK1- and 2- mediated raptor phosphorylation 
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(Carriere et al., 2008). The mechanisms by which these phosphorylation events activate 
mTORC1 is not known, and the contribution of raptor phosphorylation to mTORC1 activation in 
vivo remains elusive, but they may link one more growth and proliferation pathway, in addition 
to PI3K pathway, to the regulation of cellular growth through mTORC1. In addition, mTOR 
phosphorylates raptor at multiple residues when activated, and elimination of these 
phosphorylation events reduced mTORC1 in vitro kinase activity (Foster et al., 2010). The 
functional consequence of these phosphorylation events for cellular growth is not known, but 
they may serve as a mechanism to maintain the active state of mTORC1 for a longer time after 
the initial stimulus is lost.  
In contrast to advances in understanding TSC2 regulation, the function and regulation of 
TSC1 is mostly unknown. The fact that loss of TSC1 or TSC2 causes the same disease argues 
that TSC1 is essential for the function of the complex. There is controversy on the role of TSC1 
in TSC2 GAP function (Jansen et al., 2004; Li et al., 2004; Tee et al., 2003), and it is possible 
that TSC1 regulates some other aspect of TSC1/2 biology, such as the localization of the 
complex or its interaction with Rheb.  
A very important upstream regulator of mTORC1 that should not be overlooked is the 
tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome ten). PTEN 
opposes PI3K signaling by removing the phosphate at position 3 on phosphatidylinositol-3, 4,5-
triphosphate to produce phosphatidylinositol-4,5-diphosphate (PIP2). The tumor suppressor 
function of PTEN is well appreciated and similar to the oncogenic function of PI3K (reviewed in 
(Maehama and Dixon, 1999)). Loss of PTEN/activation of PI3K contributes to tumor formation 
by activating mTORC1 signaling, at least partially. Rapamycin treatment can alleviate neoplatic 
phenotypes induced by PTEN loss (reviewed in (Guertin and Sabatini, 2007)). In addition, 
similar to TSC, heterozygous loss of PTEN is the genetic cause of familial hamartoma 
syndromes, collectively known as PTHS (PTEN-hamartoma tumor syndrome), that includes 
Cowden disease, Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos disease and Proteus 
syndrome. Rapamycin can be a potential therapeutic agent against such hereditary diseases and 
clinical trials are ongoing for test the efficacy of rapamycin treatment (reviewed in (Krymskaya 
and Goncharova, 2009)). 
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Regulation of mTORC1 by Energy Levels and Cellular Stress 
 Ribosome biogenesis and mRNA translation are two of the major energy consuming 
processes in the cell (Mayer and Grummt, 2006), making downregulation of the mTORC1 
pathway necessary under energy depletion to conserve resources for survival. Cellular energy 
depletion can be caused by many environmental changes, such as glucose deprivation or lack of 
oxygen (hypoxia), and is detected as a drop in the ATP: AMP ratio. AMPK (AMP-activated 
protein kinase) is a cellular energy sensor that is activated under energy deprivation. A high 
AMP: ATP ratio in cells results in binding of AMP to the regulatory subunit of the kinase, and 
its allosteric activation. ATP competes with AMP for binding to protein so when the cellular 
ATP concentration is higher than that of AMP, the kinase remains inactive (reviewed in (Kahn et 
al., 2005)). TSC2 is an AMPK target, and its phosphorylation by AMPK is reported to increase 
its GAP activity towards Rheb to inhibit mTORC1 (Inoki et al., 2003b). Raptor is also 
phosphorylated by AMPK in response energy deprivation, and elimination of these 
phosphorylation sites decreases AMPK-mediated mTORC1 inhibition, showing their importance 
for the regulation of the complex. Thus, low cellular energy levels are communicated to 
mTORC1 via AMPK by activation of TSC2 and inhibition of the complex itself by raptor 
phosphorylation.  
In addition to binding of AMP, phosphorylation of AMPK at Thr 172 by LKB1 kinase is 
essential for its activation (Hawley et al., 2003; Shaw et al., 2004; Woods et al., 2003). 
Surprisingly, germline mutation of LKB1 gene causes another hereditary hamartoma syndrome 
known as Peutz-Jeghers syndrome (Hemminki et al., 1998; Jenne et al., 1998).  Consistent with 
LKB1 being a negative regulator of the mTORC1 pathway, hamartomas from LKB1-/+ mice, a 
mouse model of the disease, have elevated mTORC1 activity compared to healthy tissue (Shaw 
et al., 2004), and energy deprivation fails to inhibit mTORC1 in LKB1-null cells. In addition, 
treatment of the LKB1-/+ mice with rapamycin after hamartoma formation reduces the tumor 
burden, suggesting that rapamycin may be beneficial for the treatment of Peutz-Jeghers patients 
(Wei et al., 2008). Although regulation of LKB1 activity by upstream signals is not well 
understood, two binding partners, STRAD (ste20 related adaptor) and MO25 (mouse protein 25) 
are important for its activity and cytoplasmic localization (Baas et al., 2003; Boudeau et al., 
2003). Recently, the crystal structure of the core of this three- protein complex revealed that 
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STRAD and Mos25 activate LKB1 by enabling its active confirmation through their interactions 
with the kinase (Zeqiraj et al., 2009). 
Although long-term hypoxia may cause a reduction in intracellular ATP levels, short-
term hypoxia does not chance cellular ATP levels significantly, yet inhibits mTORC1 
independent of AMPK (Arsham et al., 2003). This inactivation can be attributed, at least 
partially, to the actions of stress-induced protein REDD1. REDD1 was first identified in 
Drosophila as suppressor of P3IK-indiced cell growth downstream of TSC1/2, upstream of S6K 
(Reiling and Hafen, 2004). Its expression is induced in response to hypoxia and glucose 
deprivation, and both loss of function and overexpression studies establish that it is necessary 
and sufficient for down-regulation of mTORC1 activity in response to hypoxia (Brugarolas et al., 
2004; Corradetti et al., 2005). Recently, DeYoung et al. showed that REDD1 inhibits mTORC1 
by releasing growth factor-induced 14-3-3 binding of TSC2 (DeYoung et al., 2008). According 
to their model, in response to various cellular stresses, REDD1 expression is induced, and it 
competes with TSC2 for binding to 14-3-3 proteins through its consensus 14-3-3 binding motif, 
leading to TSC2 activation and mTORC1 inhibition. This model explains how cellular stress can 
inhibit mTORC1 even in the presence of growth factor signaling and demonstrates the 
complexity of mTORC1 regulation by upstream signals, especially at the level of TSC2 
regulation.  
In addition to the effects of glucose deprivation on mTORC1 activity downstream of 
AMPK and TSC2, the Rheb-mTORC1 interaction is proposed to be regulated glucose levels by 
Lee et al. (Lee et al., 2009). These authors found GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) as a Rheb-interacting protein under low glucose conditions. GAPDH functions 
in the glycolytic pathway and converts glyceraldehyde-3-phosphate to glyceraldehyde-1, 6-
bisphosphate and generates NADH in the process. Addition of glucose to the media of cultured 
cells or glyceraldehyde-3-phosphate to GAPDH-Rheb in vitro binding reaction eliminates the 
GAPDH-Rheb interaction. Thus, under low glucose conditions, GAPDH prevents the mTORC1-
Rheb interaction by binding to Rheb, and the presence of glucose releases Rheb and allows 
activation of mTORC1. Although this mechanism of mTORC1 regulation may be plausible, the 
glucose concentration used in this study (25mM) is above physiological blood glucose 
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concentration (~5mM), making it hard to predict the contribution of such a mechanism to 
mTORC1 regulation by glucose in vivo. 
 
Regulation of mTORC1 by Amino Acids 
  Early experiments in rat skeletal muscle and cultured mammalian cells showed that upon 
amino acid starvation mRNA translation was inhibited and that both amino acids and insulin 
were needed to restore it (Preedy and Garlick, 1986). It is not surprising that when the building 
blocks of translation are scarce, cells downregulate protein synthesis. Initial efforts to understand 
the mechanism of amino acid starvation-induced translation inhibition focused on the already 
known players and markers like regulation of translation initiation together with S6, S6K and 
4E-BP1 phosphorylation. S6K1 and 4E-BP1 are dephosphorylated in the absence of amino acids 
in cultured mammalian cells, which can be reversed by addition of amino acids to the growth 
media, in a rapamycin sensitive manner (Hara et al., 1998). Rapamycin sensitivity of amino acid-
induced translation initiation established that activity of mTOR is regulated by amino acids, in 
addition to growth factors.  
 Although the budding yeast S.cerevisiae does not have growth factor signaling, the 
nutrient sensitive TOR pathway regulates cellular growth in response to changing environmental 
conditions similar to its behaviour in mammalian cells, underscoring the evolutionary 
conservation of TOR function. Rapamycin treatment of yeast elicits a starvation-like phenotype 
(Barbet et al., 1996), and like mammalian cells, inhibits anabolic processes while activating 
catabolic process. Although the mechanism of amino acid sensing may not be the same between 
mammals and yeast, many of the key players of amino acid-sensitive TOR pathway are 
conserved, and yeast data may help interpret and understand TOR-dependent amino acid 
signaling in mammals.   
 In budding yeast, poor nutrient conditions are sensed by the plasma membrane bound 
SPS-sensing pathway and TORC1-mediated amino acid sensing pathway. The SPS-sensing 
pathway detects the presence of extracellular amino acids and induces amino acid permease 
expression to increase their transport into cells. Binding of extracellular amino acids to the 
plasma membrane SSY protein initiates a signaling cascade to regulate nuclear localization of 
transcription factors Stp1 and Stp2 and transcription of target genes (reviewed in (Ljungdahl, 
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2009)).  Sensing of extracellular amino acids by the SPS system is independent of TORC1. 
However, TORC1 regulates transcription activity of the pathway by regulating the stability of 
Stp1. TORC1 inactivation by rapamycin treatment leads to degradation of Stp1 trough an 
unknown mechanism (Shin et al., 2009).  
The activity of the TOR pathway however, is sensitive to intracellular amino acid 
availability both in yeast and mammals (Christie et al., 2002; Sancak et al., 2008). However, 
signaling events that convey the presence or absence of amino acids to TORC1 remain unknown. 
In addition, it is not clear what is really being sensed, the amino acids themselves, their 
byproduct, or amino acid flux etc. In most mammalian cells, leucine starvation downregulates 
the activity of the mTORC1 pathway, but other amino acids can have similar effects, and there 
seems to be cell type-specific responses to removal of individual amino acids from the growth 
media. These observations suggest that not individual amino acids, but something downstream of 
amino acid availability is sensed.  
A few metazoan amino acid transporters were suggested to regulate TORC1 activity. 
Amongst these, two Drosophila genes, slimfast, and minidiscs are bona fide amino acid 
transporters, and their mutations causes growth retardation probably due to inadequate amino 
acid intake to the cells (Colombani et al., 2003; Martin et al., 2000). Another Drosophila gene, 
pathetic (path), is a growth regulator genetically upstream of TOR. Path stimulates growth when 
overexpressed and suppresses growth when knocked down. Interestingly, path has a higher 
substrate affinity and lower transport capacity than its fly and mammalian homologs (Goberdhan 
et al., 2005). Based on the growth retardation of path mutant flies and inferior transport abilities 
of the protein, Goberdhan et al. proposed that path can be a receptor/transporter and initiate a 
signaling cascade when the amino acid concentrations are low. Mammalian path homologs are 
localized both on the plasma membrane and endosomes, which would enable monitoring of both 
extracellular and intracellular amino acid levels if such a receptor/transporter function is real. 
Although very intriguing, a receptor function for path is yet to shown.  
One of the few proteins that can rescue amino acid-starvation induced mTORC1 
inactivation when overexpressed is the Rheb GTPase. In addition, Rheb is necessary for amino 
acid-induced mTORC1 activation. As a result, the TOR field assumed that amino acids must be 
affecting the pathway at the level TSC1/2 or Rheb. However, TSC2-null MEFs are not resistant 
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to mTORC1 inactivation in response to amino acid starvation, and the percentage of GTP-bound 
Rheb is not affected by amino acid starvation and stimulation (Nobukuni et al., 2005; Sancak et 
al., 2008; Smith et al., 2005). The amino acid sensitivity of TSC2-null cells also pointed to the 
necessity, but insufficiency of Rheb to activate mTORC1: Rheb can activate mTORC1 in the 
absence of amino acids only when it is overexpressed, and under endogenous expression levels, 
it cannot substitute for the amino acid input to mTORC1. Recently, new players were shown to 
be involved in activation of TORC1 in response to amino acids downstream of amino acid 
availability.  
 Vps34 (vacuolar protein sorting 34), a member of PI3K family, was identified as an 
upstream regulator of mTORC1 that functions in the amino acid-induced mTORC1 activation 
specifically. Unlike PI3K, Vps34 phosphorylates only phosphatidylinositol to generate 
phosphatidylinositol-3-phosphate (PI3P) and does not seem to affect growth factor-induced 
signaling. The activity of Vps34 decreases in response to amino acid starvation (Byfield et al., 
2005; Nobukuni et al., 2005), which leads to a decrease in the levels of PI3P. Glucose 
deprivation and AMPK activation also affect Vps34 activity, suggesting that it may not be an 
amino acid-specific regulator of mTORC1 (Byfield et al., 2005). RNAi-mediated reduction of 
Vps34 protein levels in cultured mammalian cells blunts mTORC1 activation in response to 
amino acids, however, its overexpression is not sufficient to make the pathway amino acid-
insensitive (Gulati et al., 2008). Finally, disruption of Vps34 gene in D.melanogaster or 
knockdown of it in C. elegans was reported to show no amino acid-related signaling defects, 
questioning a major role of Vps34 in amino acid signaling to mTORC1 (Avruch et al., 2009b; 
Juhasz et al., 2008). As the name suggests, Vps34 is involved in endosomal trafficking (Avruch 
et al., 2009b), and as will be discusses later, endosomal membranes has emerged as important 
players in amino acid signaling. The signaling defects reported in mammalian cells after Vps34 
knockdown can be attributed to disturbances in endosome function. It is also possible that 
mammalian cells differ from the fly and the worm in amino acid signaling to TORC1.  
 Although how the TOR pathway senses amino acid availability remains elusive, 
identification of the Rag (Ras-like GTPase) GTPases recently brought us one step closer to 
understanding the process, and has provided insight about how nutrient sensing may be 
happening as will be explained in the next section. In addition, the mechanism by which Rag 
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GTPases activate mTORC1 helps to explain some of the observations in the filed that remained 
puzzling. 
 
Summary of This Work 
 Although the effects of upstream signals on the activity of mTORC1 pathway have been 
known for a long time, what do these signals do to the complex to accomplish mTORC1 
activation or inhibition are now beginning to emerge. My thesis work aims to elucidate the 
mechanisms by which growth factors and amino acids stimulate mTORC1 activation. Finding 
new mTORC1 interacting proteins under different culture conditions using immuno-precipitation 
of complex proteins has been a very fruitful approach used in our laboratory, and led to the 
identification of PRAS40 and Rag GTPases. PRAS40 functions in the regulation of mTORC1 
activity in response to growth factors, whereas Rag GTPases are specific to amino acid signaling.  
Crucial to understanding the role of PRAS40 and Rheb in mTORC1 regulation was the 
development of an in vitro kinase assay that reflects the in vivo activity of the kinase, and 
enabled testing the effects of different proteins on mTORC1 activity in vitro. Using this assay, 
we showed that PRAS40 inhibits mTORC1 kinase activity in a phosphorylation dependent 
manner and found a major downstream effector of growth factor signaling in mTORC1 
regulation.  
The important role of Rheb in activation of mTORC1 has been well appreciated: Rheb 
overexpression can overcome any inhibitory signals upstream of the complex, and it is necessary 
for activation of mTORC1 by any stimuli. However, the direct downstream target(s) of Rheb and 
how it activates mTORC1 remained elusive for years after its placement in the mTOR pathway. 
Using the in vitro kinase assay mentioned above, we showed that addition of purified and GTP-
loaded Rheb to highly pure mTORC1 preparations was sufficient to activate the kinase and 
GDP-loaded Rheb had no affect on its kinase activity. Rheb-GTP could also oppose the 
inhibitory effects of PRAS40 in vitro. These results demonstrated for the first time that Rheb 
must activate mTORC1 by direct binding, and enabled us to propose a mechanism for growth 
factor-induced mTORC1 activation by two different proteins that function at the complex level. 
The first input is phosphorylation and inhibition of PRAS40, and the second one is activation of 
mTORC1 directly by Rheb-GTP.  
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 Mechanism of mTORC1 regulation by amino acids had been a black box until the 
discovery of the Rag GTPases, and is the major focus of my thesis work. The Rag GTPases are 
an evolutionarily conserved family of GTPases that was identified in mammalian cells based on 
their sequence similarity to Ras GTPase (Schurmann et al., 1995). Although Rag GTPases 
resemble other small GTPases, their similarity is low in the GTPase fold. In addition, they have 
an extended carboxyl terminal region that is conserved in the Rag GTPase family members 
across and within species (Figure 5).  In yeast, there are two members of Rag GTPases, Gtr1 and 
Gtr2 (GTP binding protein and negative regulator of Ran/Tc4), whereas mammals have four 
members, RagA through RagD. RagA and RagB show 52% sequence identity to Gtr1, and are 
98% identical to each other, except that RagB has a 33 amino acid extension at its N-terminus. 
Given the sequence similarity, it is not surprising that RagA and RagB are functionally 
redundant. In addition, RagA can rescue Gtr1 deficiency phenotype in yeast, showing functional 
evolutional conservation in addition to sequence conservation (Gao and Kaiser, 2006; Hirose et 
al., 1998; Sancak et al., 2008). RagC and RagD are homologs of yeast Gtr2, and show 81% and 
42% sequence homology to each other and Gtr2, respectively. RagC and RagD are also 
functionally redundant, however, human RagC cannot substitute for yeast Gtr2 (Gao and Kaiser, 
2006; Sancak et al., 2008). RagC and RagD were identified as RagA and RagB interacting 
proteins using yeast two hybrid, and the extended carboxyl-terminal region of the Rag GTPases 
mediate RagA/B-RagC/D interactions (Sekiguchi et al., 2001) (Figure 5).  
Early experiments in yeast pointed to a genetic interaction of Gtr1 and 2 with Ran 
GTPase and nucleocytoplasmic transport (reviewed in (Nishimoto, 2000)), however the 
mechanism of this interaction is not clear. More recently, others and we showed that in yeast, fly 
and mammals, Rag GTPases regulate mTOR-related processes(Dubouloz et al., 2005; Gao and 
Kaiser, 2006; Kim et al., 2008; Sancak et al., 2008). More specifically, the Rag GTPases 
function in the amino acid-sensitive mTORC1 pathway downstream of amino acid availability 
and upstream of mTORC1, and do not affect growth factor signaling directly. The involvement 
of Rag GTPases in the regulation of mTORC1 is explained in more detail in Chapters 3 and 4 
and will only be summarized here.  
We found the Rag GTPases as raptor-interacting proteins and confirmed that they bind to 
raptor both in vivo and in vitro. This binding is unusual in the sense that it requires one member 
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of RagA/B and one member of RagC/D. Even more peculiar is the observation that RagA/B 
should be bound to GTP for raptor interaction, and the strength of this interaction can be 
increased if RagC/D is GDP-bound (Sancak et al., 2008). Specific GTP or GDP binding of the 
GTPases was achieved by mutating certain amino acids in the GTPase fold- a common trick used 
for GTPases-, but we also realized that in vivo Rag-raptor interaction can be observed only in the 
presence of amino acids, suggesting that the nucleotide bound to the Rag GTPases change in 
response to amino acids. Indeed we showed that in amino acid starved cells, RagA/B is mostly 
GDP-bound and RagC/D is mostly GTP bound, and amino acid stimulation reverses the 
nucleotide bound to each.  
Loss and gain of function experiments in mammals, Drosophila and yeast clearly showed 
that Rag GTPases are necessary for amino acid-induced TORC1 activation and are sufficient to 
mimic amino acid availability (Binda et al., 2009; Kim et al., 2008; Sancak et al., 2008). Like 
raptor binding, activation of TORC1 by Rag GTPases requires GTP-bound RagA/B, and 
presence of GDP-bound RagC/D enhances the effect. What is the effect of Rag-raptor interaction 
on TORC1, and how does this activate mTORC1? Rag GTPases did not seem to affect the kinase 
activity of mTORC1 since addition of them in vitro to kinase assays did not enhance or suppress 
substrate phosphorylation. However, we made a critical observation that cellular mTOR 
localization in amino acid starved cells differs from that in amino acid replete cells. When 
starved for amino acids, mTOR shows a cytoplasmic location and in response to amino acids, it 
moves to peri-nuclear vesicles in a raptor and Rag-dependent manner (Sancak et al., 2008). We 
also showed that these peri-nuclear vesicles are lysosomes, where the Rag GTPases reside 
independently of amino acid availability.  
In yeast, Gtr1 and Gtr2 reside on the vacuole, the lysosome equivalent organelle of 
S.cerevisiae (Binda et al., 2009; Dubouloz et al., 2005; Gao and Kaiser, 2006; Gao et al., 2005). 
Although the significance of vacuole/lysosome localization of Rag GTPase and TORC1 are not 
clear, one can speculate. Lysosomes and vacuoles are the main site of protein degradation and 
amino acid recycling, and in yeast, vacuoles also serve as amino acid storage facilities whose 
function is important for a proper starvation response (reviewed in (Li and Kane, 2009)). The 
function of lysosomes in amino acid-related processes seems to be conserved throughout the 
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evolution, and it would not be surprising if amino acid sensing and signaling were initiated in 
these compartments.  
In light of the data explained above, together with the knowledge that Rheb can also be 
found on the lysosomes (Saito et al., 2005; Sancak et al., 2008) we proposed a model for amino 
acid-induced mTORC1 activation: amino acid stimulation brings mTORC1 and Rheb in close 
proximity, which leads to activation of the complex. This model can explain why in the absence 
of amino acids, even if growth factors are present, mTORC1 cannot be activated, and the 
observation that only Rheb overexpression, but not 100% GTP loading, can overcome mTORC1 
inactivation in the absence of amino acids. Growth factor stimulation alone cannot activate 
mTORC1 without amino acids due to absence of mTORC1-Rheb co-localization. When Rheb is 
overexpressed however, it mislocalizes, and can interact with mTORC1 in the cytoplasm to 
activate it independent of amino acid availability. Overall, it seems like the mTORC1-Rheb 
interaction is the determining factor for activation of the complex.  
To test this model, we developed ways to constitutively target mTORC1 to the lysosomal 
surface or to the plasma membrane as explained in Chapter 4. Consistent with our model, when 
mTORC1 was always on the lysosomes, its activity was insensitive to amino acid starvation as 
long as Rheb was there. When Rheb was knocked down by RNAi, mTORC1 activation by amino 
acids was severely blunted. Under these conditions, Rag GTPase function was obsolete for 
mTORC1 activity, since mTORC1 was on the lysosomes constitutively. More importantly, co-
localization of both mTORC1 and Rheb on the plasma membrane also made the pathway 
insensitive to amino acid starvation, in agreement with our model.  
Although Rag GTPases are lysosome-associated proteins, they do not contain a lipid 
modification or lysosome-targeting signal. This suggested that there must be other proteins that 
tether the Rags to the lysosomes. This prompted us to identify new Rag-interacting proteins and 
test if any of these interacting proteins will serve as Rag lysosome localizers. Our efforts were 
fruitful and we found that a complex of three proteins, p14, p18 and MP1, which were shown to 
form a lysosome-associated complex (Nada et al., 2009), are necessary for constitutive 
localization of Rag GTPases to the lysosomes, and for mTORC1 signaling. We named this 
complex “Ragulator” to reflect its involvement in Rag-dependent mTORC1 signaling. When 
either of these proteins is lost, the Rag GTPases become cytoplasmic, and mTORC1 cannot be 
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recruited to the lysosomes in response to amino acids, and thus cannot be activated by them. 
Surprisingly, in yeast, Gtr1 and 2 interacting Ego1 and Ego3 proteins serve this function, and 
they are also required for TORC1 signaling (Dubouloz et al., 2005; Gao and Kaiser, 2006). 
There is no sequence homology between the Ragulator and the Ego proteins; however, their 
function seems to be conserved.  
How amino acid availability is detected still waits to be elucidated. The emergence of a 
key role for lysosomes in this process certainly will concentrate efforts on understanding 
signaling function of these membranes. In addition, currently unidentified upstream regulators of 
the Rag GTPases, GEFs (GTPase exchange factors) or GAPs, will likely to be involved in amino 
acid sensing. 
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Table 1 
	  	  	  	   	  	  
 
 
 
 
 
 
 
Table 1: List of genes upstream of the mTOR signaling pathway whose mutations lead to 
hereditary diseases characterized by the presence of benign tumors. Adapted from (Inoki et al., 
2005)
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Figure 1 	  	  	  	  	  	  	  	  	  	  	  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Domain structure of mTOR. The kinase domain is surrounded by the FAT domain N-
terminaly and the FATC domain C-terminaly. The FRB is the FKBP12-rapamycin binding site. 
The HEAT repeats are involved in protein-protein interactions. Adapted from (Harris and 
Lawrence, 2003) 	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Figure 2 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 2: Serine and threonine residues phosphorylated by mTOR. The phosphorylated amino 
acids are shown in red. In 4E-BP1, the presence of a proline (green) before the target site defines 
the phosphorylation motif. Other substrates of mTOR are phosphorylated at amino acids 
surrounded by hydrophobic amino acid (purple). This figure is courtesy of Peggy Hsu. 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Overview of mTOR signaling pathway. Adapted from (Sabatini, 2006)
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Domain structures of mTOR substrates. mTOR phosphorylates some members of the 
AGC kinase family. S6K is phosphorylated by mTORC1, and others are mTORC2 substrates. 
PH is pleckstrin homology domain; C1 and C2 are conserved region 1 and 2, respectively.   
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Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Domain structure and alignment of Rag GTPases. (A) The Rag GTPases are composed 
of an N-terminal GTPase domain and an extended C-terminal domain (Gtr1) that is conserved 
within the Rag GTPase family and is important for the Rag-Rag interaction. (B) Alignment of 
human Rag A, B, C and D. The black box is the GTPase fold and the green box is the Gtr1 
domain. (C) Alignment of RagB from different species.  	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Summary 
 
 
The heterotrimeric mTORC1 protein kinase nucleates a signaling network that promotes 
cell growth in response to insulin and becomes constitutively active in cells missing the TSC1 or 
TSC2 tumor suppressors. Insulin stimulates the phosphorylation of S6K1, an mTORC1 substrate, 
but it is not known how mTORC1 kinase activity is regulated. We identify PRAS40 as a raptor-
interacting protein that binds to mTORC1 in insulin-deprived cells and whose in vitro interaction 
with mTORC1 is disrupted by high salt concentrations. PRAS40 inhibits cell growth, S6K1 
phosphorylation, and rheb-induced activation of the mTORC1 pathway, and in vitro prevents the 
great increase in mTORC1 kinase activity induced by rheb1-GTP. Insulin stimulates Akt/PKB-
mediated phosphorylation of PRAS40, which prevents its inhibition of mTORC1 in cells and in 
vitro. We propose that the relative strengths of the rheb- and PRAS40-mediated inputs to 
mTORC1 set overall pathway activity and that insulin activates mTORC1 through the 
coordinated regulation of both. 
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Introduction 
 
The evolutionarily conserved TOR pathway is a critical controller of growth in 
eukaryotes, regulating cell as well as organ and body size in a variety of organisms (reviewed 
in (Sarbassov et al., 2005; Wullschleger et al., 2006)). The pathway was discovered in studies 
into the mechanism of action of rapamycin, an immunosuppressive and anti-restenosis drug 
that is also in clinical trials as a cancer therapy. The mammalian TOR (mTOR) pathway 
integrates signals from growth factors, nutrients, and stresses to regulate many growth-
related processes, including mRNA translation, small molecule metabolism, cell survival, 
and autophagy. Emerging evidence indicates that deregulation of the mTOR pathway occurs 
in common diseases, including cancer and diabetes, underscoring the importance of 
identifying and understanding the function of the components of the mTOR signaling 
network.   
The central component of the pathway, the large protein kinase mTOR, nucleates two 
distinct multi-protein complexes called mTOR Complex 1 (mTORC1) and 2 (mTORC2) 
(reviewed in (Sabatini, 2006)). mTORC1 is a heterotrimer consisting of the mTOR catalytic 
subunit and two associated proteins, raptor and mLST8/GbL. mTORC2 also contains mTOR 
and mLST8/GbL, but, instead of raptor, the rictor and mSin1 proteins. The molecular 
functions of most mTOR-associated proteins are not understood, but raptor has been 
proposed to be a docking site for substrates on mTORC1 and to regulate mTOR kinase 
activity (Hara et al., 2002; Kim et al., 2002; Nojima et al., 2003; Schalm et al., 2003). The 
best-characterized downstream effectors of mTORC1 are S6 Kinase 1 (S6K1) and 4E-BP1, 
two translational regulators that mTORC1 directly phosphorylates (Brunn et al., 1997; 
Burnett et al., 1998; Gingras et al., 2001).  
As judged by the phosphorylation state of S6K1 or 4E-BP1, the mTORC1 pathway 
senses many upstream signals, including growth factors like insulin as well as environmental 
nutrient levels. The mechanisms underlying mTORC1 regulation are not well understood but 
a key upstream player is clearly the GTP-binding protein rheb, which is negatively regulated 
by the dimeric TSC1-TSC2 GTPase Activating Protein (GAP) (Castro et al., 2003; Garami 
et al., 2003; Inoki et al., 2003a; Saucedo et al., 2003; Stocker et al., 2003; Tee et al., 2002; 
Tee et al., 2003b; Zhang et al., 2003). When TSC1 or TSC2 is lost, such as in the cancer-
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prone syndrome Tuberous Sclerosis Complex (TSC), rheb becomes constitutively loaded 
with GTP, rendering the mTORC1 pathway active and insensitive to insulin. It is now 
appreciated that several pathways in addition to the insulin-stimulated PI3K/Akt pathway 
signal to mTORC1 by modulating TSC1-TSC2 activity towards rheb. For example, energy 
deprivation sensed by AMPK (Inoki et al., 2003b), MAPK signaling (Ma et al., 2005; Roux 
et al., 2004; Tee et al., 2003a), and hypoxia and stress sensing (Brugarolas et al., 2004; 
Corradetti et al., 2005; Reiling and Hafen, 2004) all regulate TSC1-TSC2 activity and the 
GTP-loading of rheb. Within cells rheb overexpression strongly activates the mTORC1 
pathway and the overexpressed protein binds to the mTOR kinase domain (Long et al., 
2005). However, it is still not clear if endogenous rheb acts by binding directly to mTORC1 
or if it requires an unknown intermediate. 
Here, we identify PRAS40 as a raptor-binding protein that potently inhibits mTORC1 
kinase activity in vitro and mTORC1 signaling within cells. Insulin-stimulated 
phosphorylation of PRAS40 by Akt/PKB suppresses its mTORC1 inhibitory activity. Thus, 
we propose that insulin activates mTORC1 through the coordinated regulation of rheb, an 
mTORC1 activator, and PRAS40, an mTORC1 inhibitor.  
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Results 
A salt-sensitive factor inhibits the kinase activity of mTORC1 
 We previously developed protocols for immunopurifying intact mTORC1 and an in vitro 
assay for measuring its kinase activity towards full length S6K1 (Guertin et al., 2006). 
Surprisingly, this assay does not detect any difference between the activity of mTORC1 from 
serum-deprived and insulin-stimulated HEK-293E cells, even though insulin robustly increases 
S6K1 phosphorylation in these cells (Figure 1A). We speculated that an unknown factor 
important for conferring insulin sensitivity is lost from mTORC1 during the washing of 
immunoprecipitates with buffers containing high salt concentrations. Indeed, when washed with 
buffers containing 150 but not 300 or 400 mM NaCl, mTORC1 from insulin-stimulated cells has 
much higher activity than that from serum-deprived cells (Figure 1B). By avoiding high salt 
buffers we showed that insulin also activates endogenous mTORC1 from HeLa cells and mouse 
embryonic fibroblasts (MEFs) (Figure 1C), as well as mTORC1 containing recombinant HA-
raptor stably expressed in HEK-293E cells (Figure 1D). High salt washing eliminates the insulin-
induced difference in mTORC1 activity by increasing the activity of mTORC1 from serum-
deprived cells (Figure 1B). This indicates that a salt-sensitive factor inhibits mTORC1 during 
insulin deprivation and suggests that loss or repression of this factor participates in activating 
mTORC1 in response to insulin. 
 Inactivation of the TSC1 or TSC2 tumor suppressor leads to insulin-insensitive and 
constitutively high S6K1 phosphorylation (Garami et al., 2003; Inoki et al., 2002; Manning et 
al., 2002; Zhang et al., 2003). Paradoxically, however, we find that the in vitro kinase activity of 
mTORC1 from TSC2-null MEFs treated with or without insulin is very repressed, being similar 
in magnitude to that of mTORC1 from wild-type MEFs deprived of insulin (Figure 1E). 
Substantial evidence (Harrington et al., 2004; Shah et al., 2004) indicates that hyperactive 
mTORC1 signaling down-regulates the insulin/PI3K pathway so that TSC2-null MEFs are in a 
state equivalent to insulin-deprivation. Consistent with this, high salt washes activate mTORC1 
from TSC2-null MEFs (Figure 1E), just as they do mTORC1 from insulin-deprived wild-type 
MEFs (Figure 1E) or HEK-293E cells (Figure 1B). Thus, in TSC2-null MEFs an mTORC1 
activator must exist that overcomes repression of mTORC1 by the salt-sensitive inhibitor and 
leads to the hyperactive mTORC1 signaling characteristic of these cells. Such an activator is 
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likely lost from mTORC1 during its purification, explaining the low in vitro activity of mTORC1 
from TSC2-null cells. 
An obvious candidate for such an mTORC1 activator is rheb—the small GTPase that 
becomes constitutively loaded with GTP in the absence of TSC1 or TSC2. Previous studies show 
that overexpressed rheb1 strongly activates the mTORC1 pathway and binds to the mTOR 
kinase domain (Long et al., 2005). We confirmed these studies (data not shown) but, despite 
considerable effort, we were unable to detect endogenous rheb bound to immunopurified 
mTORC1 (data not shown), probably because the rheb-mTORC1 interaction is transient and too 
weak to survive even the gentlest immunopurifications. Thus, to determine if rheb can activate 
mTORC1 in vitro, we added GTP-loaded rheb1 or control proteins to mTORC1 immunopurified 
under low salt conditions and measured its kinase activity towards S6K1. Rheb1-GTP, but not 
rheb1-GDP, rap2a-GTP, or rap2a-GDP, dramatically activated endogenous  (Figure 2A) or 
recombinant (Figure 2B) mTORC1 from serum-deprived HEK-293E cells and also boosted the 
activity of mTORC1 from insulin-stimulated cells (Figure 2C). Rheb1-GTP also strongly 
activated mTORC1 from TSC2-null MEFs (Figure 2D). Lastly, rheb1-GTP also activated 
mTORC1 kinase activity towards 4E-BP1 (Figure 2E). To our knowledge these are the first 
demonstrations that soluble GTP-loaded rheb1 directly activates mTORC1 in vitro. We conclude 
that rheb1-GTP can overcome, like high salt washes, the suppression of in vitro mTORC1 
activity caused by insulin-deprivation or TSC2-null status, suggesting that rheb1-GTP can 
counter the actions of the salt-sensitive inhibitor.  
 
PRAS40 is a raptor-binding protein that interacts with mTORC1 
To identify the salt-sensitive inhibitor of mTORC1 we searched for proteins that co-
purify with mTORC1 when raptor or mTOR immunoprecipitates are washed with buffers 
containing low but not high salt concentrations. This led to the identification by mass 
spectrometry of PRAS40, a 28 kDa proline-rich protein lacking named domains but which is 
known to be phosphorylated near its C-terminus by Akt/PKB (Kovacina et al., 2003) and 
potentially other kinases (Huang and Porter, 2005) (Figure 3A). Interestingly, the gene for 
PRAS40 (called AKT1S1) is located at chromosome 19q13.33, a region thought to contain an 
unknown tumor suppressor associated with gliomas (Hartmann et al., 2002). PRAS40 is not 
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conserved in budding or fission yeast but has a putative Drosophila orthologue named Lobe 
(Chern and Choi, 2002).  
Using immunoblot analyses of raptor immunoprecipitates we confirmed that PRAS40 co-
purifies with endogenous mTORC1, but not a control protein, when it is isolated under low salt 
conditions and that high salt washes greatly reduce the amount of PRAS40 bound to mTORC1 
(Figure 3B). In HEK-293E cells, acute insulin stimulation of serum-deprived cells decreases the 
amount of PRAS40 bound to mTORC1 without affecting its expression level (Figure 3B). 
mTOR is part of two distinct complexes within cells, mTORC1 and mTORC2, but PRAS40 only 
interacts with mTORC1 (Figure 3C). 
Endogenous PRAS40 interacts, in an insulin-sensitive fashion, with mTORC1 containing 
recombinant raptor (Figure 3D), suggesting that recombinant proteins can be used to identify the 
PRAS40 binding site on mTORC1. To do so, we co-expressed flag-PRAS40 with HA-raptor 
and/or myc-mTOR and isolated mTORC1 using anti-HA or anti-myc immunoprecipitations 
(Figure 3E). PRAS40 robustly co-immunoprecipititates with HA-raptor and the co-expression of 
myc-mTOR did not significantly increase the amount of PRAS40 recovered with HA-raptor. 
While relatively small amounts of PRAS40 co-immunoprecipitate with myc-mTOR, the co-
expression of HA-raptor significantly increases the amount of PRAS40 recovered with myc-
mTOR. These results indicate that PRAS40 preferentially binds the raptor component of 
mTORC1 and are consistent with PRAS40 not binding to mTORC2, which does not contain 
raptor. PRAS40 binds better to the N- than C-terminal half of raptor but the degree of binding 
obtained to all raptor fragments tested is much less than that to full-length raptor (data not 
shown). Consistent with PRAS40 binding to raptor, in cells with RNAi-induced partial decreases 
in raptor or mTOR expression, the amount of PRAS40 recovered in raptor or mTOR 
immunoprecipitates correlates with the amount of raptor but not mTOR in the 
immunoprecipitates (Figure 3F).  
Because previous work (Kovacina et al., 2003) indicates that PRAS40 is phosphorylated 
on T246 in an Akt/PKB-dependent fashion we asked how insulin affects the phosphorylation 
status of PRAS40 bound to mTORC1 (Figure 3G). As expected, lysates of HEK-293E and HeLa 
cells treated with insulin had much greater levels of phosphorylated PRAS40 than lysates of 
serum-deprived cells. Despite the fact that insulin decreases the amount of PRAS40 bound to 
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mTORC1 in HEK-293E and HeLa cells, the PRAS40 that remains bound is highly 
phosphorylated. Thus, PRAS40 phosphorylation does not preclude the binding of PRAS40 to 
mTORC1 although it may weaken the interaction. This is consistent with the results of similar 
experiments in wild-type MEFs, where insulin causes a large increase in the phosphorylation of 
the PRAS40 that is bound to mTORC1 but only a modest decrease in the amount of total 
PRAS40 bound to mTORC1 (Figure 3G). In TSC2 null MEFs insulin does not increase PRAS40 
phosphorylation, as expected from the profound inhibition of insulin signaling and Akt/PKB 
activity in these cells (Figure 3G). The fact that PRAS40 phosphorylation on T246 positively 
correlates with the in vitro activation of mTORC1 by insulin suggests that this phosphorylation 
event may promote mTORC1 activation. 
 
PRAS40 is an inhibitor of mTORC1 in vitro 
 To begin to investigate potential roles for PRAS40 in the regulation of the mTORC1 
pathway we asked if it affects mTORC1 kinase activity in vitro. We have described three ways 
of obtaining active mTORC1: (1) by washing mTORC1 from serum-deprived cells with buffers 
containing high salt concentrations; (2) by immunopurifying mTORC1 from cells stimulated 
with insulin; or (3) by adding rheb1-GTP to mTORC1 from serum-deprived cells. In the 
experiments described below we tested the in vitro effect of PRAS40 on mTORC1 activity using 
recombinant PRAS40 overexpressed in and purified from HEK-293T cells. In a dose sensitive 
fashion PRAS40, but not a control protein, inhibited the in vitro kinase activity of mTORC1 
activated with high salt washes (Figure 4A) or insulin stimulation (Figures 4B and 4F). PRAS40 
is a potent inhibitor, with half maximal inhibition occurring at or below 20 nM. PRAS40 also 
blocks the massive activation of mTORC1 caused by 100 nM GTP-loaded rheb1 (Figure 4C), 
and, as is the case with activation caused by high salt washes or insulin stimulation, half maximal 
inhibition occurred at around 20 nM PRAS40 (Figure 4D). Thus, PRAS40 is a potent inhibitor of 
mTORC1 and accounts for the salt-sensitive inhibition of mTORC1 we observe.  
It is clear that PRAS40 can inhibit rheb1-GTP activation of mTORC1, but several of the 
findings we have presented also strongly suggest that at high concentrations rheb1-GTP can 
overcome PRAS40-mediated inhibition of mTORC1. For example, the addition of rheb1-GTP to 
mTORC1 from serum-deprived (Figures 3ABC) or TSC2 null (Figure 3D) cells—two situations 
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where PRAS40 is bound to mTORC1—stimulates mTORC1 activity. To formally prove that 
rheb1-GTP can reverse PRAS40-mediated inhibition of mTORC1, we incubated mTORC1 with 
a constant amount of PRAS40 (40 nM) and increasing amounts of rheb1-GTP and measured 
mTORC1 kinase activity. Indeed, in a dose sensitive fashion rheb1-GTP re-activates PRAS40-
inhibited mTORC1 (Figure 4E). 40 nM PRAS40 completely inhibits mTORC1 obtained from 
insulin-stimulated cells and a 9-fold higher concentration (360 nM) of rheb1-GTP is required to 
restore mTORC1 activity. These results indicate that at elevated levels of rheb1-GTP—as would 
be expected in TSC2 null cells—the molar ratio of rheb1-GTP to PRAS40 is sufficiently high to 
overcome inhibition of mTORC1 by PRAS40. 
 
PRAS40 is an inhibitor of the mTORC1 pathway in mammalian cells 
 To determine if the in vivo correlates of our in vitro findings are true, we began by using 
overexpression to test the effects of PRAS40 on the mTORC1 pathway within cells. In HEK-
293E cells transient overexpression of PRAS40, but not a control protein, blocks the insulin-
induced phosphorylation of T389 on co-expressed S6K1 (Figure 5A). Furthermore, co-
expression of PRAS40 with rheb1 eliminates the very large increase in S6K1 phosphorylation 
that is normally caused by the overexpression of rheb1 in HEK-293E and HEK-293T cells 
(Figure 5B). When stably overexpressed using retroviral transduction, PRAS40 reduces cell size 
in HEK-293E cells (Figure 5C). Moreover, stable overexpression of PRAS40 in TSC2 null MEFs 
reduces the enlarged cell phenotype of these cells (Figure 5C). Thus, as in vitro, PRAS40 
overexpression within cells strongly inhibits the mTORC1 pathway. 
 Because PRAS40 overexpression is sufficient to inhibit the mTORC1 pathway, we asked 
if endogenous PRAS40 normally has an inhibitory function within cells. Our expectation was 
that if PRAS40 plays a role in the mTORC1 pathway inhibition that occurs in insulin-deprived 
cells, a loss of PRAS40 expression should boost the phosphorylation state of S6K1 even in the 
absence of insulin. Indeed, using two independent PRAS40-directed lentivirally expressed 
shRNAs, knockdowns of PRAS40 in wild-type MEFs and in human HT-29 colon cancer cells 
increased the phosphorylation of S6K1 in serum-deprived cells (Figures 5D and 5E). The 
increase in S6K1 phosphorylation caused by the PRAS40 knockdown was not as great as that 
caused by insulin stimulation, but this is not surprising because in the absence of insulin cells are 
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missing the mTORC1-activating input coming from rheb. In addition, the mTORC1 and S6K1 
activation caused by the PRAS40 knockdown should trigger feedback inhibition of PI3K/Akt 
signaling, which will suppress rheb and thus limit mTORC1 activation. A knockdown of 
PRAS40 expression only slightly increased the phosphorylation of S6K1 in cells growing in the 
presence of insulin (Figure 5E), suggesting that insulin represses the inhibitory properties of 
PRAS40. 
 
Lobe is an inhibitor of the dTORC1 pathway in Drosophila cells 
The inhibitory function of PRAS40 on the mTORC1 pathway is conserved in Drosophila 
tissue culture cells. Transfection into S2 cells of two distinct non-overlapping RNAi-inducing 
dsRNAs against Lobe, the PRAS40 orthologue, increased dS6K phosphorylation and cell 
diameter, although not to as large of an extent as a dsRNA targeting dTSC2 (Figures 6AB). In 
Kc167 cells, the sequential knockdown of dTOR and then Lobe blocks the increase in dS6K 
phosphorylation caused by the solo knockdown of Lobe, consistent with Lobe being upstream of 
dTOR (Figure 6C). In contrast, Lobe function does not depend on dRheb, as the sequential 
knockdown of Lobe and then dRheb partially restores the levels of dS6K phosphorylation 
compared to cells having a knockdown of dRheb alone. Using cell size as a phenotype, we next 
used the most active Lobe dsRNA to place within the dTOR pathway Lobe with respect to 
dRheb and dTOR (Figure 6D). The sequential knockdown of dRheb and then Lobe did not alter 
the approximately 10% increase in mean cell volume caused by the knockdown of Lobe alone, 
which is consistent with Lobe function not depending on dRheb. On the other hand, the 
sequential knockdown of dRheb and then dTSC2 completely blocked the increase in cell size 
caused by the knockdown of dTSC2 alone, in accord with the established placement of dRheb 
downstream of dTSC2 (Gao et al., 2002; Saucedo et al., 2003; Stocker et al., 2003; Zhang et 
al., 2003). The sequential knockdown of dTOR and then either Lobe or dTSC2 eliminated the 
increase in cell size caused by the knockdown of Lobe or dTSC2 alone (Figure 6D). This is 
consistent with dTOR being downstream of both Lobe and dTSC2 and required for the cell size 
increases caused by the Lobe and dTSC2 knockdowns. We conclude that in mammalian and 
Drosophila cells PRAS40 negatively regulates the TORC1 pathway. 
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Akt/PKB-mediated phosphorylation of PRAS40 blocks its inhibitory activity towards 
mTORC1   
Insulin-stimulated activation of the in vitro kinase activity of mTORC1 correlates with an 
increase in the T246 phosphorylation of the PRAS40 bound to mTORC1, suggesting that this 
phosphorylation event may relieve the inhibitory action of PRAS40 on mTORC1 (Figures 1 and 
3G). As Akt/PKB is an insulin-stimulated kinase that phosphorylates PRAS40 on T246 
(Kovacina et al., 2003), we hypothesized that Akt/PKB activates mTORC1 by phosphorylating 
and suppressing PRAS40. The in vitro addition of active T308D Akt/PKB and ATP to mTORC1 
obtained from serum-deprived cells substantially increases mTORC1 kinase activity (Figure 7A). 
Consistent with a key role for PRAS40 in this activation, Akt/PKB does not activate mTORC1 
that has been washed with buffers containing high salt concentrations, conditions that strip off 
PRAS40 (Figure 3B). To directly test the role of PRAS40 phosphorylation on mTORC1 activity, 
we generated phosphorylated PRAS40 by incubating it with active Akt/PKB and ATP. As a 
control we mock phosphorylated PRAS40 by incubating it with active Akt/PKB in the absence 
of ATP. As before (Figure 4A), the addition of 40 nM non-phosphorylated PRAS40 strongly 
inhibited the activity of mTORC1 washed with buffers containing high salt concentrations while, 
in contrast, the equivalent amount of phosphorylated PRAS40 had a much reduced inhibitory 
effect (Figure 7B). These results suggest that although 14-3-3 proteins interact with 
phosphorylated PRAS40 (Kovacina et al., 2003), the binding of 14-3-3 to PRAS40 is not 
necessary to repress the inhibitory function of PRAS40 on the in vitro kinase activity of 
mTORC1. Of course, it is possible that 14-3-3 does have a necessary role within cells that we do 
not detect in vitro. 
 To confirm the role of PRAS40 phosphorylation in regulating mTORC1 within cells, we 
co-expressed in HEK-293E cells an HA-GST-S6K1 reporter together with low amounts of wild-
type or T246A mutant PRAS40 and stimulated the cells with insulin (Figure 7C). As expected, 
insulin strongly boosted the T389 phosphorylation of the S6K1 reporter and the low amounts of 
co-expressed wild-type PRAS40 only weakly diminished this phosphorylation. On the other 
hand, the expression of the T246A mutant of PRAS40, completely blocked insulin stimulated 
phosphorylation of T389 of S6K1 (Figure 7C). We obtained equivalent results in a conceptually 
similar experiment in which we used the expression of constitutively active Akt/PKB (myr-Akt) 
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instead of insulin to promote S6K1 phosphorylation (Figure 7D). As with insulin, the expression 
of low amounts of T246A, but not wild-type, PRAS40 mutant blocked the increase in T389 
phosphorylation caused by the expression of constitutively active Akt/PKB. Thus, both in vitro 
and within cells, Akt/PKB mediated phosphorylation of PRAS40 represses its inhibitory 
function. 
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Discussion 
A frustrating aspect of studying mTORC1 has been the difficulty of preserving its regulation in 
vitro. Even when isolated from cells with vastly different levels of mTORC1 signaling (like 
serum deprived and insulin stimulated cells), the mTORC1 obtained through most purification 
protocols exhibits at best modest differences in mTORC1 kinase activity. Using a newly 
developed purification protocol and mTORC1 kinase assay, we provide two findings that help 
explain this discrepancy. First, the in vitro addition of soluble rheb1-GTP to mTORC1 
dramatically activates mTORC1 kinase activity, but even the gentlest purification schemes do 
not preserve the interaction between endogenous mTORC1 and rheb. Therefore, in cellular states 
where rheb plays a major role in activating the mTORC1 pathway—like in insulin stimulated 
cells—the in vitro kinase activity of mTORC1 will be artificially low and not reflect true 
mTORC1 activity within cells. Second, we identify PRAS40 as a raptor-binding protein that 
inhibits mTORC1 activity in vitro and mTORC1 signaling within cells. PRAS40 is largely lost 
from mTORC1 under purification conditions in which its core, evolutionarily-conserved 
components—mTOR, raptor, and mLST8/GbL—remain together. Thus, as PRAS40 negatively 
regulates the mTORC1 kinase, its loss artifactually increases the in vitro activity of mTORC1 
from insulin-deprived cells.  
The fact that both PRAS40 and rheb-GTP strongly regulate mTORC1 activity raises the 
question of which protein is the predominant regulator of mTORC1 in cells. Our overexpression 
and in vitro work shows that either regulator is capable of overcoming the effects of the other. 
However, in normal cells insulin-stimulated Akt/PKB signaling aligns the activities of PRAS40 
and rheb so that both push mTORC1 activity in the same direction (Figure 7E). That is, in insulin 
treated cells, phosphorylated PRAS40 does not repress mTORC1 while GTP-loaded rheb 
activates it. In serum-deprived cells, dephosphorylated PRAS40 represses mTORC1 while GDP-
loaded rheb does not activate it. So far, we know of only one signaling state, that of TSC2 null 
MEFs, in which PRAS40 and rheb push mTORC1 activity in opposite directions (Figure 7E). In 
these cells, rheb is constitutively loaded with GTP while PRAS40 is in its dephosphorylated 
inhibitory state because of suppressed insulin signaling. The high and constitutive activity of 
mTORC1 within TSC2 null MEFs indicates that hyperactive rheb can overcome PRAS40-
mediated inhibition of mTORC1. Interestingly, the battle between PRAS40 and rheb1-GTP can 
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be observed in vitro. The kinase activity of mTORC1 purified from TSC2 null MEFs under 
conditions that preserve the PRAS40 interaction is very low, but can be activated by the in vitro 
addition of rheb1-GTP or removal of PRAS40.  
The relative strengths of the rheb and PRAS40 inputs to the mTORC1 pathway may vary 
in different cell types depending on the activity and abundance of each protein. In the serum-
deprived cells we have examined, partial depletion of PRAS40 has modest activating effects on 
the mTORC1 pathway, presumably because in the absence of insulin the positive signal from 
rheb to mTORC1 is missing. Although our work has focused on the coordinated regulation of 
rheb and PRAS40 by insulin, it is likely that pathways exist that can signal to PRAS40 and rheb 
independently, allowing cells to fine tune mTORC1 activity to specific environmental 
conditions.  
A recent parallel study also identifies PRAS40 as an mTORC1 interacting protein (Haar 
et al., 2007) and focuses on its role in modulating the feedback loop between mTORC1 and the 
IRS/PI3K pathway. While this study shows that PRAS40 suppresses mTORC1 signaling within 
cells, our in vitro data reveals that PRAS40 is a direct inhibitor of the mTORC1 kinase and that it 
antagonizes the activation of mTORC1 caused by rheb1-GTP. We also come to differing 
conclusions on a number of important points. First, a key question is whether PRAS40 or rheb1 
plays the dominant role in establishing mTORC1 activity within cells. Haar et al. conclude from 
experiments based on tissue culture cells that PRAS40 has dominant effects over the 
TSC1/TSC2-rheb axis. However, our results with TSC2-null MEFs and in vitro kinase assays 
suggest that the situation is more complicated, and that either component can overcome the 
effects of the other when sufficiently activated. Second, our in vitro data suggests that 14-3-3 
binding is not required for the Akt/PKB mediated repression of PRAS40, though we 
acknowledge that 14-3-3 may play a role in insulin stimulation of mTORC1 within cells. Third, 
Haar et al. describe PRAS40 as an mTOR-binding protein, but we find clear evidence for 
preferential binding to raptor, a result that is more consistent with the finding that PRAS40 binds 
only to mTORC1. Fourth, we have been unable to observe any effect of amino acid signaling on 
the mTORC1-PRAS40 interaction, and suspect that different cell lysis conditions between our 
two studies accounts for this discrepancy. In contrast to our previous work (Kim et al., 2002), we 
have now developed mild lysis and purification conditions under which the integrity of the 
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mTOR-raptor interaction is not affected by changes in environmental leucine levels. Haar et al. 
do not examine the effects of leucine on PRAS40 phosphorylation and we believe that the 
leucine-induced decrease in the amount of PRAS40 recovered in mTOR immunoprecipitates 
correlates with a similar decrease in the amount of raptor bound to mTOR. 
Given the complexity of the mTORC1 pathway and the presence of feedback loops 
between components, it is likely that a full understanding of the physiologic consequences of 
altering the rheb-PRAS40 balance will require the development of animal models overexpressing 
or missing these proteins.  
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Materials and Methods 
Materials 
Reagents were obtained from the following sources: antibodies to raptor, human 
PRAS40, and multi species phospho-T246 PRAS40, as well as GTPgS, GDP and T308D 
Akt/PKB from Upstate/Millipore; an antibody to mouse PRAS40 from Biosource; antibodies to 
mTOR, b-catenin, and S6K1 as well as HRP-labeled anti-mouse, anti-goat, and anti-rabbit 
secondary antibodies from Santa Cruz Biotechnology; antibodies to phospho-T389 S6K1, 
phospho-T37/T46 4E-BP1, phospho-S473 Akt/PKB, phospho-T398-dS6K, phospho-S505 dAkt, 
Akt (pan), 4E-BP1, and the myc epitope from Cell Signaling Technology; an antibody to HA 
from Bethyl laboratories; FLAG M2 affinity gel, FLAG M2 antibody, ATP, and human 
recombinant insulin from Sigma Aldrich; protein G-sepharose and immobilized glutathione from 
Pierce; DMEM from SAFC Biosciences; LY294002 from Calbiochem; PreScission protease 
from Amersham Biosciences; FuGENE 6 and Complete Protease Cocktail from Roche; 4E-BP1 
from A.G. Scientific; and SimplyBlue Coomassie G, Schneider's medium, Drosophila-SFM, and 
Inactivated Fetal Calf Serum (IFS) from Invitrogen. The dS6K antibody was a generous gift 
from Mary Stewart (North Dakota State University). 
 
Cell Lines and Tissue Culture 
The HEK-293E cell line was kindly provided by John Blenis (Harvard Medical School).  
p53-/-/TSC2-/- as well as p53-/-/TSC2+/+ mouse embryonic fibroblasts (MEFs) were kindly 
provided by David Kwiatkowski (Harvard Medical School).  Cell lines were cultured in the 
following media: HEK-293E, HEK-293T, HeLa, and HT-29 cells and MEFs in DMEM with 
10% IFS. HEK-293E and HEK-293T cells express E1a and SV40 large T antigen, respectively. 
In HEK-293E, but not HEK-293T, cells the mTORC1 pathway is strongly regulated by serum 
and insulin.  
 
Cell Lysis and Immunoprecipitations 
Cells rinsed once with ice-cold PBS were lysed in ice-cold lysis buffer (40 mM HEPES 
[pH 7.4], 2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 0.3% CHAPS, and 
one tablet of EDTA-free protease inhibitors (Roche) per 25 ml).  The soluble fractions of cell 
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lysates were isolated by centrifugation at 13,000 rpm for 10 min in a microcentrifuge.  For 
immunoprecipitations, primary antibodies were added to the lysates and incubated with rotation 
for 1.5 hours at 4°C. 60 ml of a 50% slurry of protein G-sepharose was then added and the 
incubation continued for an additional 1 hour.  Immunoprecipitates were washed three times 
each with low salt wash buffer (40 mM HEPES [pH 7.4], 150 mM NaCl, 2 mM EDTA, 10 mM 
pyrophosphate, 10 mM glycerophosphate, 0.3% CHAPS). When specified, wash buffers 
contained the indicated increased concentrations of NaCl. Immunoprecipitated proteins were 
denatured by the addition of 20 ml of sample buffer and boiling for 5 minutes, resolved by 8%–
16% SDS-PAGE, and analyzed by immunoblotting as described (Kim et al., 2002).  
 
In Vitro Kinase Assay for mTORC1 Activity 
For kinases assays, immunoprecipitates were washed 3 times in low salt wash buffer, or 
once in low salt wash buffer followed by two additional washes in buffers containing the NaCl 
concentrations indicated in the figures.  Immunoprecipates were then washed twice in 25 mM 
HEPES [pH 7.4], 20 mM potassium chloride. Kinase assays were performed for 20 min at 30°C 
in a final volume of 15 ml consisting of mTORC1 kinase buffer (25 mM Hepes [pH 7.4], 50 mM 
KCl, 10 mM MgCl2, 250 mM ATP) and 150 ng inactive S6K1 or 4E-BP1 as the substrate. 
Reactions were stopped by the addition of 30 ml of sample buffer and boiling for 5 min and 
analyzed by SDS-PAGE and immunoblotting. Note: the kinase assay buffer used in this work 
does not contain manganese, which is present in buffers we have used previously (Kim et al., 
2002). PRAS40, tubulin, rheb1, or rap2a were added to mTORC1 for 5-20 minutes before the 
addition of ATP to the kinase assay.  
 
Preparation of S6K1, PRAS40, phosphorylated PRAS40, rheb1, rap2a, and a-tubulin for 
Use in mTORC1 Kinase Assays 
Full-length rat p70 S6K1 was cloned into an HA-GST pRK5 vector modified so as to 
contain a PreScission protease site between the GST tag and the initiator codon of S6K1.   The 
expression construct was transfected into HEK-293T cells using Fugene6 and, after 48 hours, the 
cells were treated with 20 mM LY294002 for 1 hour prior to cell harvesting and lysis.   HA-
GST-PreSciss-S6K1 was purified as described (Burnett et al., 1998), and the affinity tag 
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removed with the PreScission protease.  S6K1 was separated from free GST by gel filtration on a 
HiLoad 16/60 Superdex 200 column (Amersham) and the purified protein stored at -80°C in 
20% glycerol.  
Rheb1 or rap2a cDNAs in HA-GST-prk5 were transfected as above into HEK-293T cells. 
Cell were lysed with rheb lysis buffer (the lysis buffer used above but without EDTA and 
containing 5 mM MgCl2) and cleared lysates were incubated with immobilized glutathione for 2 
hours at 4°C. Beads were washed twice with rheb lysis buffer and once with rheb storage buffer 
(20 mM Hepes [pH 8.0], 200 mM NaCl, and 5 mM MgCl2). GST-rheb1 and rap2a were eluted 
from the beads with 10 mM glutathione in rheb storage buffer. Eluted proteins were incubated 
with 10 mM EDTA and 1 mM GDP or 0.1 mM GTPgS at 30°C for 10 min. 20 mM MgCl2 was 
then added and the proteins kept on ice until use. PRAS40 or a-tubulin cDNAs in flag-prk5 were 
transfected into HEK-293T cells, the cells treated with 20 mM LY294002 for 15 min prior to 
lysis, and the proteins purified using immobilized FLAG-antibody resin. Proteins were eluted 
from the resin with rheb storage buffer containing 50 mg/ml flag peptide, and stored on ice until 
use. In the experiments using PRAS40 phosphorylated by Akt/PKB, flag-PRAS40 still bound to 
the FLAG-antibody resin was incubated for 30 minutes at 30°C in mTORC1 kinase assay buffer 
containing 400 ng of T308D Akt/PKB in the presence or absence of 500 mM ATP. The resin-
bound flag-PRAS40 was then washed three times with mTORC1 kinase assay buffer and eluted 
as above and stored on ice until use. 
 
Mass Spectrometric Analysis 
mTOR and raptor immunoprecipitates prepared from 30 million HEK-293E cells were 
resolved by SDS-PAGE and the Coomassie stained 40 kDa band corresponding to PRAS40 was 
excised and digested with trypsin overnight.  The resulting peptides were separated by liquid 
chromatography (NanoAcquity UPLC, Waters) using a self-packed Jupiter 3 micron C18 
column. The eluting peptides were mass analyzed prior to collisionally induced dissociation 
(CID) using a ThermoFisher LTQ linear ion trap mass spectrometer equiped with a nanospray 
source. Selected mass values from the MS/MS spectra were used to search the human segment of 
the NCBI non-redundant protein database using Xcalibur Mass Spectrometry software (Thermo 
	   77 
Fischer Scientific). Depending on the purification, 2-6 distinct PRAS40-derived peptides were 
identified. 
 
Cell Size Determinations 
To measure cell size, cells were grown to confluence in 6 cm culture dishes, harvested, 
diluted 1:10, and re-plated into fresh media.  12 hours later the cells were harvested by 
trypsinization in a 1 ml volume, diluted 1:20 with counting solution (Isoton II Diluent, Beckman 
Coulter), and cell diameters and volumes determined using a particle size counter (Coulter Z2, 
Beckman Coulter) with Coulter Z2 AccuComp software. 
 
cDNA Manipulations, Mutagenesis, and Sequence Alignments as well as Drosophila and 
Mammalian RNAi and Analysis 
 The cDNA for PRAS40 (NCBI gene symbol: AKT1S1) was obtained from Origene. The 
PRAS40 cDNA were amplified by PCR using pCMV6-XL5 as a template and the product 
subcloned into the Sal 1 and Not 1 sites of pRK5, the Xho I and Not I sites of MSCV, and the Sal 
I and Not 1 sites of flag-prk5. All constructs were verified by DNA sequencing. The PRAS40 
cDNA in pRK5 was mutagenized using the QuikChange XLII mutagenesis kit (Stratagene) with 
oliogonucleotides obtained from Integrated DNA Technologies.  NCBI Blosum62 Blast searches 
were used to identify blocks of similar sequence between PRAS40 orthologues. 
 
Mammalian lentiviral shRNAs 
Lentiviral shRNAs to human raptor and mTOR were previously described (Sarbassov et 
al., 2005).  All other shRNA were obtained from the collection of The RNAi Consortium (TRC) 
at the Broad Institute (Moffat et al., 2006).   These shRNAs are named with the numbers found at 
the TRC public website 
(http://www.broad.mit.edu/genome_bio/trc/publicSearchForHairpinsForm.php):  
Mouse raptor shRNA: TRCN0000077472; NM_028898.1-3729s1c1 
Mouse PRAS40 #1 shRNA: TRCN0000181472; NM_026270.1-865s1c1  
Mouse PRAS40 #2 shRNA: TRCC0001186119; NM_032375.2-1425 
Human PRAS40 #1 shRNA: TRCC0001186123; NM_032375.2-1254 
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Human PRAS40 #2 shRNA: TRCN0000165801; NM_032375.2-1279s1c1  
shRNA-encoding plasmids were co-transfected with the Delta VPR envelope and CMV 
VSV-G packaging plasmids into actively growing HEK-293T using FuGENE 6 transfection 
reagent as previously described (Ali and Sabatini, 2005; Sarbassov et al., 2005). Virus-
containing supernatants were collected at 48 hours after transfection, filtered to eliminate cells, 
and target cells infected in the presence of 8 mg/ml polybrene.  24 hours later, cells were selected 
with puromycin and analyzed on the 2nd or 3rd day after infection.  
 
Drosophila RNAi and Analysis 
Design and synthesis of dsRNAs: 
The control GFP dsRNA has been described (Sarbassov et al., 2004). Other dsRNAs were 
designed to target all known transcripts of the target Drosophila gene. In order to minimize off-
target effects, we used the DRSC tool at http://flyrnai.org/RNAi_find_frag_free.html and 
excluded regions of 19-mer-or-greater identity to any Drosophila transcripts. Synthesis of 
dsRNAs was performed as previously described (Sarbassov et al., 2004).  
 
Primer sequences (including underlined 5' and 3' T7 promoter sequences):  
Lobe dsRNA #1 forward primer:  
GAATTAATACGACTCACTATAGGGAGAGCAGGTGTTCCAGCAGAAGTAT 
Lobe dsRNA #1 reverse primer: 
GAATTAATACGACTCACTATAGGGAGAGTGCAGTTGATGAGGTAGAGAGTG 
Lobe dsRNA #2 forward primer: 
GAATTAATACGACTCACTATAGGGAGATAAATTAGTTGCTCAACGAAACAAG 
Lobe dsRNA #2 reverse primer: 
GAATTAATACGACTCACTATAGGGAGAAGTTAGTTAACTCAATGTGCAACAGC 
dRheb dsRNA forward primer: 
GAATTAATACGACTCACTATAGGGAGA AAATCGTCGCTATGCATACAGTT 
dRheb dsRNA reverse primer: 
GAATTAATACGACTCACTATAGGGAGAAGACTTTTGGCTGGTTATCGAGT 
dTOR dsRNA forward primer:  
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GAATTAATACGACTCACTATAGGGAGAATTTGAAAAACGAGCTAACACAGTC 
dTOR dsRNA reverse primer: 
GAATTAATACGACTCACTATAGGGAGAGTACTTCAGCCAGGTATGTATGTCC 
dTSC2 dsRNA forward primer: 
GAATTAATACGACTCACTATAGGGAGATACCCCCTACCTTGACATTCTG 
dTSC2 dsRNA reverse primer:  
GAATTAATACGACTCACTATAGGGAGAATATTGCTAACGATCGAGGACATT 
 
dsRNA transfection and Drosophila cell culture:   
 Kc167 were seeded in 6-well dishes at 2 X 106 cells per well and grown in Schneider's 
medium plus 10% IFS. S2 cells were seeded in 6-well dishes at 1 X 106 cells per well and grown in 
Drosophila-SFM. For single-knockdown immunoblot experiments, dsRNAs were transfected only 
once at 1 mg/million cells. Media was refreshed at 24 hours post-transfection and cell lysates were 
prepared 43 hours post-transfection. For single-knockdown cell size experiments, dsRNAs were 
transfected on three successive days at 1 mg/million cells, and cell sizes were measured 24 hours 
after the final transfection. For sequential-knockdown experiments, the first dsRNA was transfected 
on days 1-4 at 1 mg/million cells, and the second dsRNA was transfected on days 3-4 at 2 
mg/million cells. Media was refreshed prior to transfections on day 3. Cell lysates were prepared 36 
hours following the final transfection and cell sizes were measured 24 hours following the final 
transfection. Transfection and cell lysis conditions were previously described (Sarbassov et al., 
2004). 
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Figure 1 
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Figure 1. A salt-sensitive factor inhibits the kinase activity of mTORC1. (A) When mTORC1 is 
washed with buffers containing high salt concentrations, there is no difference in the kinase 
activity of mTORC1 isolated from serum-deprived or insulin treated cells. HEK-293E cells were 
deprived of serum for 14 hours or serum-deprived and treated with 150 nM insulin for 15 
minutes. mTOR immunoprecipitates were prepared from cell lysates (1 mg total protein), washed 
with buffers containing 500 mM NaCl, and analyzed for mTORC1 kinase activity towards S6K1 
and levels of mTOR and raptor. Lysates were analyzed by immunoblotting for indicated proteins 
and phosphorylation states. (B) An insulin-stimulated difference in mTORC1 activity is detected 
only when mTORC1 is washed with low salt buffers. mTOR immunoprecipitates from HEK-
293E cells treated as in (A) were washed with buffers containing 400, 300, or 150 mM NaCl and 
analyzed for mTORC1 kinase activity. (C) Raptor immunoprecipitates were prepared from 
indicated cell types that had been serum deprived and treated with insulin as in (A), washed with 
buffers containing 150 mM NaCl, and analyzed for mTORC1 activity. Cell lysates were 
analyzed by immunoblotting for levels of indicated proteins. (D) HA-immunoprecipitates from 
HEK-293E cells stably expressing HA-raptor were prepared and analyzed for mTORC1 activity 
as in (C). (E) Raptor-immunoprecipitates from TSC2-/- or TSC2+/+ MEFs treated as in (A) were 
washed with buffers containing 150 mM or 500 mM NaCl and analyzed for mTORC1 activity. 
Cell lysates were analyzed by immunoblotting for levels of indicated proteins and 
phosphorylation states. 
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Figure 2 
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Figure 2. In vitro soluble rheb1-GTP strongly stimulates mTORC1 kinase activity towards S6K1 
and 4E-BP1. (A) Rheb1, rap2a, or material obtained in mock purifications were loaded with 
GDP or the non-hydrolyzable GTP-mimetic GTPgS and added to mTORC1 immunopurified 
from serum-deprived HEK-293E cells. mTORC1 kinase assays were performed and analyzed by 
immunoblotting for indicated proteins and phosphorylation states. (B) Experiment was 
performed as in (A) using mTORC1 from both serum-deprived and insulin-treated cells. (C) 
Experiment was performed as in (A) using mTORC1 containing HA-raptor. (D) Experiment was 
performed as in (A) using mTORC1 obtained from TSC2-/- MEFs. (E) Experiment was 
performed as in (B) using 4E-BP1 as a substrate.	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Figure 3 
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Figure 3. PRAS40 is an mTORC1 interacting protein. (A) Schematic of PRAS40 indicating the 
C-terminal domain conserved with the Drosophila Lobe protein (LCD) and the proline-rich 
regions (P). Below the PRAS40 schematic is an amino acid sequence alignment of the LCD of 
PRAS40 orthologues from indicated species showing that the T246 Akt/PKB phosphoryation 
site is conserved. (B) In HEK-293E cells the interaction of PRAS40 with mTORC1 is regulated 
by insulin and disrupted in vitro by high salt containing buffers. Raptor or p53 
immunoprecipitates were prepared from HEK-293E cells deprived of serum for 14 hours or 
serum-deprived and treated with 150 nM insulin for 15 minutes. Immunoprecipitates were 
washed with buffers containing 400 or 150 mM NaCl, and analyzed by immunoblotting for 
indicated proteins. In cell lysates levels of PRAS40 do not change upon insulin stimulation. (C) 
PRAS40 binds to mTORC1 and not mTORC2. Raptor and rictor immunoprecipitates were 
prepared from HEK-293E cells treated with insulin as in (B), washed with buffers containing 
150 mM NaCl, and analyzed by immunoblotting for the indicated proteins. (D) Endogenous 
PRAS40 binds to mTORC1 containing recombinant epitope-tagged raptor. Flag-
immunoprecipitates from HEK-293E cells expressing flag-raptor or a control vector and treated 
as in (C) were prepared and washed with buffers containing 150 mM NaCl and analyzed by 
immunoblotting for the indicated proteins. (E) PRAS40 preferentially binds the raptor 
component of mTORC1. Indicated cDNAs in expression vectors were co-transfected in HEK-
293E cells and cell lysates prepared. Half of each cell lysate was used to prepare HA-
immunoprecipitates and the other half for myc-immunoprecipitates. Both were analyzed by 
immunoblotting for the indicated proteins. Cell lysates contain equal levels of flag-PRAS40. 
Samples in which cDNAs for raptor and mTOR were co-transfected were performed in 
duplicate. (F) PRAS40 association with mTORC1 requires raptor. HEK-293E cells were infected 
with the specified lentiviral shRNAs and mTOR and raptor immunoprecipitates were analyzed 
by immunoblotting for the levels of the indicated proteins. (G) In HEK-293E and HeLa cells and 
wild-type, but not TSC2 null MEFs, insulin stimulates the phosphorylation of the PRAS40 
bound to mTORC1. Cells were treated with and without insulin as in (B). Raptor 
immunoprecipitates and cell lysates were analyzed for the levels of the indicated proteins and 
phosphorylation states.  
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Figure 4 	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Figure 4. In vitro PRAS40 potently inhibits mTORC1 kinase activity induced by insulin or 
GTP-loaded rheb1. (A) PRAS40 inhibits mTORC1 activated by washing in high salt-containing 
buffers. HA-raptor immunoprecipitates were prepared from HEK-293E cells stably expressing 
HA-raptor deprived of serum for 14 hours or serum-deprived and treated with 150 nM insulin for 
20 minutes. Immunoprecipitates were washed with buffers containing 150, or where indicated, 
500 mM NaCl. mTORC1 kinase assays containing the specified concentrations of PRAS40 or 
tubulin were performed and analyzed by immunoblotting for the indicated proteins and 
phosphorylation states. (B) PRAS40 inhibits active mTORC1 isolated from insulin-stimulated 
HEK-293E cells. Experiment was performed and analyzed as in (A) except that all 
immunoprecipitates were washed with buffers containing 150 mM NaCl. (C) PRAS40 blocks 
mTORC1 activation induced by GTP-loaded rheb1. Experiment was performed and analyzed as 
in (A) except that all immunoprecipitates were from serum-deprived cells and washed with 
buffers containing 150 mM NaCl. Kinase assays contained 100 nM rheb1 or rap2a loaded with 
GDP or GTP. (D) PRAS40 blocks, in a dose sensitive fashion, mTORC1 activation induced by 
GTP-loaded rheb1. Experiment was performed and analyzed as in (C) using indicated 
concentrations of rheb1-GTP and PRAS40. (E) At high ratios of rheb1-GTP to PRAS40, rheb1-
GTP can overcome PRAS40-mediated suppression of mTORC1. Experiment was performed and 
analyzed as in (D). (F) PRAS40 inhibits mTORC1 activity towards 4E-BP1. Experiment was 
performed as in (B) using mTORC1 obtained from insulin-stimulated cells and 4E-BP1 as the 
substrate. 
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Figure 5 
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Figure 5. In mammalian cells PRAS40 inhibits mTORC1 signaling and cell growth. (A) 
Overexpression of PRAS40 inhibits insulin-mediated phosphorylation of S6K1. HEK-293E cells 
were co-transfected with expression plasmids for HA-GST-S6K1 (500 ng) as well as myc-
tubulin or myc-PRAS40 (2 mg), serum deprived for 14 hours or serum deprived and treated with 
150 nM insulin for 15 minutes. Cell lysates were analyzed by immunoblotting for the levels of 
the indicated proteins and phosphorylation states. (B) Overexpression of PRAS40 inhibits the 
large increase in S6K1 phosphorylation caused by the overexpression of rheb1. HEK-293E cells 
were co-transfected with expression plasmids for HA-GST-S6K1 (500 ng) and 2 mg of the other 
specified plasmids. In HEK-293T cells 50 ng was used of the HA-GST-S6K1 expression plasmid 
and 1 mg of the other plasmids. Cell lysates were prepared and analyzed by immunoblotting for 
the levels of the indicated proteins and phosphorylation states. (C) Stable overexpression of 
PRAS40 inhibits cell size. HEK-293E cells or TSC2 null MEFs were infected with retroviruses 
expressing PRAS40 or tubulin and, 48 hours later, cell size was measured using a Coulter 
counter. (D) Validation of shRNAs directed against human or mouse PRAS40. HT-29 cells or 
wild-type MEFs were infected with lentiviruses expressing shRNAs targeting mouse or human 
PRAS40, respectively, and cell lysates analyzed by western blotting for the indicated proteins. 
Control shRNAs targeted raptor or luciferase. (E) Knockdown of endogenous PRAS40 activates 
the mTORC1 pathway. Wild-type MEFs or HT-29 cells infected with lentiviruses expressing 
shRNAs targeting the indicated genes were incubated in the presence or absence of serum for 3 
hours. Cell lysates were analyzed by immunoblotting for the levels of the indicated proteins and 
phosphorylation states. 
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Figure 6 
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Figure 6. In Drosophila cells Lobe inhibits dTORC1 signaling and cell growth. (A) A 
knockdown of Lobe using two distinct dsRNAs increases dS6K phosphorylation. S2 cells were 
transfected with the indicated dsRNAs as described in the Experimental Procedures. (B) A 
knockdown of Lobe increases the mean size of S2 cells. Cells were transfected as in (A) with the 
GFP, Lobe #1, Lobe #2, or dTSC2 dsRNAs and cell size measured with a Coulter counter. Mean 
cells diameters ± standard error for n = 3 are: GFP dsRNA, 10.71 ± 0.02 mm; Lobe #1 dsRNA, 
10.98 ± 0.03 mm; Lobe #2 dsRNA, 10.95 ± 0.04 mm; dTSC2 dsRNA, 11.26 ± 0.02 mm. The 
differences in cell diameter between cells transfected with the GFP dsRNA and the Lobe or 
dTSC2 dsRNAs is significant to at least p < 0.05. For clarity, histogram shows data for only one 
of the Lobe dsRNAs. (C) A Lobe knockdown suppresses the decrease in dS6K-phosphorylation 
caused by a knockdown of dRheb but not of dTOR. Kc167 cells were transfected as described in 
the Experimental Procedures. Cell lysates were analyzed with immunoblotting for the levels and 
phosphorylation states of the indicated proteins. (D) A knockdown of Lobe increases S2 cell size 
in a dTOR-dependent but dRheb-independent fashion. Cells were transfected as in (C) with the 
indicated dsRNAs and cell sizes were measured 24 hours after the final transfection. Cell 
volumes were normalized within each group of three in order to compare the cell volume 
changes that occur when Lobe or dTSC2 is knocked down alone or together with dRheb or 
dTOR. Error bars indicate standard deviations for n = 3. 	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Figure 7 
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Figure 7. Akt/PKB-mediated phosphorylation of PRAS40 blocks its inhibition of mTORC1. (A) 
The addition of active T308D Akt/PKB stimulates the kinase activity of mTORC1 washed with 
low but not high salt buffers. Raptor immunoprecipitates from serum-deprived cells were washed 
with buffers containing 150 or 500 mM NaCl as described in the Experimental Procedures. 
mTORC1 kinase activity in the immunoprecipitates was assayed in the presence or absence of 
400 ng active Akt/PKB and levels and phosphorylation state of S6K1 was analyzed by 
immunoblotting. (B) PRAS40 phosphorylated by Akt/PKB has a reduced capacity to inhibit 
mTORC1. 40 nM of non-phosphorylated or phosphorylated PRAS40 was added to mTORC1 
immunoprecipitates washed with high salt. Kinase assays were performed and analyzed by 
immunoblotting for the levels of the indicated proteins and phosphorylation states. (C) 
Expression of T246A PRAS40 blocks insulin-stimulated phosphorylation of S6K1. HEK-293E 
were co-transfected with expression plasmids for HA-GST-S6K1 (500 ng) as well as low (25 ng) 
or high (250 ng) amounts of expression plasmids for wild-type or T246A myc-PRAS40. 250 ng 
was used of the plasmid encoding myc-tubulin. Cells were deprived of serum or serum-deprived 
and stimulated with 150 nM insulin for 20 minutes. Cell lysates were analyzed by 
immunoblotting for the levels of the indicated proteins and phosphorylation states. (D) 
Expression of T246A PRAS40 blocks phosphorylation of S6K1 induced by the expression of 
constitutively active myristoylated Akt/PKB (myr-Akt). HEK-293E cells were co-transfected 
and analyzed as above except that 2 mg of the expression plasmid for myr-Akt was included 
were indicated. The increasing amounts of PRAS40 expression vectors used were: 3, 10, 30, 100, 
and 300 ng. (E) Models depicting regulation of mTORC1 signaling by rheb and PRAS40 in 
insulin treated (+Insulin), serum deprived (-Insulin), and TSC2 null (TSC2-/-) cells. Green and 
red colors indicate active and inactive components and signaling events, respectively. In insulin 
treated cells, GTP-loaded rheb stimulates mTORC1 while phosphorylated PRAS40 does not 
repress mTORC1. In serum-deprived cells, GDP-loaded rheb is inactive while dephosphorylated 
PRAS40 represses mTORC1. In TSC2 null cells GTP-loaded rheb overcomes the mTORC1 
inhibition mediated by dephosphorylated PRAS40. 
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Summary 
 
The multiprotein mTORC1 protein kinase complex is the central component of a pathway 
that promotes growth in response to insulin, energy levels, and amino acids, and is deregulated in 
common cancers. We find that the Rag proteins—a family of four related small guanosine 
triphosphatases (GTPases)—interact with mTORC1 in an amino acid sensitive manner and are 
necessary for the activation of the mTORC1 pathway by amino acids. A Rag mutant that is 
constitutively bound to GTP interacted strongly with mTORC1 and its expression within cells 
made the mTORC1 pathway resistant to amino acid deprivation. Conversely, expression of a 
GDP-bound Rag mutant prevented stimulation of mTORC1 by amino acids. The Rag proteins do 
not directly stimulate the kinase activity of mTORC1, but, like amino acids, promote the 
intracellular localization of mTOR to a compartment that also contains its activator Rheb. 
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Introduction 
 
The mTOR Complex 1 (mTORC1) branch of the mammalian target of rapamycin 
(mTOR) pathway is a major driver of cell growth in mammals and is deregulated in many 
common tumors (Guertin and Sabatini 2007). It is also the target of the drug rapamycin, which 
has generated considerable interest as an anticancer therapy. Diverse signals regulate the 
mTORC1 pathway, including insulin, hypoxia, mitochondrial function, and glucose and amino 
acid availability. Many of these are integrated upstream of mTORC1 by the Tuberous Sclerosis 
Complex (TSC1-TSC2) tumor suppressor, which acts as an important negative regulator of 
mTORC1 through its role as a GTPase activating protein (GAP) for Rheb, a small guanosine 
triphosphate (GTP)-binding protein that potently activates the protein kinase activity of 
mTORC1 (Sarbassov et al., 2005a). Loss of either TSC protein causes hyperactivation of 
mTORC1 signaling even in the absence of many of the upstream signals that are normally 
required to maintain pathway activity. A notable exception is the amino acid supply, as the 
mTORC1 pathway remains sensitive to amino acid starvation in cells lacking either TSC1 or 
TSC2 (Byfield et al., 2005; Nobukuni et al., 2005; Smith et al., 2005)  
The mechanisms through which amino acids signal to mTORC1 remain mysterious. It is 
a reasonable expectation that proteins that signal the availability of amino acids to mTORC1 are 
also likely to interact with it, but so far no good candidates have been identified. Because most 
mTORC1 purifications rely on antibodies to isolate mTORC1, we wondered if in previous 
work antibody heavy chains obscured, during SDS-PAGE analysis of purified material, 
mTORC1-interacting proteins of 45-55 kD. Indeed, using a purification strategy that avoids 
this complication  (materials and methods), we identified the 44 kD RagC protein as co-
purifying with overexpressed raptor, the defining component of mTORC1 (Hara et al., 2002; 
Kim et al., 2002; Loewith et al., 2002; Wedaman et al., 2003) 
RagC is a Ras-related small GTP-binding protein and one of four Rag proteins in 
mammals (RagA, RagB, RagC, RagD). RagA and RagB are very similar to each other and are 
orthologues of budding yeast Gtr1p whereas RagC and RagD are similar and are orthologues 
of yeast Gtr2p (Bun-Ya et al., 1992; Hirose et al., 1998; Schurmann et al., 1995). In yeast and 
in human cells the Rag and Gtr proteins function as heterodimers consisting of one Gtr1p-like 
	   102 
(RagA or RagB) and one Gtr2p-like (RagC or RagD) component (Nakashima et al., 1999; 
Sekiguchi et al., 2001). The finding that RagC co-purifies with raptor was intriguing to us 
because in yeast Gtr1p and Gtr2p regulate the intracellular sorting of the Gap1p amino acid 
permease (Gao and Kaiser, 2006) and microautophagy (Dubouloz et al., 2005), processes 
modulated by amino acid levels and the TOR pathway (Chen and Kaiser, 2003; Kunz et al., 
2004; Roberg et al., 1997). The Gtr proteins have been proposed to act downstream or in parallel 
to TORC1 in yeast because their overexpression induces microautophagy even in the presence of 
rapamycin, which normally suppresses it (Dubouloz et al., 2005). 
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Results 
Rag heterodimers interact with mTORC1 in a fashion that depends on the nucleotide 
binding state of RagB 
To verify our identification of RagC as an mTORC1 interacting protein, we expressed 
raptor with different pairs of Rag proteins in human embryonic kidney (HEK)-293T cells. 
Consistent with the Rags functioning as heterodimers, raptor co-purified with RagA-C or 
RagB-C, but not with RagA-B or the Rap2A control protein (Fig. 1A). Because the nucleotide 
loading state of most GTP-binding proteins regulates their functions, we generated RagB, 
RagC, and RagD mutants predicted (Dubouloz et al., 2005; Gao and Kaiser, 2006; Nakashima 
et al., 1999) to be restricted to the GTP- or GDP-bound conformations (for simplicity we call 
these mutants RagBGTP, RagBGDP, etc.) (materials and methods). When expressed with 
mTORC1 components, Rag heterodimers containing RagBGTP immunoprecipitated with more 
raptor and mTOR than did complexes containing wild-type RagB or RagBGDP (Fig. 1B). The 
GDP-bound form of RagC increased the amount of co-purifying mTORC1, so that RagBGTP-
CGDP recovered the highest amount of endogenous mTORC1 of any heterodimer tested (Fig. 
1C). Giving an indication of the strength of the mTORC1-RagBGTP-CGDP association, in this 
same assay we could not detect co-immunoprecipitation of mTORC1 with Rheb1 (Fig. 1C), an 
established interactor and activator of mTORC1 (Guertin and Sabatini 2007). When expressed 
alone, raptor, but not mTOR, associated with RagBGTP-DGDP, suggesting that raptor is the key 
mediator of the Rag-mTORC1 interaction (Fig. 1D). Consistent with this, rictor, an mTOR-
interacting protein that is only part of mTORC2 (Guertin and Sabatini 2007), did not co-purify 
with any Rag heterodimer (Fig. 1C and 1F).  Lastly, highly purified raptor interacted in vitro 
with RagB-D and, to a larger extent, with RagBGTP-DGDP, indicating that the Rag-raptor 
interaction is most likely direct (Fig. 1E).  
 
Effects of overexpressed RagBGTP –containing heterodimers on the mTORC1 pathway 
and its response to leucine, amino acids and insulin 
We tested whether various Rag heterodimers affected the regulation of the mTORC1 
pathway within human cells. In HEK-293T cells, expression of the RagBGTP-DGDP 
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heterodimer, which interacted strongly with mTORC1, not only activated the pathway but also 
made it insensitive to deprivation for leucine or total amino acids, as judged by the 
phosphorylation state of the mTORC1 substrate T389 of S6K1 (Fig. 2A and B). The wild-type 
RagB-D heterodimer had milder effects than RagBGTP-DGDP, making the mTORC1 pathway 
insensitive to leucine deprivation, but not to the stronger inhibition caused by total amino acid 
starvation (Fig. 2A and B). Expression of RagBGDP-DGTP, a heterodimer that did not interact 
with mTORC1 (Fig. 1C and D), had dominant negative effects, as it eliminated S6K1 
phosphorylation in the presence as well as absence of leucine or amino acids (Fig. 2A and B). 
Expression of RagBGDP alone also suppressed S6K1 phosphorylation (Fig. 2E). These results 
suggest that the activity of the mTORC1 pathway under normal growth conditions depends on 
endogenous Rag function. 
 
Insensitivity of the mTORC1 pathway to amino acid deprivation in cells stably expressing 
RagBGTP 
To verify the actions of the Rags in a more physiological setting than that achieved by 
transient cDNA transfection, we generated HEK-293T cell lines stably expressing Rheb1, 
RagB, or RagBGTP (attempts to generate lines stably expressing RagBGDP failed). Under normal 
growth conditions these cells were larger than control cells and had higher levels of mTORC1 
pathway activity (Fig. 3A). Unlike transient Rheb1 overexpression (Fig. 2A and B), stable 
expression did not make the mTORC1 pathway insensitive to leucine or amino acid starvation 
(Fig. 3B and C), consistent with evidence that transiently overexpressed Rheb may have non-
physiological consequences on amino acid signaling to mTORC1 (Nobukuni et al., 2005; 
Smith et al., 2005). Stable expression of a Rheb1GTP mutant was also unable to make the 
mTORC1 pathway resistant to amino acid deprivation (Fig. 2F). In contrast, stable expression 
of RagBGTP eliminated the sensitivity of the mTORC1 pathway to leucine or total amino acid 
withdrawal, whereas that of wild-type RagB overcame sensitivity to leucine but not to amino 
acid starvation (Fig. 3B and C). Thus, transient or stable expression of the appropriate Rag 
mutants is sufficient to put the mTORC1 pathway into states that mimic the presence or 
absence of amino acids.  
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To determine if the Rag mutants affect signaling to mTORC1 from inputs besides 
amino acids, we tested whether in RagBGTP-expressing cells the mTORC1 pathway was 
resistant to other perturbations known to inhibit it. This was not the case, as oxidative stress, 
mitochondrial inhibition, or energy deprivation still reduced S6K1 phosphorylation in these 
cells (Fig. 2G). Moreover, in HEK-293E cells, expression of RagBGTP-DGDP did not maintain 
mTORC1 pathway activity in the absence of insulin (Fig. 2C). Expression of the dominant 
negative RagBGDP-DGTP heterodimer did, however, block insulin-stimulated phosphorylation of 
S6K1 (Fig. 2C), as did amino acid starvation (Fig. 2D). Thus, although RagBGTP expression 
mimics amino acid sufficiency, it cannot substitute for other inputs that mTORC1 normally 
monitors.  
This evidence for a primary role of the Rag proteins in amino acid signaling to 
mTORC1 raised the question of where, within the pathway that links amino acids to mTORC1, 
the Rag proteins might function. The existence of the Rag-mTORC1 interaction (Fig. 1), the 
effects on amino acid signaling of the Rag mutants (Fig. 2 and 3), and the sensitivity to 
rapamycin of the S6K1 phosphorylation induced by RagBGTP (Fig. 2G), strongly suggested that 
the Rag proteins function downstream of amino acids and upstream of mTORC1. To verify this 
we took advantage of the established finding that cycloheximide re-activates mTORC1 
signaling in cells starved for amino acids by blocking protein synthesis and thus boosting the 
levels of the intracellular amino acids sensed by mTORC1 (Beugnet et al., 2003; Christie et al., 
2002; Price et al., 1989). Thus, if the Rag proteins act upstream of amino acids, cycloheximide 
should overcome the inhibitory effects of the RagBGDP-CGTP heterodimer on mTORC1 
signaling, but if they are downstream, cycloheximide should not reactivate the pathway. The 
results were clear: cycloheximide treatment of cells reversed the inhibition of mTORC1 
signaling caused by leucine deprivation, but not that caused by expression of RagBGDP-CGTP 
(Fig. 3I). Given the placement of the Rag proteins downstream of amino acids and upstream of 
mTORC1, we determined whether amino acids regulate the Rag-mTORC1 interaction within 
cells. Initial tests using transiently co-expressed Rag proteins and mTORC1 components did 
not reveal any regulation of the interaction. Because we reasoned that pronounced 
overexpression might overcome the normal regulatory mechanisms that operate within the cell, 
we developed an assay (materials and methods), based on a reversible chemical cross-linker, 
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which allows us to detect the interaction of stably expressed FLAG-tagged Rag proteins with 
endogenous mTORC1. With this approach we readily found that amino acids, but not insulin, 
promote the Rag-mTORC1 interaction when using either FLAG-tagged RagB or RagD to 
isolate mTORC1 from cells (Fig. 3D and 3J). As the GTP-loading state of the Rag proteins 
also regulates the Rag-mTORC1 interaction (Fig. 1), we determined whether amino acids 
modulate the amount of GTP bound to RagB. Indeed, amino acid stimulation of cells increased 
the GTP loading of RagB (Fig. 3E). Consistent with this, amino acids did not further augment 
the already high level of interaction between mTORC1 and the RagBGTP mutant (Fig. 3D).  
To determine if the Rag proteins are necessary for amino acids to activate the mTORC1 
pathway we used combinations of lentivirally-delivered shRNAs to suppress RagA and RagB or 
RagC and RagD at the same time. Loss of RagA and RagB also led to the loss of RagC and 
RagD and vice versa, suggesting that within cells the Rag proteins are unstable when not in 
heterodimers (Fig. 3F). In cells with a reduction in the expression of all the Rag proteins, 
leucine-stimulated phosphorylation of S6K1 was strongly reduced (Fig. 3G). The role of the Rag 
proteins appears to be conserved in Drosophila cells as dsRNA-mediated suppression of the 
Drosophila orthologues of RagB or RagC eliminated amino acid-induced phosphorylation of 
dS6K (Fig. 3H). Consistent with amino acids being necessary for activation of mTORC1 by 
insulin, a reduction in Rag expression also suppressed insulin-stimulated phosphorylation of 
S6K1 (Fig. 3K). Thus, the Rag proteins appear to be both necessary and sufficient for mediating 
amino acid signaling to mTORC1. 
 
Rag-dependent regulation by amino acids of the intracellular localization of mTOR 
Unlike Rheb (Long et al., 2005; Sancak et al., 2007), the Rag heterodimers did not 
directly stimulate the kinase activity of mTORC1 in vitro (Fig. 4E), so we considered the 
possibility that the Rag proteins regulate the intracellular localization of mTOR. mTOR is found 
on the endomembrane system of the cell, including the endoplasmic reticulum, Golgi apparatus, 
and endosomes (Drenan et al., 2004; Mavrakis et al., 2007). The intracellular localization of 
endogenous mTOR, as revealed with an antibody that we validated recognizes mTOR in 
immunofluorescence assays (Fig. 4F), was strikingly different in cells deprived of amino acids 
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than in cells starved and briefly re-stimulated with amino acids (Fig. 4A and 5E) or growing in 
fresh complete media (Fig. 4G). In starved cells mTOR was in tiny puncta throughout the 
cytoplasm, whereas in cells stimulated with amino acids for as little as 3 minutes, mTOR 
localized to the peri-nuclear region of the cell, to large vesicular structures, or to both (Fig. 4A). 
Rapamycin did not block the change in mTOR localization induced by amino acids (Fig. 4A), 
indicating that it is not a consequence of mTORC1 activity but rather may be one of the 
mechanisms that underlies mTORC1 activation. The amino acid-induced change in mTOR 
localization required expression of the Rag proteins and of raptor (Fig. 4B and C), and amino 
acids also regulated the localization of raptor (Fig. 4H).  
In cells overexpressing RagB, Rheb1, or Rheb1GTP, mTOR behaved as in control cells, its 
localization changing upon amino acid stimulation from small puncta to the peri-nuclear region 
and vesicular structures (Fig. 4D). In contrast, in cells overexpressing the RagBGTP mutant that 
eliminates the amino acid sensitivity of the mTORC1 pathway, mTOR was already present on 
the peri-nuclear and vesicular structures in the absence of amino acids, and became even more 
localized to them upon the addition of amino acids (Fig. 4D).  Thus, there is a correlation, under 
amino acid starvation conditions, between the activity of the mTORC1 pathway and the 
subcellular localization of mTOR, implicating a role for Rag-mediated mTOR translocation in 
the activation of mTORC1 in response to amino acids. 
 
Amino acids promote the localization of mTOR to a Rab7-positive compartment that also 
contains Rheb 
We failed to find an established marker of the endomembrane system that co-localized 
with mTOR in amino acid starved cells. However, in cells stimulated with amino acids, mTOR 
in the peri-nuclear region and on the large vesicular structures overlapped with Rab7 (Fig. 5A), 
indicating that a significant fraction of mTOR translocated to the late endosomal and lysosomal 
compartments in amino acid replete cells. In cells expressing RagBGTP, mTOR was present on 
the Rab7-positive structures even in the absence of amino acids (Fig. 5B). 
The peri-nuclear region and vesicular structures on which mTOR appears after amino 
acid stimulation are similar to the Rab7-positive structures where GFP-tagged Rheb localizes in 
human cells (Buerger et al., 2006; Saito et al., 2005). Unlike mTOR, however, amino acids did 
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not appreciably affect the localization of Rheb, as GFP-Rheb1 co-localized with dsRed-Rab7 in 
the presence or absence of amino acids (Fig. 5C). Unfortunately, it is currently not possible to 
compare, in the same cells, the localization of endogenous mTOR with that of Rheb because the 
signal for GFP-Rheb or endogenous Rheb is lost after fixed cells are permeabilized to allow 
access to intracellular antigens (Buerger et al., 2006; Saito et al., 2005). Nevertheless, given that 
both mTOR and Rheb are present in Rab7-positive structures after amino acid stimulation, we 
propose that amino acids might control the activity of the mTORC1 pathway by regulating, 
through the Rag proteins, the movement of mTORC1 to the same intracellular compartment that 
contains its activator Rheb (see model in Fig. 5D). This would explain why activators of Rheb, 
like insulin, do not stimulate the mTORC1 pathway when cells are deprived of amino acids, and 
why Rheb is necessary for amino acid-dependent mTORC1 activation (Nobukuni et al., 2005) 
(Fig. 5F and 5G).  When Rheb is highly overexpressed, some might become mis-localized and 
inappropriately encounter and activate mTORC1, explaining why Rheb overexpression, but not 
loss of TSC1 or TSC2 makes the mTORC1 pathway insensitive to amino acids (Nobukuni et al., 
2005; Smith et al., 2005). 
In conclusion, the Rag GTPases bind raptor, are necessary and sufficient to mediate 
amino acid signaling to mTORC1, and mediate the amino acid induced re-localization of mTOR 
within the endomembrane system of the cell. Given the prevalence of cancer-linked mutations in 
the pathways that control mTORC1 (Guertin and Sabatini 2007), it is possible that Rag function 
is also deregulated in human tumors. 
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Materials and Methods 
 
Materials 
Reagents were obtained from the following sources: antibody to raptor from 
Upstate/Millipore; HRP-labeled anti-mouse, anti-goat, and anti-rabbit secondary antibodies from 
Santa Cruz Biotechnology; antibodies to phospho-T389 S6K1, S6K1, RagA, RagB, RagC and 
RagD, mTOR, rictor, phospho-T398 dS6K, and the myc epitope from Cell Signaling 
Technology; an antibody to the HA tag from Bethyl laboratories; an antibody to RagB from 
Novus Biologicals; Cellulose PEI TLC plates, RPMI, FLAG M2 affinity gel, FLAG M2 
antibody, ATP, cycloheximide, valinomycin, H202, 2-deoxyglucose, amino acids, and human 
recombinant insulin from Sigma Aldrich; DSP, protein G-sepharose, and immobilized 
glutathione beads from Pierce; DMEM from SAFC Biosciences; FuGENE 6 and Complete 
Protease Cocktail from Roche; Alexa 488 or Texas-Red-X conjugated secondary antibodies, 
Schneider's media, Express Five Drosophila-SFM, and Inactivated Fetal Calf Serum (IFS) from 
Invitrogen; and amino acid-free RPMI, amino acid- and phosphate- free RPMI, and amino acid-
free Schneider’s media from US Biological.  The dS6K antibody was a generous gift from Mary 
Stewart (North Dakota State University). 
 
Cell lines and tissue culture 
HEK-293E, HEK-293T, and HeLa cells were cultured in DMEM with 10% IFS. In HEK-
293E, but not HEK-293T, cells the mTORC1 pathway is strongly regulated by serum and insulin 
(Sancak et al., 2007). The HEK-293E cell line was kindly provided by John Blenis (Harvard 
Medical School). 
 
Leucine or amino acid starvation and stimulation of cells 
 Almost confluent cultures in 10 cm culture plates were rinsed with leucine-free RPMI 
once, incubated in leucine-free RPMI for 50 minutes, and stimulated with 52 µg/ml leucine for 
10 minutes. For amino acid starvation, cells in 10 cm culture dishes or coated glass cover slips 
were rinsed with and incubated in amino acid-free RPMI for 50 minutes, and stimulated with a 
10X amino acid mixture for 3-30 minutes as indicated in the figures. After stimulation, the final 
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concentration of amino acids in the media was the same as in RPMI. Cells were processed for 
biochemical or immunofluorescence assays as described below. The 10X amino acid mixture 
was prepared from individual amino acid powders. 
 
Cell lysis, immunoprecipitations, and kinase assays 
Cells were rinsed once with ice-cold PBS and lysed in ice-cold lysis buffer (40 mM 
HEPES [pH 7.4], 2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, and 0.3% 
CHAPS or 1% Triton X-100, and one tablet of EDTA-free protease inhibitors (Roche) per 25 
ml).  The soluble fractions of cell lysates were isolated by centrifugation at 13,000 rpm for 10 
minutes by centrifugation in a microfuge.  For immunoprecipitations, primary antibodies were 
added to the lysates and incubated with rotation for 1.5 hours at 4°C. 60 µl of a 50% slurry of 
protein G-sepharose was then added and the incubation continued for an additional 1 hour.  
Immunoprecipitates were washed three times with lysis buffer containing 150 mM NaCl. 
Immunoprecipitated proteins were denatured by the addition of 20 µl of sample buffer and 
boiling for 5 minutes, resolved by 8%–16% SDS-PAGE, and analyzed by immunoblotting as 
described (Kim et al., 2002). For FLAG and GST purifications, immobilized glutathione or Flag 
M2 affinity resins were washed with lysis buffer 3 times. 20 µl of a 50% slurry of the resins was 
then added to pre-cleared cell lysates and incubated with rotation for 2 hours at 4°C. Finally, the 
beads were washed 3 times with lysis buffer containing 150 mM NaCl. For elution of FLAG-
tagged proteins, beads were incubated in elution buffer (50 mM HEPES pH 7.4, 500 mM NaCl, 
0.5% CHAPS, 50 µg/µl FLAG peptide) for 30 min at 30 °C. Elution of proteins from glutathione 
beads and kinase assays were performed as previously described (Sancak et al., 2007). 
 
cDNA manipulations and mutagenesis  
 The cDNAs for human RagA, RagB, RagC and RagD were obtained from Open 
Biosystems. The cDNAs were amplified by PCR and the products were subcloned into Sal I and 
Not I sites of HA-GST-pRK5, HA-pRK5 and FLAG-pRK5. The cDNAs were mutagenized 
using the QuickChange XLII mutagenesis kit (Stratagene) with oligonucleotides obtained from 
Integrated DNA Technologies. All constructs were verified by DNA sequencing. The Rag 
mutants used in our experiments are: RagBGTP = Q99L RagB; RagBGDP = T54L RagB; RagCGTP 
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= Q120L RagC; RagCGDP = S75L RagC; RagDGTP = Q121L RagD; and RagDGDP = S77L RagD. 
Rheb1GTP = Q64L Rheb1. 
 FLAG-tagged wild type and mutant RagB and RagD cDNAs or GFP-tagged Rheb1 were 
amplified by PCR and cloned into the Age I and Bam HI sites of a modified pLKO.1 vector 
having a CMV promoter (pLJM1). After sequence verification, these plasmids were used, as 
described below, in transient cDNA transfections or to produce the lentiviruses needed to 
generate cell lines stably expressing the proteins. An expression plasmid encoding DsRed-Rab7 
was obtained from Addgene.  
 
cDNA transfection-based experiments 
For co-transfection experiments, 2 million HEK-293T or HEK-293E cells were plated in 
10 cm culture dishes. 24 hours later, cells were transfected with the prk5-based cDNA expression 
plasmids indicated in the figures in the following amounts: 500 ng myc-mTOR; 50 ng myc- or 
HA-raptor (Kim et al., 2002); 100 ng myc-rictor (Sarbassov et al., 2004); 100 ng HA-GST-, HA- 
or FLAG-tagged Rap2A (Sancak et al., 2007); 100 ng HA-GST-, HA-, or FLAG-tagged Rheb1 
(Sancak et al., 2007); 100 ng HA-tagged RagA; 100 ng HA-GST- or HA-tagged RagB; 100 ng 
HA-GST- or HA-tagged RagC; 100 ng HA-GST- or FLAG-tagged RagD; 1 ng of FLAG-S6K1. 
Transfection mixes were taken up to a total of 2 µg of DNA using empty pRK5.  
 
In-cell cross-linking assay 
DSP was dissolved in DMSO to a final concentration of 250 mg/ml to make a 250X stock 
solution for the in-cell cross-linking assay. HEK-293T cells stably expressing FLAG-tagged 
RagB, RagBGTP, or RagD and growing in 10 cm culture dishes were starved for amino acids or 
starved and then stimulated as described above. At the end of the starvation or stimulation 
period, cells were rinsed once with cold PBS and incubated with 4 ml of PBS containing 1 
mg/ml DSP for 7 minutes at room temperature. The cross-linking reaction was quenched by 
adding 1M Tris pH 8.5 to a final concentration of 100 mM followed by a 1-minute incubation. 
The cells were rinsed once with ice cold PBS, and lysed with RIPA buffer (40 mM HEPES [pH 
7.4], 2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 1% sodium deoxycholate, 
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1% NP40, 0.1% SDS, and one tablet of EDTA-free protease inhibitors per 25 ml). FLAG-
immunoprecipitates were prepared as described above.  
 
Identification of RagC as a raptor-associated protein 
FLAG-raptor was immunoprecipitated with the FLAG M2 affinity gel from 30 million 
HEK-293T cells stably expressing FLAG-raptor. Proteins eluted with the FLAG peptide from 
the affinity matrix were resolved by SDS-PAGE, stained with silver, and the 45-55 kD region of 
the gel excised and digested with trypsin overnight.  The resulting peptides were separated by 
liquid chromatography (NanoAcquity UPLC, Waters) using a self-packed Jupiter 3 micron C18 
column. The eluting peptides were mass analyzed prior to collisionally induced dissociation 
(CID) using a ThermoFisher LTQ linear ion trap mass spectrometer equipped with a nanospray 
source. Selected mass values from the MS/MS spectra were used to search the human segment of 
the NCBI non-redundant protein database using Xcalibur Mass Spectrometry software (Thermo 
Fischer Scientific). In 4 independent purifications of FLAG-raptor performed as above, this 
procedure led to the identification of a total of 20 peptides matching RagC that were not present 
in control FLAG-tubulin samples. 
 
Cell size determinations 
To measure cell size, 2 million cells were plated into 10 cm culture dishes. 24 hours later 
the cells were harvested by trypsinization in a 4 ml volume, diluted 1:20 with counting solution 
(Isoton II Diluent, Beckman Coulter), and cell diameters determined using a particle size counter 
(Coulter Z2, Beckman Coulter) with Coulter Z2 AccuComp software.  
 
Mammalian lentiviral shRNAs 
 TRC lentiviral shRNAs targeting RagA, RagB, RagC and RagD were obtained from 
Sigma. The TRC number for each shRNA is as follows:  
Human RagA shRNA #1: TRCN0000047305 
 Human RagA shRNA #2: TRCN0000047307    
 Human RagB shRNA #1: TRCN0000047308 
 Human RagB shRNA #2: TRCN0000047311 
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 Human RagC shRNA #1: TRCN0000072874 
 Human RagC shRNA #2: TRCN0000072877    
 Human RagD shRNA #1: TRCN0000059533 
 Human RagD shRNA #2: TRCN0000059534 
 
The shLuc and shGFP control shRNAs and the shRNAs targeting mTOR and raptor are 
previously described and validated (Sarbassov et al., 2005b). Lentiviral shRNAs targeting Rheb1 
were cloned into LKO.1 vector as described (Sarbassov and Sabatini, 2005). The target 
sequences for the Rheb1 shRNAs are: 
Human Rheb1 shRNA#1: CCTCAGACATACTCCATAGAT 
 Human Rheb1 shRNA#2: TTATGTTGGTTGGGAATAAGA 
 
 shRNA-encoding plasmids were co-transfected with Delta VPR envelope and CMV 
VSV-G packaging plasmids into actively growing HEK-293T cells using FuGENE 6 transfection 
reagent as previously described (Ali  and Sabatini 2005; Sarbassov and Sabatini, 2005). Virus-
containing supernatants were collected 48 hours after transfection, filtered to eliminate cells and 
target cells were infected in the presence of 8 µg/ml polybrene. 24 hours later, cells were 
selected with puromycin and analyzed on the 2nd or 3rd day after infection. 
 
In vitro Rag-raptor binding assay 
2 million HEK-293T cells were plated into 10 cm culture dishes. 24 hours later, the cells 
were transfected with 2 µg HA-GST-Rap2a, 2 µg HA-GST-Rheb1, or 2 µg HA GST-RagB 
together with 2 µg of HA GST-RagC (wild type or Rag mutants as indicated). 2 days after 
transfection, the cells were lysed in Rheb lysis buffer containing 1% Triton X-100 (Sancak et al., 
2007), and cleared lysates were incubated with glutathione beads for 1.5 hours at 4°C with 
rotation. The beads were washed 3 times with lysis buffer and two times with Rheb storage 
buffer (Sancak et al., 2007). 1/4 of the glutathione beads were incubated with 300 ng of FLAG-
raptor in Rheb lysis buffer with 0.3% CHAPS for 30 min at 4°C with rotation. The glutathione 
beads were washed twice with Rheb lysis buffer containing 0.3% CHAPS and proteins were 
denatured by the addition of 20 µl of sample buffer and boiling for 5 minutes and analyzed by 
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SDS-PAGE and immunoblotting. FLAG-raptor was purified from HEK-293T cells stably 
expressing FLAG-raptor. Following the affinity-tag purification, the protein was further purified 
as described (Sancak et al., 2007) by gel filtration using a Superose 6 10/300GL column (GE 
Healthcare) to obtain FLAG-raptor that by silver and coomasie staining was 99% pure.  
 
Determination of guanyl nucleotide binding state of RagB in cells  
 Determination of the guanyl nucleotides bound to RagB in cells was performed 
essentially as previously described for Rheb (Long et al., 2005). HEK-293T cells were cultured 
in fibronectin coated 6-well dishes until confluent, rinsed once with phosphate-and serum-free 
DMEM, and then incubated in phosphate-and serum-free DMEM containing 1 mCi 32P 
orthophosphate (Perkin Elmer) for 4 hours. After 4 hours, cells were rinsed once with serum-, 
amino acid-, and phosphate-free RPMI, incubated with serum-, amino acid-, and phosphate-free 
media containing 1 mCi 32P orthophosphate for 50 minutes, and stimulated with amino acids as 
described above. After rinsing with ice-cold PBS, cells were lysed in 0.5 ml lysis buffer (50 mM 
HEPES KOH (pH 7.4), 100 mM NaCl, 1 mM KH2PO4, 1 mM ATP, 100 µM GDP, 100 µM 
GTP, 5 mM MgCl2, 1% Triton X-100), and the lysate microcentrifuged for 10 minutes at 13,000 
rpm at 4°C. The supernatant was incubated with 15 µl of RagB antibody (Novus Biologicals) for 
1 hour at 4°C. 20 µl of protein G beads were added to the lysates and the incubation continued 
for another 45 minutes. The beads were washed 8 times with wash buffer (50 mM HEPES KOH 
[pH 7.4], 500 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100, 0.005% SDS) and bound nucleotides 
were eluted in 23 µl of elution buffer (10 mM EDTA, 2 mM DTT, 0.2% SDS, 0.5 mM GDP, 0.5 
mM GTP) at 60 °C for 10 minutes. 15 µl of the eluate was transferred to a clean tube. 60 µl of 
methanol and then 30 µl of chloroform were added to the tube, each addition followed by brief 
vortexing and microcentrifugation. After the addition of 45 µl of water, the samples were 
vortexed vigorously, microcentrifuged for 1 minute at 13,000 rpm and the aqueous phase 
transferred to a clean tube. Using a speedvac the samples were dried and then re-suspended in 15 
µl of deionized water. Samples were spotted on PEI cellulose TLC plates and the plates 
developed with 1.2 mM ammonium formate and 0.8 mM HCl, and the radioactivity detected 
with a phosphoimager. After background subtraction, the intensities of the GTP and GDP spots 
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were determined. The percent of GTP nucleotide was calculated using the following formula: 
[(GTP/3)/((GTP/3) + (GDP/2))] X 100%. 
 
Immunofluorescence assays 
150,000 HEK-293T cells were plated on fibronectin-coated glass coverslips in 12-well 
tissue culture plates. 24 hours later cells were starved for and stimulated with amino acids as 
described above, rinsed with PBS once and fixed for 5 minutes with 4% paraformaldehyde in 
PBS warmed to 37°C. The coverslips were rinsed twice with PBS and permealized with 0.2% 
Triton X-100 in PBS for 15 minutes. After rinsing twice with PBS, the coverslips were blocked 
for one hour in blocking buffer (0.25% BSA in PBS) and incubated with primary antibody in 
blocking buffer overnight at 4°C, rinsed twice with blocking buffer and incubated with 
secondary antibodies (diluted in blocking buffer 1:1000) for one hour at room temperature in 
dark. The coverslips were mounted on glass slides using Vectashield (Vector Laboratories) and 
imaged with a 63X objective using epifluorescence microscopy. 
Where indicated, 1-2 ng of plasmids encoding GFP-Rheb1 or dsRed-Rab7 were 
transfected per well of a 12-well dish. 
 
Drosophila cell experiment 
dsRNA transfection and amino acid starvation and stimulation 
5 million S2 cells were plated in 6-cm culture dishes in 5 ml of Express Five SFM media. 
Cells were transfected with 1 µg of dsRNA per million cells. 4 days later, cells were rinsed once 
with amino acid-free Schneider’s medium, and starved for amino acids by replacing the media 
with amino acid-free Schneider’s medium for 1.5 hours. To stimulate with amino acids, the 
amino acid-free medium was replaced with complete Schneider’s medium for 20 minutes. Cells 
were then washed with ice cold PBS twice, lysed, and processed as described (Sancak et al., 2007). 
The pH of the amino acid free media was made to match that (pH 6.70) of an opened bottle of 
full Schneider’s media. 
 
Design and synthesis of dsRNAs 
The control GFP dsRNA has been described (Sarbassov et al., 2004). Other dsRNAs 
were designed to target all known transcripts of the target Drosophila gene. In order to minimize 
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off-target effects, we used the DRSC tool at http://flyrnai.org/RNAi_find_frag_free.html and 
excluded regions of 19-mer-or-greater identity to any Drosophila transcripts. The Drosophila 
genome encodes for one RagA/B-like gene (CG11968) and one RagC/D-like gene (CG8707). 
We designed and tested two distinct dsRNAs to each gene. Synthesis of dsRNAs was performed 
as previously described (Sarbassov et al., 2004) using the primers indicated below. 
 
Primer sequences (including underlined 5' and 3' T7 promoter sequences) 
 
dRagB (CG11968) dsRNA_1 forward primer:  
GAATTAATACGACTCACTATAGGGAGACGCTCCATTATCTTTGCTAACTATAT 
 
dRagB (CG11968) dsRNA_1 reverse primer: 
GAATTAATACGACTCACTATAGGGAGACATCAAACACATAAATCAGCACTTC 
 
dRagB (CG11968) dsRNA_2 forward primer: 
GAATTAATACGACTCACTATAGGGAGAATAGAGCGCGACATCCATTACTAC 
 
dRagB (CG11968) dsRNA_2 reverse primer:  
GAATTAATACGACTCACTATAGGGAGACTTGATGATGTTGGACACCTTTT 
 
dRagC (CG8707) dsRNA_1 forward primer:  
GAATTAATACGACTCACTATAGGGAGAGAGTCGACCAGTAAGATCGTGAA 
 
dRagC (CG8707) dsRNA_1 reverse primer:  
GAATTAATACGACTCACTATAGGGAGATGTAGTCATCCTTGGCATCG 
 
dRagC (CG8707) dsRNA_2 forward primer: 
GAATTAATACGACTCACTATAGGGAGAAGTTCGAGGTGTTTATACACAAGGT 
 
dRagC (CG8707) dsRNA_2 reverse primer: 
GAATTAATACGACTCACTATAGGGAGAAAGATGGAGTGGTCGTATATGGAG 
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Figure 1 
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Figure 1. Interaction of Rag heterodimers with recombinant and endogenous mTORC1 in a manner 
that depends on the nucleotide binding state of RagB. In (A) through (D) HEK-293T cells were 
transfected with the indicated cDNAs in expression vectors, cell lysates prepared, and lysates and 
HA- or FLAG-immunoprecipitates were analyzed by immunoblotting for the amounts of the 
specified recombinant or endogenous proteins. (E) In vitro binding of purified FLAG-raptor with 
wild type RagB-D or RagBGTP-DGDP. (F) Rag heterodimers do not interact with rictor. HEK-293T 
cells were transfected with the indicated cDNAs in expression vectors, cell lysates prepared, and 
lysates and HA-immunoprecipitates analyzed for the levels of the specified proteins. This experi- 
ment was performed side-by-side with that shown in Figure 1A and is displayed here for space 
reasons. 
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Figure 2 
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Figure 2. Effects of overexpressed RagBGTP-containing heterodimers on the mTORC1 pathway and 
its response to leucine, amino acids, or insulin. Effects of expressing the indicated proteins on the 
phosphorylation state of co-expressed S6K1 in response to deprivation and stimulation with (A) 
leucine, (B) total amino acids, or (C) insulin. Cell lysates were prepared from HEK-293T cells 
deprived for 50 minutes of serum, and (A) leucine or (B) amino acids, and then, where indicated, 
stimulated with leucine or amino acids for 10 minutes. HEK-293E cells (C) were deprived of serum 
for 50 minutes and where indicated stimulated with 150 nM insulin for 10 minutes. Lysates and 
FLAG-immunoprecipitates were analyzed for the levels of the specified proteins and the 
phosphorylation state of S6K1. (D) Effects of amino acid deprivation on insulin- mediated 
activation of mTORC1. HEK-293E cells were starved for serum and amino acids or just serum for 
50 minutes, and where specified, stimulated with 10 or 150 nM insulin. Cell lysates were analyzed 
for the level and phosphorylation state of S6K1. (E) Expression of RagBGDP alone suppresses 
endogenous mTORC1 signaling. Cell lysates were prepared from HEK-293T cells transfected with 
the indicated cDNAs and deprived for 50 minutes of serum and amino acids, and where indicated, 
stimulated with amino acids for 10 minutes. Lysates and FLAG-immunoprecipitates were analyzed 
for the levels of the specified proteins and the phosphorylation state of S6K1. (F) Stable expression 
of Rheb1 or Rheb1GTP does not eliminate the sensitivity of the mTORC1 to amino acids. HEK-
293T cells stably expressing the indicated proteins were deprived of serum and amino acids for 50 
minutes, and where indicated, stimulated with amino acids for 10 minutes. Lysates were analyzed 
for the levels of the specified proteins and the phosphorylation state of S6K1. (G) Effects of various 
insults on mTORC1 signaling in cells expressing RagBGTP. HEK-293T cells stably expressing 
Rap2A or RagBGTP and growing in full media were un- treated (control), or deprived of amino acids 
for 30 minutes, or treated for 30 minutes with 20 nM rapamycin, 100 mM 2-deoxyglucose (energy 
deprivation), 1 mM H2O2 (oxidative stress), or 1 µM valinomycin (mitochondrial proton gradient 
inhibition). Cell lysates were prepared and analyzed for the levels of the specified proteins and the 
phosphorylation state of S6K1. 
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Figure 3 
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Figure 3. Insensitivity of the mTORC1 pathway to amino acid deprivation in cells stably 
expressing RagBGTP. (A) Cell size distributions (graphs) and S6K1 phosphorylation 
(immunoblot) of cells stably expressing RagB, Rheb1, RagBGTP, or Rap2A. Mean cell diameters 
± S.D. (µm) are: Rap2A, 16.05 ± 0.07; Rheb1, 16.79 ± 0.06; RagB, 16.40 ± 0.08; and RagBGTP, 
16.68 ± 0.06 (n = 4 and p < 0.0008 for all comparisons to Rap2A-expressing cells). HEK-293T 
cells transduced with lentiviruses encoding the specified proteins were deprived for 50 minutes 
for serum and (B) leucine or (C) total amino acids, and, where indicated, re-stimulated with 
leucine or amino acids for 10 minutes. Cell lysates were analyzed for the levels of the specified 
proteins and the phosphorylation state of S6K1. (D) Amino acid-stimulated interaction of the 
Rag proteins with mTORC1. HEK-293T cells stably expressing FLAG-tagged RagB, RagD, or 
RagBGTP were starved for amino acids and serum for 50 minutes and, where indicated, re-
stimulated with amino acids for 10 minutes. Cells were then processed with a chemical cross-
linking assay and cell lysates and FLAG-immunoprecipitates analyzed for the levels of the 
indicated proteins. (E) Effects of amino acid stimulation on GTP loading of RagB. Values are 
mean ± s.d. for n = 3 (p < 0.02 for increase in GTP loading caused by amino acid stimulation). 
(F) Abundance of RagA, RagB, RagC, and RagD in HeLa cells expressing the indicated 
shRNAs. (G) S6K1 phosphorylation in HeLa cells expressing shRNAs targeting RagC and 
RagD. Cells were deprived of serum and leucine for 50 minutes, and, where indicated, re-
stimulated with leucine for 10 minutes. (H) Effects of dsRNA-mediated knockdowns of 
Drosophila orthologues of RagB or RagC on amino acid-induced phosphorylation of dS6K. (I) 
Inhibition of protein synthesis with cycloheximide does not prevent RagBGDP-CGTP from 
inhibiting the mTORC1 pathway. HEK-293T cells were transfected with the indicated cDNAs in 
expression vectors, and starved for 50 minutes for serum and leucine, and, where indicated, 
stimulated with leucine or 10 µg/ml cycloheximide for 20 minutes. Cell lysates and FLAG-
immunoprecipitates were analyzed for the levels of the specified proteins and the 
phosphorylation state of S6K1. (J) Insulin does not increase the interaction between mTORC1 
and the Rag proteins. Hela cells stably expressing FLAG-RagD were starved for serum for 50 
minutes and, where indicated, stimulated with 100 nM insulin for 10 minutes. Cells were then 
processed with a chemical cross-linking assay and cell lysates and FLAG- immunoprecipitates 
analyzed for the levels of the indicated proteins. (K) Knockdowns of RagC and RagD suppress 
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insulin-stimulated phosphorylation of S6K1. HeLa cells expressing shRNAs targeting RagC and 
RagD were prepared as in (B). Cells were deprived of serum for 50 minutes, and, where 
indicated, re-stimulated with 100 nM insulin for 10 minutes. Cell lysates were prepared and 
analyzed for the levels and phosphorylation state of S6K1. 
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Figure 4 
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Figure 4. Rag-dependent regulation by amino acids of the intracellular localization of mTOR. 
(A) HEK-293T cells were starved for serum and amino acids for 50 minutes or starved and then 
re- stimulated with amino acids for the indicated times in the presence or absence of rapamycin. 
Cells were then processed in an immunofluorescence assay to detect mTOR (green), co- stained 
with DAPI for DNA content (blue), and imaged. 80-90% of the cells exhibited the mTOR 
localization pattern shown. (B) and (C) mTOR localization in HEK-293T cells expressing the 
indicated shRNAs and deprived and re-stimulated with amino acids as in (A). Immunoblot of 
raptor expression levels. (D) mTOR localization in HEK-293T cells stably expressing RagB, 
Rheb1, RagBGTP, or Rheb1GTP and deprived and re-stimulated with amino acids as in (A). (E) 
Rag heterodimers do not activate the in vitro kinase activity of mTORC1 in assays in which 
Rheb1 does. In vitro kinase assays containing 300 ng of each of the indicated proteins or Rag 
heterodimers were performed as described in the methods using mTORC1 immunopurified from 
HEK-293T cells with a raptor antibody. Rap2A, Rheb1, and the Rag heterodimers were 
expressed in HEK-293T cells and purified under conditions where the endogenous nucleotides 
remained bound. (F) Validation that an mTOR antibody detects mTOR in an 
immunofluorescence assay. HEK-293T cells expressing a control shRNA (sh-Luc) or an shRNA 
targeting mTOR (sh-mTOR) that is known to reduce mTOR expression (see methods) were 
processed in an immunofluorescence assay with an mTOR antibody (green) and co- stained with 
DAPI for DNA content (blue). (G) Localization of mTOR in HEK-293T cells growing in normal 
growth media. Where indicated, cells were deprived of amino acids for 50 minutes. For cells 
growing in normal media, the media was replaced with fresh media 1 hour before processing. 
Cells were processed in an immunofluorescence assay with an mTOR antibody (green) and 
imaged. (H) Raptor localization in cells deprived of or stimulated with amino acids. HEK-293T 
cells stably expressing FLAG-raptor were deprived of serum and amino acids for 50 minutes and 
where indicated stimulated with amino acids for 10 minutes. Cells were processed in an 
immunofluroescence assay with FLAG antibody (green), co-stained with DAPI for DNA content 
(blue), and imaged.  
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Figure 5. Amino acids promote the localization of mTOR to a Rab7-positive compartment that 
also contains Rheb. (A) mTOR and Rab7 localization in cells deprived or stimulated with amino 
acids. HEK-293T cells transiently transfected with a cDNA for dsRed-Rab7 were starved for 
serum and amino acids for 50 minutes and, where indicated, stimulated with amino acids for 10 
minutes. Cells were then processed to detect mTOR (green), Rab7 (red), and DNA content 
(blue), and imaged. Two examples are shown of mTOR localization in the presence of amino 
acids. (B) HEK-293T cells stably expressing RagBGTP and transiently transfected with a cDNA 
for dsRed-Rab7 were treated and processed as in (A). (C) Rheb1 and Rab7 localization in cells 
deprived or stimulated with amino acids. HEK-293T cells transiently transfected with 1-2 ng of 
cDNAs for GFP-Rheb1 and dsRed-Rab7 were treated as in (A), processed to detect Rheb1 
(green), Rab7 (red), and DNA content (blue), and imaged. (D) Model for role of Rag GTPases in 
signaling amino acid availability to mTORC1. (E) mTOR localization in HeLa cells starved and 
stimulated for amino acids as in Figure 4. Cells were processed in an immunofluorescence assay 
with an mTOR antibody (green) and co-stained with DAPI for DNA content (blue). (F) 
Validation that the two independent shRNAs targeting Rheb1 reduce its expression. Immuno- 
blot analysis of Rheb1 in HEK-293T cells expressing the indicated shRNAs. (G) Cells from (F) 
were deprived of serum and leucine for 50 minutes, and, where indicated, re-stimulated with 
leucine for 10 minutes. Cell lysates were prepared and analyzed for the levels and 
phosphorylation state of S6K1. 
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MP1, p14 and p18 were identified as mTORC1 interacting proteins by YS and LBP. 
Experiments shown in Figures 2, 5, 7, 8, 9, 10 were performed by YS; experiments shown in 
Figures 3, 6, 9 were performed by LBP; experiments shown in Figures 1 and 4 were perfomed by 
RZ; experiments shown in Figure 9 were perfomed by LBP and RZ 
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Summary 
 
 
The mTORC1 kinase promotes growth in response to growth factors, energy levels, and 
amino acids and its activity is often deregulated in disease. The Rag GTPases interact with 
mTORC1 and are proposed to activate it in response to amino acids by promoting the 
translocation of mTORC1 to a membrane-bound compartment that contains the mTORC1 
activator Rheb. We show that amino acids induce the movement of mTORC1 to lysosomal 
membranes, where the Rag proteins reside in an amino acid-independent fashion. The Ragulator, 
a complex encoded by the MAPKSP1, ROBLD3, and c11orf59 genes, interacts with the Rag 
GTPases, localizes them to lysosomes, and is essential for mTORC1 activation. Constitutive 
targeting of mTORC1 to the lysosomal surface is sufficient to render the mTORC1 pathway 
resistant to amino acid deprivation and independent of Rag and Ragulator, but not Rheb, 
function. Thus, Rag-Ragulator mediated translocation of mTORC1 to lysosomal membranes is 
the key event governing amino acid signaling to mTORC1. 
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Introduction 
The multi-component kinase mTORC1 (mammalian target of rapamycin complex 1) 
regulates cell growth by coordinating upstream signals from growth factors, intracellular energy 
levels, and amino acid availability, and is deregulated in diseases such as cancer and diabetes 
(reviewed in (Guertin and Sabatini 2007)). The TSC1 and TSC2 proteins form a tumor 
suppressor complex that transmits growth factor and energy signals to mTORC1 by regulating 
the GTP-loading state of Rheb, a Ras-related GTP-binding protein. When bound to GTP, Rheb 
interacts with and activates mTORC1(Inoki et al., 2003; Long et al., 2005; Sancak et al., 2007; 
Saucedo et al., 2003; Stocker et al., 2003; Tee et al., 2003) and appears to be necessary for the 
activation of mTORC1 by all signals, including amino acid availability (Avruch et al., 2006; 
Nobukuni et al., 2005; Sancak et al., 2008; Saucedo et al., 2003; Tee et al., 2005; Tee et al., 
2003; Zhang  et al., 2003). In contrast, TSC1-TSC2 is dispensable for the regulation of mTORC1 
by amino acids and, in cells lacking TSC2, the mTORC1 pathway is sensitive to amino acid 
starvation but resistant to growth factor withdrawal (Roccio et al., 2006; Smith et al., 2005.).  
Recently, the Rag GTPases, which are also members of the Ras-family of GTP-binding 
proteins, were shown to be amino acid-specific regulators of the mTORC1 pathway (Kim et al., 
2008; Sancak et al., 2008). Mammals express four Rag proteins—RagA, RagB, RagC, and 
RagD—that form heterodimers consisting of RagA or RagB with RagC or RagD. RagA and 
RagB, like RagC and RagD, are highly similar to each other and are functionally redundant 
(Hirose et al., 1998; Sancak et al., 2008; Schurmann et al., 1995; Sekiguchi et al., 2001). Rag 
heterodimers containing GTP-bound RagB interact with mTORC1, and amino acids induce the 
mTORC1-Rag interaction by promoting the loading of RagB with GTP, which enables it to 
directly interact with the raptor component of mTORC1 (Sancak et al., 2008). The activation of 
the mTORC1 pathway by amino acids correlates with the movement of mTORC1 from an 
undefined location to a compartment containing Rab7 (Sancak et al., 2008), a marker of both late 
endosomes and lysosomes (Chavrier et al., 1990; Luzio et al., 2007). How the Rag proteins 
regulate mTORC1 is unknown, but, in cells expressing a RagB mutant that is constitutively 
bound to GTP (RagBGTP), the mTORC1 pathway is insensitive to amino acid starvation and 
mTORC1 resides in the Rab7-positive compartment even in the absence of amino acids (Sancak 
et al., 2008). We previously proposed that amino acids promote the translocation of mTORC1—
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in a Rag-dependent fashion—to the surface of an endomembrane compartment where mTORC1 
can find its well-known activator Rheb. Here, we show that the lysosomal surface is the 
compartment where the Rag proteins reside and to which mTORC1 moves in response to amino 
acids. We identify the trimeric Ragulator protein complex as a new component of the mTORC1 
pathway that interacts with the Rag GTPases, is essential for localizing them and mTORC1 to 
the lysosomal surface, and is necessary for the activation of the mTORC1 pathway by amino 
acids. In addition, by expressing in cells a modified raptor protein that targets mTORC1 to the 
lysosomal surface, we provide evidence that supports our model of mTORC1 pathway activation 
by amino acids. 
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Results 
Amino acids cause the translocation of mTORC1 to lysosomal membranes, where the Rag 
GTPases are already present 
To better define the compartment to which mTORC1 moves upon amino acid 
stimulation, we co-stained human cells with antibodies to endogenous mTOR, raptor, or RagC as 
well as to various endomembrane markers (data not shown). This revealed that in the presence, 
but not the absence, of amino acids mTOR and raptor co-localized with LAMP2 (Figures 1A and 
1B), a well-characterized lysosomal marker (reviewed in (Eskelinen, 2006)).  Amino acid 
stimulation also resulted in an appreciable increase in the average size of lysosomes, which, as 
determined by live cell imaging, was most likely caused by lysosome-lysosome fusion (R.Z., 
unpublished results). The amino acid-induced movement of mTOR to the LAMP2-positive 
compartment depends on the Rag GTPases as it was eliminated by the RNAi mediated co-
knockdown of RagA and RagB (Figures 1H and 1I). Endogenous RagC also co-localized 
extensively with LAMP2, but, unlike mTORC1, this co-localization was unaffected by amino 
acid availability (Figure 1C). Consistent with amino acids not regulating the interaction between 
RagC and RagA or RagB (Figure 1D), an antibody that recognizes RagA and RagB stained 
lysosomes in both amino acid-starved and replete cells (Figure 1E). Lastly, GFP-tagged wild-
type and GTP-bound mutants of RagB (RagBGTP) and RagD (RagDGTP) behaved identically to 
their endogenous counterparts (Figures 1F and 1G). Thus, amino acids stimulate the 
translocation of mTORC1 to the lysosomal surface, where the Rag GTPases reside irrespective 
of their GTP-loaded states or amino acid availability. Given that mTORC1 interacts with the Rag 
heterodimers in an amino acid-dependent fashion (Sancak et al., 2008), the mTORC1 and Rag 
localization data are consistent with the Rag GTPases serving as an amino acid-regulated 
docking site for mTORC1 on lysosomes.   
 
The translocation of mTORC1 to lysosomes does not depend on growth factors, Rheb, or 
mTORC1 activity 
The movement of mTORC1 to lysosomes is a specific response to amino acids. In wild-
type mouse embryonic fibroblasts (MEFs), amino acids promoted the translocation of mTORC1 
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to lysosomes even when cells were cultured in the absence of serum (Figure 2A), a condition in 
which mTORC1 signaling, as detected by phosphorylated S6K1, is not active (Figure 2B). 
Conversely, in the absence of amino acids, neither serum stimulation nor constitutive activation 
of Rheb caused by the loss of TSC2, led to the lysosomal translocation of mTORC1 (Figure 2A). 
In both wild-type and TSC2-null MEFs, RNAi-mediated suppression of Rheb1 expression 
inhibited mTORC1 activation by amino acids (Figure 2C), but did not interfere with the amino 
acid-induced movement of mTOR to lysosomes (Figure 2D). Thus, the amino acid-induced 
translocation of mTORC1 to the lysosomal surface occurs independently of mTORC1 activity 
and does not require TSC2, Rheb, or growth factors.  
 
The trimeric Ragulator complex interacts with the Rag GTPases and co-localizes with them 
on lysosomal membranes 
 Inspection of the amino acid sequence of the Rag GTPases did not reveal any obvious 
lipid modification signals that might mediate Rag recruitment to lysosomal membranes. Thus, 
we pursued the possibility that unknown Rag-interacting proteins are needed to localize the Rag 
GTPases to lysosomes and play a role in mTORC1 signaling. To identify such proteins we used 
protein purification approaches that have led to the discovery of other mTOR pathway 
components (see methods). Mass spectrometric analysis of anti-FLAG immunoprecipitates 
prepared from human HEK-293T cells stably expressing FLAG-RagB or FLAG-RagD, but not 
FLAG-Rap2a, consistently revealed the presence of proteins encoded by the MAPKSP1, 
ROBLD3, and c11orf59 genes (Figure 3A). Furthermore, the same proteins were also detected in 
immunoprecipitates of endogenous RagC but not control proteins like p53 or tubulin. Previous 
work indicates that these three small proteins interact with each other, localize to endosomes and 
lysosomes, and play positive roles in the MAPK pathway (Lunin et al., 2004; Nada et al., 2009; 
Schaeffer et al., 1998; Teis et al., 2006; Teis et al., 2002; Wunderlich et al., 2001). The proteins 
encoded by MAPKSP1, ROBLD3, and c11orf59 have been called MP1, p14, and p18, 
respectively, and we use these names throughout this study. For convenience and because MP1, 
p14, and p18 are Rag and mTORC1 regulators (see below) we refer to the trimeric complex as 
the ‘Ragulator’.  
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Orthologues of MP1, p14, and p18 are readily detectable in vertebrates as well as in 
Drosophila (Figure 3A), but extensive database searches did not reveal any potential orthologues 
in budding or fission yeast. The amino acid sequences of MP1, p14, and p18 reveal little about 
their function and other than p14, which has a roadblock domain of unknown function (Koonin 
and Aravind, 2000), the proteins do not share sequence homology amongst themselves or with 
any other proteins in the databases besides their direct orthologues. In particular, they do not 
share any sequence similarity with the Ego1p or Ego3p, proteins, which interact with Gtr1p and 
Gtr2p (Dubouloz et al., 2005; Gao and Kaiser, 2006), the orthologues of the Rag proteins in 
budding yeast (Gao and Kaiser, 2006; Schurmann et al., 1995). The lysosomal localization of 
p18 requires its lipidation through N-terminal myristoylation and palmitoylation sites and p18 
likely serves as a platform for keeping MP1 and p14 on the lysosomal surface (Nada et al., 
2009). 
In humans a mutation that leads to a partial reduction in the expression of p14 causes a 
pronounced growth defect so that individuals carrying the mutation are below the third percentile 
in age-adjusted height (Bohn et al., 2006). Furthermore, mice engineered to lack either p14 or 
p18 die around embryonic day 7-8 and exhibit severe growth retardation (Nada et al., 2009; Teis 
et al., 2006). Given the major role of the mTORC1 pathway in growth control, these loss of 
function phenotypes were of interest to us. 
 As an initial step in verifying our mass spectrometric identification of MP1, p14, and p18 
as Rag-interacting proteins, we co-expressed them along with RagB and RagD in HEK-293T 
cells and found that the Ragulator, but not the control Rap2A protein, co-immunoprecipitated 
both Rag GTPases but not the metap2 protein that has the same molecular weight as tagged 
RagB (Figure 3B). Furthermore, when co-expressed with a RagB mutant (RagBGTP) that binds 
constitutively to GTP, the Ragulator co-immunoprecipitated the mTORC1 components raptor 
and mTOR (Figure 3C), consistent with the GTP-loading of RagB promoting the interaction of 
the Rag heterodimers with mTORC1 (Sancak et al., 2008). Furthermore, endogenous RagA, 
RagB, and RagC co-purified with recombinant Ragulator (Figure 3D) and endogenous Ragulator 
components co-purified with the recombinant RagB-RagD heterodimer (Figure 3E). Lastly, 
endogenous p14 and MP1 were present in immunoprecipitates prepared with an antibody 
directed against endogenous RagC that readily co-immunoprecipitates RagA (Figure 3F).  
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Amino acids did not appreciably regulate the interaction of recombinant p18 with 
endogenous p14, MP1 or the Rag GTPases (Figure 3G). Similarly, amino acids did not affect the 
interaction of endogenous Ragulator with endogenous Rag A/B (Figure 3H). The amounts of 
p14, p18, and MP1 that co-immunoprecipitated with the GTP-bound RagB mutant (RagBGTP) 
were slightly less than with wild-type RagB (Figure 3I). Because mTORC1 pathway activity is 
high in cells expressing RagBGTP (Sancak et al., 2008) the reduced Ragulator-Rag interaction in 
these cells may reflect a compensatory mechanism to reduce mTORC1 activity. To test if the 
Rag GTPases interact with one or more Ragulator components directly, we performed in vitro 
binding assays between purified RagB-RagD heterodimers and individual Ragulator proteins. 
p18 interacted with RagB-RagD in vitro, but not with the Rap2a control protein (Figure 3K). In 
contrast, we did not detect a direct interaction between either p14 or MP1 and the Rag GTPases 
(data not shown), suggesting that p18 is the principal Rag-binding subunit of the Ragulator. 
Lastly, within HEK-293T cells, GFP-tagged p18 co-localized with endogenous RagA/B and 
RagC (Figure 3J). Collectively, these results show that the Ragulator interacts with the Rag 
GTPases and that a super-complex consisting of Ragulator, a Rag heterodimer, and mTORC1 
can exist within cells. 
 
Ragulator localizes the Rag proteins to the lysosomal surface and is necessary for the 
amino acid-dependent recruitment of mTORC1 to the same compartment 
Because the Rag GTPases interact with Ragulator and given the function of p18 in 
localizing MP1 and p14 to lysosomes (Nada et al., 2009), it seemed possible that the Ragulator is 
necessary for localizing the Rag proteins to the lysosomal surface. Indeed, in cells lacking p14 or 
p18 (Nada et al., 2009; Teis et al., 2006), endogenous RagC was localized in small puncta 
throughout the cytoplasm of the cells rather than to lysosomes (Figure 4A), the morphology of 
which was not obviously affected by the loss of either protein. In contrast, in p14+/+ cells or p18-
null cells reconstituted with wild-type p18 (p18rev), RagC constitutively co-localized with the 
LAMP2 lysosomal marker (Figure 4A). Analogous results were obtained in HEK-293T cells 
with an RNAi-mediated reduction in MP1 expression (Figure 5A). Consistent with the essential 
role of the Rag proteins in the translocation of mTORC1 to the lysosomal surface (Figures 1H 
and 1I ), in cells lacking p14 or p18 or in HEK-293T cells with p14, p18, or MP1 knockdowns, 
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amino acids failed to induce lysosomal recruitment of mTOR, which was found throughout the 
cytoplasm in both amino acid starved and stimulated cells (Figures 4B, 5B, and 5D). Thus, all 
Ragulator subunits are required for lysosomal targeting of the Rag GTPases and mTORC1. 
To determine if Ragulator is sufficient to control the intracellular localization of the Rag 
proteins, it was necessary to target Ragulator to a location that is distinct from the lysosomal 
surface. As p18 binds both p14 and MP1 and is necessary for targeting them to the lysosomal 
surface (Nada et al., 2009), we chose to manipulate the intracellular localization of p18. To 
accomplish this we generated a variant of p18, called p18mito, which lacks its N-terminal 
lipidation sites but is fused at its C-terminus to the transmembrane region of OMP25, which is 
sufficient to target heterologous proteins to the mitochondrial surface (Nemoto and De Camilli, 
1999). When expressed in p18-null cells, p18mito was associated with mitochondria as verified by 
co-localization with the established mitochondrial protein Cytochrome c (Figure 5E). 
Remarkably, in the p18-null cells expressing p18mito, RFP-tagged RagB co-localized with the 
mitochondrial marker GFP-mito (Figure 4C). In contrast, RFP-RagB did not co-localize with 
GFP-mito in p18-null cells (p18-/-) or p18rev cells, and instead was present in a cytoplasmic or 
lysosomal pattern, respectively (Figure 4C). In cell expressing p18mito, mTORC1 activity 
remained very low and mTOR was not recruited to the mitochondria (Figures 5E and 5F), likely 
because the mitochondrial surface does not contain the machinery necessary to load the Rag 
GTPases with the appropriate nucleotides. These results indicate that the location of p18 is 
sufficient to define that of the Rag proteins and are consistent with Ragulator serving as a 
constitutive docking site on lysosomes for the Rag heterodimers, which, in amino acid-replete 
cells, have an analogous function for mTORC1. 
 
Ragulator is necessary for TORC1 activation by amino acids in mammalian and 
Drosophila cells 
 We employed the cells lacking p14 or p18 to determine if Ragulator is necessary for 
mTORC1 activation by amino acids. Strikingly, in both p14- and p18-null cells, but not in 
control cells, amino acids were incapable of activating the mTORC1 pathway as detected by the 
phosphorylation of S6K1 (Figures 6A and 6B) and 4E-BP1 (Figure 6H). Similarly, cells derived 
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from patients with a homozygous mutation in the p14 gene that causes a reduction in p14 
expression (Bohn et al., 2006) showed a defect in amino acid-induced mTORC1 activation 
compared to cells derived from a healthy donor (Figure 6E). In addition, autophagy, a process 
normally inhibited by mTORC1, was activated in p14-null cells, as detected by an increase 
compared to in control cells in the size and number of GFP-LC3-II puncta (Figure 6I). mTORC1 
activity was also suppressed in HEK-293T cells with RNAi-induced reductions in p14, p18, or 
MP1 levels (Figures 6C and 5C). Consistent with the known requirement of amino acids and Rag 
function for growth factors to activate mTORC1 (Sancak et al., 2008), serum was also incapable 
of activating the mTORC1 pathway in cells null for p14 or p18 (Figures 6A and 6B). In contrast, 
no defect was observed in the level of S473 phosphorylation of Akt (Figure 6D). In fact, Akt 
phosphoylation was slightly higher in the p14-null and p18-null cells than in controls cells, 
which likely results from the lack of the well-appreciated inhibitory input from mTORC1 to the 
PI3K pathway in these cells (reviewed in (Manning, 2004)). As mTORC2 is the growth factor-
regulated S473 kinase of Akt (Sarbassov et al., 2005), these results also indicate that the 
Ragulator does not play a detectable positive role in mTORC2 signaling. Interestingly, in the 
p18-null cells the expression of RagA and RagC was higher than in control cells (Figure 6B), 
suggesting that feedback signals in these cells may be trying to overcome the defect in mTORC1 
activity by boosting Rag expression or that Ragulator also negatively controls Rag GTPase 
levels. Consistent with p18, p14, and MP1 forming a complex, the expression or stability of the 
Ragulator proteins seems to be co-regulated because in cells that lack p14, p18 protein levels are 
also reduced, and, similarly, in cells that lack p18, p14 protein levels are also low (Figure 3L). A 
well-known function of the mTORC1 pathway is the positive regulation of cell growth, so that 
inhibition of the pathway leads to a reduction in cell size (Fingar et al., 2002; Kim et al., 2002). 
Consistent with Ragulator being a positive component of the mTORC1 pathway, the p14- and 
p18-null cells were smaller in size than their respective controls (Figure 6F). 
 Many components of the TORC1 pathway, such as the Rag proteins, have conserved 
roles in mammalian and Drosophila cells (Kim et al., 2008; Sancak et al., 2008). RNAi-inducing 
dsRNAs that target the Drosophila orthologues of MP1 (CG5110), p14 (CG5189), and p18 
(CG14184) were as effective at blocking amino acid-stimulated activation of dTORC1 in 
Drosophila S2 cells as dsRNAs targeting dRagC (Figure 6G). Our loss of function experiments 
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indicate that Ragulator is a component of the TORC1 pathway that, like the Rag GTPases, is 
essential for amino acids to activate TORC1 signaling in mammalian and Drosophila cells. 
  
Forced targeting of mTORC1 to the lysosomal surface eliminates the amino acid sensitivity 
of the mTORC1 pathway 
The findings we have presented so far are consistent with the amino acid-induced 
movement of mTORC1 to the lysosomal surface being necessary for the activation of mTORC1 
by amino acids. To test if the placement of mTORC1 on lysosomal membranes is sufficient to 
mimic the amino acid input to mTORC1, it was necessary to force mTORC1 onto these 
membranes in the absence of amino acids. To accomplish this we expressed in HEK-293T cells 
modified raptor proteins that consist of epitope-tagged raptor fused to the intracellular targeting 
signals of Rheb1 or Rap1b, small GTPases that localize, in part, to the lysosomal surface (Pizon 
et al., 1994; Saito et al., 2005; Sancak et al., 2008). Because the targeting signals of these 
proteins are in their C-terminal tails, we added the last 15 or 17 amino acids of Rheb1 or Rap1b, 
respectively, to the C-terminus of raptor (Figure 7A). For simplicity, we refer to these fusion 
proteins as raptor-Rheb15 and raptor-Rap1b17. As a control we generated a raptor fusion protein 
that lacks the CAAX box of the Rheb1 targeting signal (raptor-Rheb15DCAAX) and so cannot 
associate with membranes (Buerger et al., 2006; Clark et al., 1997; Takahashi et al., 2005).  
When expressed in cells together with myc-mTOR, raptor-Rheb15 and raptor-Rap1b17 localized 
to lysosomes in the presence or absence of amino acids, as judged by co-staining with LAMP2 
(Figure 7B). In contrast, raptor-Rheb15DCAAX behaved like wild-type raptor and localized to 
lysosomes only upon amino acid stimulation (Figure 7B). In all cases the localization of the co-
expressed myc-mTOR mirrored that of the wild-type or altered forms of raptor, indicating that 
C-terminal modifications of raptor do not perturb its interaction with mTOR (Figure 7C), which 
was confirmed in co-immunoprecipitation experiments (Figure 10A). 
Remarkably, transient expression of raptor-Rheb15 or raptor-Rap1b17 in HEK-293T 
cells was sufficient to render the mTORC1 pathway, as judged by the phosphorylation of S6K1, 
resistant to amino acid starvation (Figure 8A). In contrast, the expression of wild-type raptor or 
raptor-Rheb15DCAAX did not affect the amino acid sensitivity of the pathway (Figure 8A). In 
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HEK-293E cells, the expression of raptor-Rheb15 made S6K1 phosphorylation insensitive to 
amino acid starvation, but did not affect its regulation by insulin (Figure 8B). Thus, lysosomal 
targeting of mTORC1 can substitute for the amino acid, but not growth factor, input to 
mTORC1. This is consistent with previous work showing that growth factors signal to mTORC1 
in large part through the TSC1-TSC2-Rheb axis (Dan et al., 2002; Gao and Pan, 2001; Garami et 
al., 2003; Inoki et al., 2002; Ma et al., 2005; Manning et al., 2002; Potter et al., 2001; Potter et 
al., 2002), and not through the Rag GTPases (Sancak et al., 2008). 
To verify the effects of lysosomally-targeted mTORC1 in a more physiological setting 
than that achieved by transient cDNA expression, we generated HEK-293T cell lines stably 
expressing FLAG-tagged raptor-Rheb15 or wild-type raptor. In cells expressing the lysosomally-
targeted but not wild-type raptor, mTOR was always associated with lysosomes, irrespective of 
amino acids (Figure 8C). As with the transient expression of raptor-Rheb15, its stable expression 
rendered the mTORC1 pathway fully resistant to amino acid starvation (Figure 8D). 
Furthermore, under normal growth conditions these cells had an increase in mTORC1 activity 
and were larger than controls (Figure 8E). 
We next examined if the targeting of mTORC1 to membranes other than lysosomal 
membranes could also eliminate the amino acid sensitivity of the mTORC1 pathway. This was 
not the case because although the stable expression of a raptor variant consisting of raptor fused 
to the last 25 amino acids of H-Ras (raptor-HRas25) (Figures 7A and 10B) was sufficient to 
target a fraction of cellular mTOR to the plasma membrane (Figure 8C), it did not render the 
mTORC1 pathway resistant to amino acid starvation (Figure 8D). 
 
Forced targeting of mTORC1 to the lysosomal surface eliminates the requirement in 
mTORC1 signaling for Rag and Ragulator, but not Rheb, function 
The ability to constitutively localize mTORC1 to lysosomal membranes enabled us to 
probe in more detail the role of the Rag and Rheb GTPases, as well as Ragulator, in the 
activation of mTORC1 by amino acids. We hypothesized that if the major role of the Rag 
GTPases is to allow mTORC1 to localize to lysosomes, then in cells that express raptor-Rheb15, 
mTORC1 activity should be independent of Rag function. Indeed, while in control cells the 
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RNAi-mediated knockdown of both RagA and RagB strongly blunted the activation of mTORC1 
by amino acids, it did not reduce the amino acid-insensitive mTORC1 activity observed in 
raptor-Rheb15 expressing cells (Figure 9A). As an additional approach to inhibit Rag function, 
we exploited the fact that co-expression of a GDP-bound RagB mutant (RagBGDP) and a GTP-
bound RagD mutant (RagDGTP) eliminates mTORC1 pathway activity within cells (Kim et al., 
2008; Sancak et al., 2008). Expression of RagBGDP-RagDGTP completely prevented mTORC1 
activation by amino acids in control cells, but had no effect on the amino acid-insensitive 
mTORC1 activity of cells expressing raptor-Rheb15 (Figure 9B).  
If the main function of Ragulator in the mTORC1 pathway is to localize the Rag 
GTPases to the lysosomes then it should be possible to reactivate the mTORC1 pathway in 
Ragulator-null cells by expressing raptor-Rheb15. Remarkably, the stable expression of raptor-
Rheb15, but not wild-type raptor, in p14- or p18-null cells reactivated mTORC1 signaling and 
made it insensitive to amino acid deprivation (Figures 9C and 9D). Furthermore, expression of 
raptor-Rheb15 in the p18-null cells was sufficient to increase their size (Figure 9E). In contrast to 
the results observed with the Rag GTPases and Ragulator, RNAi-mediated suppression of Rheb1 
blocked amino acid-induced mTORC1 activation in cells expressing raptor-Rheb15 to the same 
extent as it did in control cells (Figure 9F). 
To test whether the presence of mTORC1 and Rheb on the same membrane compartment 
is sufficient to render the mTORC1 pathway insensitive to amino acid levels, we generated cells 
in which mTORC1 and Rheb are both present on the plasma membrane. To accomplish this we 
prepared a Rheb1 variant, called Rheb1-HRas25, that localizes to the plasma-membrane (Figure 
10C) because it contains the C-terminal 25 amino acids of H-Ras instead of the normal Rheb1 
localization signal. When Rheb1-HRas25 was stably co-expressed with raptor-HRas25, but not 
wild-type raptor, the mTORC1 pathway became insensitive to amino acid starvation (Figure 9G). 
Importantly, mTORC1 signaling remained amino acid-sensitive in cells in which either Rheb or 
mTORC1, but not both, was targeted to the plasma membrane (Figure 9G).  
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Discussion 
Our findings, together with previous work showing that Rheb is required for amino acids 
to activate the mTORC1 pathway (Avruch et al., 2006; Nobukuni et al., 2005; Sancak et al., 
2008; Saucedo et al., 2003; Tee et al., 2005; Tee et al., 2003) and can localize to late 
endosomes/lysosomes (Saito et al., 2005; Sancak et al., 2008), is consistent with a model in 
which amino acids induce mTORC1 to associate with the endomembrane system of the cell and 
thus allow it to encounter its activator Rheb. In this model the essential role of the Ragulator-Rag 
complex is to serve as an amino acid-regulated docking site for mTORC1 on lysosomal 
membranes (see schematic in Figure 9H). The proposed link between the Rag and Rheb GTPases 
in the regulation of the mTORC1 pathway provides an explanation for why activation of 
mTORC1 occurs only when activators of both Rheb (e.g., growth factors and energy) and the 
Rags (i.e., amino acids) are available. For technical reasons (Buerger et al., 2006; Sancak et al., 
2008), it has not been possible to determine the intracellular localization of endogenous Rheb 
and work using overexpressed GFP-tagged Rheb1 has placed it on various endomembrane 
compartments, including endosomes and lysosomes (Buerger et al., 2006; Saito et al., 2005; 
Sancak et al., 2008; Takahashi et al., 2005). Our results suggests that at some point in its life 
cycle Rheb must traverse the lysosomal surface in order to encounter mTORC1 and so in our 
model we have chosen to place Rheb on this compartment (Figure 9H). However, at any given 
time only a small fraction of cellular Rheb may actually be on the lysosomal surface or, 
alternatively, some of the mTORC1 within the cell may move to a non-lysosomal 
endomembrane compartment that also contains Rheb. These issues will only be answered once a 
definitive location for endogenous Rheb can be determined. 
The trimeric p14, p18, and MP1 protein complex, which we call Ragulator, is a Rag-
interacting complex that is essential for amino acid signaling to mTORC1 and represents an 
additional critical component of the TORC1 signaling pathway in mammals and flies. p18 
directly interacts with the Rag GTPases (Figure 3K) as well as with p14 and MP1 (Nada et al., 
2009) and so may serve as a scaffold to bring the Rag GTPases and MP1-p14 next to each other.  
In vitro we have not detected a direct interaction between the Rag GTPases and either MP1 or 
p14, but both proteins are, like p18, necessary for localizing the Rag GTPases to the lysosomal 
surface. p14 is required to maintain normal p18 expression levels (Figure 3L), suggesting that 
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within cells p14 and MP1 form a crucial part of the Ragulator structure. Given the non-specific 
nature of the p14 and p18 names, in the future it may be best to rename these proteins, perhaps to 
names that reflect their essential roles in the mTORC1 pathway. 
The location of the Rag GTPases, the Ragulator, and mTORC1 on the lysosomal surface 
implicates this organelle as the site of a yet to be discovered sensing system that signals amino 
acid availability to the Ragulator-Rag complex. The lysosomal location of the amino acid 
sensing branch of the mTORC1 pathway is consistent with increasing evidence that lysosomes, 
and their yeast counterparts, vacuoles, are at the nexus of amino acid metabolism within cells. 
Lysosomes are a major site of protein degradation and amino acid recycling and vacuoles store 
amino acids at high concentrations (reviewed in (Li and Kane, 2009)). Thus, mTORC1 and its 
regulators may reside on the lysosomal surface so as to sense a currently unknown aspect of 
lysosomal function that reflects the intracellular pools of amino acids. 
It is interesting to consider the differences and similarities between the still poorly 
understood amino acid signaling mechanisms employed by the mTORC1 and yeast TORC1 
pathways. Consistent with previous work in mammalian cells (Sancak et al., 2008), the Gtr1p-
Gtr2p heterodimer that is orthologous to RagA/B-RagC/D, interacts with yeast TORC1 when 
Gtr1p is GTP-loaded (Binda et al., 2009). TORC1 and the Gtr proteins are located on the surface 
of the vacuole (Berchtold and Walther, 2009; Binda et al., 2009), the yeast equivalent of 
lysosomes, but, unlike in mammals, yeast TORC1 does not leave the vacuolar surface upon 
amino acid deprivation although amino acids do control the interaction of TORC1 with Gtr1p-
Gtr2p (Binda et al., 2009). This finding suggests that there must exist a distinct mechanism for 
retaining TORC1 at the vacuolar surface and that in yeast the interaction between TORC1 and 
Gtr1p-Gtr2p serves other purposes besides controlling the intracellular location of TORC1. In 
contrast, our current work argues that in mammals the main role of the Rag GTPase and the 
associated Ragulator complex is to control the association of mTORC1 with the cellular 
endomembrane system, in particular, lysosomes. Rheb, which is essential for the activation of 
mTORC1 by all upstream signals (Avruch et al., 2006; Nobukuni et al., 2005; Sancak et al., 
2008; Saucedo et al., 2003; Tee et al., 2005; Tee et al., 2003), does not appear to be part of the 
TORC1 pathway in S. cerevisiae (reviewed in (Berchtold and Walther, 2009)). As we suggest 
that the Rag-dependent and amino acid-regulated translocation of mTORC1 to the lysosomal 
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surface may ultimately be a mechanism for controlling the access of mTORC1 to Rheb, the 
absence of Rheb in the yeast TORC1 pathway may make regulation of TORC1 localization 
unnecessary. That known Rag- and Gtr-interacting proteins share no sequence homology also 
suggests that the mechanisms through which the Rag and Gtr GTPases regulate mTORC1 and 
yeast TORC1, respectively, have diverged. Although it is clear that the Ragulator and EGO 
complexes both control the intracellular localization of the Rag (this paper) and Gtr (Gao and 
Kaiser, 2006) GTPases, respectively, whether these complexes have additional functions remains 
to be determined. 
Previous studies suggest that MP1-p14-p18 complex plays an adaptor role in the MAP 
Kinase (MAPK) pathway (reviewed in (Dard and Matthias, 2006)) and our current findings do 
not contradict these results. However, considering the very strong inhibition of the mTORC1 
pathway that occurs in cells lacking p14 or p18, it seems possible that some of the impairment in 
MAPK signaling observed in those cells reflects an altered feedback signaling from Akt to the 
MAPK pathway. For example, in Ragulator-null cells, Akt is slightly activated, almost certainly 
because the well-known inhibitory signal from mTORC1 to PI3K is absent. As Akt suppresses 
MAPK signaling by phosphorylating and inhibiting Raf (Zimmermann and Moelling, 1999), it is 
conceivable that the activation of Akt that occurs in Ragulator-null cells could account, at least in 
part, for the inhibition of MAPK signaling that has been observed in these cells. 
Mice lacking either p14 or p18 die around embryonic day 7.5-8 and have obvious growth 
defects (Nada et al., 2009; Teis et al., 2006). We would not be surprised if, when generated, mice 
lacking the Rag proteins die at around the same age and present similar defects. On the other 
hand, mice lacking the core mTORC1 component raptor die earlier (before embryonic day 6.5) 
than p14- and p18-null mice (Guertin et al., 2006). This may be expected because although loss 
of p14 or p18 completely blocks mTORC1 activation by amino acids, cells lacking the Ragulator 
proteins are likely to retain a low residual level of mTORC1 activity that may be sufficient to 
support development further than in embryos completely lacking mTORC1 function. Lastly, our 
results suggest that the strong growth retardation observed in humans with a mutation that 
reduces p14 expression (Bohn et al., 2006), is a result of partial suppression of the mTORC1 
pathway. If this turns out to be the case, it would represent the first human example of a loss of 
function mutation in a positive component of the mTORC1 pathway. 
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Materials and Methods 
 
Materials 
Reagents were obtained from the following sources: antibodies to phospho-T389 S6K1, 
S6K1, mTOR, raptor, RagA/B, RagC, p14, p18, MP1, the myc epitope, the HA epitope, the 
FLAG epitope (unconjugated and alexa fluor conjugated), TSC2, phospho-T398 dS6K, phospho-
S473 Akt, Akt1, phospho-T70 4E-BP1, 4E-BP1, and Rheb from Cell Signaling Technology; 
antibodies to LAMP2 from Abcam (ab25631 and ab13524); antibody to raptor (for 
immunostaining) from Millipore; antibody to Cytochrome c from BD Biosciences; HRP-labeled 
anti-mouse, anti-goat, and anti-rabbit secondary antibodies from Santa Cruz Biotechnology; 
FLAG M2 affinity gel, FLAG M2 antibody, human recombinant insulin, from Sigma Aldrich; 
protein G-sepharose and dialysis cassettes from Thermo Scientific; DMEM from SAFC 
Biosciences; FuGENE 6 and Complete Protease Cocktail from Roche; alexa fluor conjugated 
secondary antibodies from Invitrogen; 16% paraformaldehyde solution from Electron 
Microscopy Sciences; fibronectin from Jackson Immunoresearch Laboratories; 35 mm glass 
bottom dishes from Mattek Corporation; glass coverslips from Ted Pella, Inc; amino acid and 
glucose-free RPMI from United States Biological; Schneider's medium, Drosophila-SFM, and 
Inactivated Fetal Calf Serum (IFS) from Invitrogen. The dS6K antibody was a generous gift 
from Mary Stewart (North Dakota State University).  
 
Identification of Ragulator Components as Rag-associated Proteins 
 Ragulator components (MP1, p14, and p18) were detected in anti-FLAG 
immunoprecipitates prepared from HEK-293T cells stably expressing FLAG-RagB or FLAG-
RagD as well as in immunoprecipitates of endogenous RagC prepared from HEK-293T cells. 
Immunoprecipitates were prepared as described (Sancak et al., 2008). Proteins were eluted with 
the FLAG peptide from the anti-FLAG affinity matrix or recovered from the protein G-sepharose 
by boiling with sample buffer, resolved by SDS-PAGE, and stained with simply blue stain 
(Invitrogen). Each gel lane was sliced into 10-12 pieces and the proteins in each gel slice 
digested overnight with trypsin. The resulting digests were analyzed by mass spectrometry as 
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described (Sancak et al., 2008). 2-3 peptides corresponding to each Ragulator component were 
identified in the FLAG-RagB and endogenous RagC immunoprecipitates, while no peptides 
corresponding to any of the proteins were ever found in the FLAG-Rap2a, p53, or a-tubulin 
immunoprecipitates that served as controls.  
 
Cell Lines and Tissue Culture 
HEK-293E cells; HEK-293T cells; TSC2+/+, TSC2-/-, p14+/+, and p14-/- MEFs were 
cultured in DMEM with 10% IFS. p18rev, p18mito, and p18-/- cells were cultured in DMEM with 
10% FBS. HEK-293E and HEK-293T cells express E1a and SV40 large T antigen, respectively. 
In HEK-293E, but not HEK-293T, cells the mTORC1 pathway is strongly regulated by serum 
and insulin (Sancak et al., 2007). TSC2-/-, p53-/- and TSC2+/+, p53-/- MEFs were kindly provided 
by Dr. David Kwiatkowski (Harvard Medical School). The HEK-293E cell line was kindly 
provided by Dr. John Blenis (Harvard Medical School). p14-/- and control MEFs were kindly  
provided by Dr. Lukas A. Huber (Innsbruck Medical University) and described in (Teis et al., 
2006). p18-/- cells are epithelial in nature and p18rev cells are p18-/- cells in which wild-type p18 
has been re-expressed (Nada et al., 2009). Patient-derived cells with a homozygous mutation in 
the p14 gene and control healthy donor-derived cells were kindly provided by Dr. Christoph 
Klein (Universität München) and have been described in (Bohn et al., 2006) 
 
Amino Acid and Serum Starvation and Stimulation of Cells 
Serum and/or amino acid starvation of HEK-293T cells, HEK-293E cells, p14-null and 
control cells, p18-null and control cells, MEFs, patient-derived and healthy donor-derived cells 
were performed essentially as described (Sancak et al., 2008). Serum was dialyzed against PBS 
in dialysis cassettes (Thermo Scientific) having a 3,500 molecular weight cut off.  
 
Preparation of Cell Lysates and Immunoprecipitations 
Cell lysate preparation, cell lysis and immunoprecipitations were done as described 
(Sancak et al., 2008).  
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For co-transfection experiments, 2 million HEK-293T or HEK-293E cells were plated in 
10 cm culture dishes. 24 hours later, cells were transfected with the indicated plasmids as 
follows: 50 ng or 1500 ng myc-mTOR in pRK5; 20 ng or 500 ng HA-, myc- or FLAG-Raptor in 
pRK5 or pLJM1 with or without the targeting signals; 100 ng HA-GST-Rap2a in pRK5; 100 ng 
HA-GST-Rheb1 in pRK5; 100 ng HA-GST-RagB in pRK5, 100 ng HA-GST-RagD in pRK5; 1 
ng FLAG-S6K1 in pRK7; 50 ng or 600 ng HA- or FLAG-p14 in pRK5; 75 ng or 600 ng HA-
MP1 in pRK5; 50 ng or 800 ng HA-p18 in pRK5. The total amount of plasmid DNA in each 
transfection was normalized to 2 µg using empty pRK5.  
 
Cell Size Determinations 
To measure cell size, 2 million HEK-293T cells or 200,000 of other cell types were 
plated into 10 cm culture dishes. 24 hours later the cells were harvested by trypsinization in a 4 
ml volume and diluted 1:20 with counting solution (Isoton II Diluent, Beckman Coulter). Cell 
diameters were determined using a particle size counter (Coulter Z2, Beckman Coulter) running 
Coulter Z2 AccuComp software.  
 
Mammalian Lentiviral shRNAs and cDNAs 
Lentiviral shRNAs targeting human Rheb1, RagB, and RagC have been described 
(Sancak et al., 2008). Lentiviral shRNAs targeting mouse Rheb1 and human p14 were obtained 
from Sigma-Aldrich. Lentiviral shRNAs targeting the mRNA for human MP1 and human p18 
were cloned into pLKO.1 vector as described (Sarbassov et al., 2005). The target sequences are 
as follows:  
MP1_1: GAGATGGAGTACCTGTTATTA 
MP1_2: ATATCAATCCAGCAATCTTTA 
p18: AGACAGCCAGCAACATCATTG 
Virus generation and infection was done as previously described (Sancak et al., 2008).  
Raptor was cloned into the AgeI and BamHI sites of a modified pLKO.1 vector (pLJM1) 
(Sancak et al., 2008) with or without the Rheb1, Rap1b and HRas targeting signals or cloned into 
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the pRK5 vector with or without the same localization signals. After sequence verification, 
pLJM1 based plasmids were used in transient cDNA transfections or to produce lentivirus 
needed to generate cell lines stably expressing these proteins. pRK5 based plasmids were also 
used for transient transfection experiments. The p18mito expression plasmid was generated by 
cloning a mutant p18 with amino acids 2-5 changed to alanines into a modified version of the 
pLKO.1 vector that added, to the C-terminus of p18, the mitochondrial localization signal of 
OMP25 protein. This plasmid was used in transient cDNA transfections or to produce lentivirus 
needed to generate stable cell lines. HA-Rheb1 and HA-Rheb1-HRas25 were cloned into pLJM5, 
a derivative of pLJM1 carrying a hygromycin instead of puromycin resistance gene. The vectors 
were used as above for lentivirus production. 
 
Amino Acid Starvation and Stimulation and dsRNA-mediated Knockdowns in Drosophila 
Cells 
 Amino acid starvation and stimulation of Drosophila S2 cells was performed as 
described(Sancak et al., 2008). The design and synthesis of dsRNAs has also been described 
(Sancak et al., 2008).  
 Primer sequences used to amplify DNA templates for dsRNA synthesis for dp14, dp18, 
and dMP1, including underlined 5’ and 3’ T7 promoter sequences, are as follows:  
dp14 (CG5189) dsRNA forward primer: 
GAATTAATACGACTCACTATAGGGAGACTCTATTGGCCTACTCCGGTTAT  
dp14 (CG5189) dsRNA reverse primer: 
GAATTAATACGACTCACTATAGGGAGATATGAGGCCGAGATCTGCTTA 
dp18 (CG14184) dsRNA forward primer: 
GAATTAATACGACTCACTATAGGGAGAGCAGAATACTGCGATAAACATGATA 
dp18 (CG14184) dsRNA reverse primer: 
GAATTAATACGACTCACTATAGGGAGATGGATAGGTTGGCTTAGACAGATAG 
dMP1 (CG5110) dsRNA forward primer: 
GAATTAATACGACTCACTATAGGGAGAGTCGGACGACATCAAGAAGTATTTA  
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dMP1 (CG5110) dsRNA reverse primer: 
GAATTAATACGACTCACTATAGGGAGAAGTACATGGAGATGATGGTCTTGTT 
 
Immunofluorescence Assays 
50,000 HEK-293T cells or 20,000 of other cell types were plated on fibronectin coated 
glass coverslips in 12-well tissue culture plates. 24 hours later, the slides were rinsed with PBS 
once and fixed for 15 minutes with 4% paraformaldehyde in PBS warmed to 37°C. The slides 
were rinsed twice with PBS and cells were permealized with 0.05% Triton X-100 in PBS for 30 
seconds. After rinsing twice with PBS, the slides were incubated with primary antibody in 5% 
Normal Donkey Serum for 2 hours at room temperature, rinsed four times with PBS and 
incubated with secondary antibodies produced in donkey (diluted 1:1000 in 5% Normal Donkey 
Serum) for one hour at room temperature in the dark, washed four times with PBS. Slides were 
mounted on glass coverslips using Vectashield (Vector Laboratories) and imaged. 
 
In vitro Binding Assay 
2 million HEK-293T cells were transfected with 2 µg FLAG-p18 (lipidation mutant 
G2A), 2 µg HA-GST-Rap2a, or 2 µg HA-GST-RagB together with 2 µg of HA-GST-RagC. 2 
days after transfection, the cells were lysed in lysis buffer containing 1% Triton X-100 as 
described (Sancak et al., 2007) and cleared lysates were incubated with glutathione- or FLAG-
beads for 3 hours at 4°C with rotation. The beads were washed 3 times with lysis buffer and two 
times with lysis buffer containing 0.3% CHAPS. FLAG-p18 was eluted from FLAG beads with 
the FLAG peptide and 1/8 of the eluate was incubated with 1/4 of the Rag-containing glutathione 
beads in lysis buffer with 0.3% CHAPS for 45 min at 4°C. The glutathione beads were washed 
three times with lysis buffer containing 0.3% CHAPS and 150 mM NaCl. Proteins were 
denatured by the addition of 20 µl of sample buffer and boiling for 5 minutes and analyzed by 
SDS-PAGE and immunoblotting. 
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Transient Transfections for Immunofluorescence Assays 
For myc-mTOR and HA-raptor co-transfection experiments, HEK-293T cells were 
seeded in 60 mm culture plates. 24 hours later, cells were transfected with 500 ng myc-mTOR 
and 50 ng HA-Raptor. 24 hours after transfections, cells were split and plated on fibronectin 
coated glass coverslip in 12-well culture plates and processed as above.  
For GFP-RagB, GFP-RagD, p18-GFP, GFP-Mito, RFP-RagB, and LAMP1-mRFP co-
transfection experiments, HEK-293T cells (250,000 cells/dish) or p18-/-, p18rev or p18mito cells 
(50,000 cells/dish) were plated on 35 mm, glass-bottom Mattek dishes. The next day, each dish 
was transfected with 100 ng of GFP-RagB or GFP-RagD, p18-GFP, GFP-mito, RFP-RagB or 
LAMP1-mRFP using fugene. At 18-24 hours post transfections, cells were fixed and imaged. 
GFP-Mito has been described (Nemoto and De Camilli, 1999). 
For GFP-LC3 localization experiments, 2 million cells were transfected by 
electroporation with 1 µg of GFP-LC3 plasmid, and plated on 35 mm glass-bottom Mattek 
dishes. The next day the cells were starved for 3 hours in serum- and amino acid-free RPMI to 
induce autophagy and processed for imaging as above. 
All images were acquired with a spinning disk confocal microscope (Perkin Elmer) equipped 
with a Hamamatsu 1k X 1k EM-CCD camera. For each image, 8-10 optical slices were acquired 
and displayed as maximum projections.  
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Figure 1 
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Figure 1. mTORC1 localizes to lysosomal membranes in an amino acid-dependent fashion while 
the Rag GTPases are constitutively localized to the same compartment. (A) Images of HEK-
293T cells co-immunostained for lysosomal protein LAMP2 (green) and mTOR (red). Cells 
were starved of and restimulated with amino acids for the indicated times before processing and 
imaging. (B) Images of HEK-293T cells co-immunostained for LAMP2 (green) and raptor (red). 
Cells were treated and processed as in (A). (C) Images of HEK-293T cells co-immunostained for 
LAMP2 (green) and RagC (red). Cells were treated and processed as in (A). 
(D) RagC interacts with RagA and RagB independently of amino acid availability. RagC-
immunoprecipitates were prepared from HEK-293T cells starved or stimulated with amino acids 
as in (A), and immunoprecipitates and lysates were analyzed by immunoblotting for the 
indicated proteins. (E) Images of HEK-293T cells co-immunostained for RagA/B (green) and 
LAMP2 (red). Cells were treated, processed, and imaged as in (A). (F) GFP-RagB and GFP-
RagBGTP co-localize with co-expressed LAMP1-mRFP independently of amino acid availability. 
HEK-293T cells transfected with the indicated cDNAs were treated and processed as in (A). (G) 
GFP-RagD and GFP-RagDGTP co-localize with co-expressed LAMP1-mRFP independently of 
amino acid availability. HEK-293T cells transfected with the indicated cDNAs were treated and 
processed as in (A). (H) Immunoblot analysis of RagB and raptor protein levels in HEK-293T 
cells with an RNAi-mediated knockdown of a control protein or RagA and RagB. (I) Images of 
cells with knockdowns of RagA and RagB and co-immunostained for mTOR (green) and 
LAMP2 (red) after starvation and restimulation with amino acids for the indicated times. HEK-
293T cells expressing the indicated shRNAs were starved and restimulated with amino acids as 
indicated and processed in the immunofluorescence assay. In all images, insets show selected 
fields that were magnified five times and their overlays. Scale bar is 10 µm. 
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Figure 2 
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Figure 2. TSC1/2, Rheb and growth factors do not regulate the lysosomal localization of 
mTORC1. (A) mTOR co-localizes with LAMP2 only in the presence of amino acids and 
independently of serum stimulation. Images show co-immunostaining of mTOR (green) and 
LAMP2 (red) in TSC2+/+ and TSC2-/- MEFs after indicated treatments. Cells were starved for 
serum and amino acids, and stimulated with dialyzed serum, amino acids, or both before 
processing in the immunofluorescence assay. (B) Lysates from TSC2+/+ and TSC2-/- MEFs 
starved and stimulated as in (A) were analyzed by immunobloting for the activity of the 
mTORC1 pathway. (C) Loss of Rheb expression inhibits mTORC1 signaling in TSC2+/+ and 
TSC2-/- MEFs. Cells expressing the indicated shRNAs were starved for amino acids or starved 
and restimulated with amino acids and lysates analyzed by immunobloting for mTORC1 
pathway activity and Rheb1 levels. (D) mTOR co-localizes with LAMP2 only in the presence of 
amino acids and independently of Rheb or TSC2. Images show co-immunostaining of mTOR 
(green) and LAMP2 (red) in TSC2+/+ and TSC2-/- MEFs treated as in (C). In all images, insets 
show selected fields that were magnified five times and their overlays. Scale bar is 10 µm. 
 
	   162 
Figure 3 
	   163 
Figure 3. The trimeric Ragulator complex interacts and co-localizes with the Rag GTPases. (A) 
Schematic amino acid sequence alignment of human MP1, p14, and p18 and their corresponding 
Drosophila orthologs. (B) Recombinant epitope-tagged Ragulator co-immunoprecipitates 
recombinant RagB and RagD. Anti-FLAG immunoprecipitates were prepared from HEK-293T 
cells co-transfected with the indicated cDNAs in expression vectors and cell lysates and 
immunoprecipitates analyzed by immunoblotting for levels of indicated proteins. The * indicates 
the band corresponding to the metap2 protein as it has the same apparent molecular weight as 
HA-GST-RagB. (C) Recombinant Ragulator co-immunoprecipitates mTORC1 when it is co-
expressed with the GTP-bound mutant of RagB. HEK-293T cells were co-transfected with the 
indicated cDNAs in expression vectors and analyzed as in (B). The * indicates the bands 
corresponding to metap2 as it has the same apparent molecular weight as HA-GST-RagB. 
(D) Recombinant Ragulator co-immunoprecipitates endogenous RagA, RagB, and RagC. HEK-
293T cells were co-transfected with indicated cDNAs in expression vectors and anti-FLAG 
immunoprecipitates analyzed as in (B). (E) Recombinant RagB-RagD heterodimers co-
immunoprecipitate endogenous p14, MP1, and p18. HEK-293T cells were co-transfected with 
indicated cDNAs in expression vectors and anti-FLAG immunoprecipitates analyzed as in (B). 
(F) Endogenous RagC co-immunoprecipitates endogenous p14 and MP1. Anti-RagC 
immunoprecipitates were prepared from HEK-293T cells and analyzed for the levels of the 
indicated proteins. (G) Amino acids do not regulate the amounts of endogenous MP1, p14, 
RagA, or RagB that co-immunoprecipitate with recombinant p18. p18-null cells (p18-/-) or p18-
null cells stably expressing FLAG-p18 (p18rev) were starved for amino acids for 50 min or 
starved and restimulated with amino acids for 10 min. After in-cell cross-linking, anti-FLAG 
immunoprecipitates were prepared from cell lysates and analyzed for the levels of the indicated 
proteins by immunoblotting. (H) Amino acids do not affect the amounts of endogenous p14 and 
p18 that co-immunoprecipitate with endogenous RagA/B. HEK-293T cells were treated as in (G) 
and anti-RagA/B immunoprecipitates analyzed by immunoblotting for the indicated proteins. 
(I) Endogenous Ragulator co-immunoprecipitates with FLAG-RagB independently of amino 
acid availability and GTP-loading of RagB. HEK-293T cells stably expressing FLAG-RagB or 
FLAG-RagBGTP were starved and restimulated with amino acids as in (G) and anti-FLAG 
immunoprecipitates analyzed for the levels of indicated proteins. 
	   164 
(J) The Rag GTPases co-localize with GFP-tagged p18. HEK-293T cells were transfected with a 
cDNA encoding p18-GFP, processed for immunostaining for endogenous RagA/B or RagC, and 
imaged for the RagA/B (red) or RagC (red) signal as well as for p18-GFP fluorescence (green). 
Note: not all cells express p18-GFP. In all images, insets show selected fields that were 
magnified five times and their overlays. Scale bar is 10 µm. (K) In vitro binding assay using 
purified soluble FLAG-p18 and HA-GST-RagB/HA-GST-RagD heterodimer bound to 
glutathione beads was performed as described in the methods. (L) p14 protein levels are lower in 
p18-null cells than in p18-null cells expressing FLAG-p18 (p18rev). Similarly, in cells that lack 
p14 (p14-/-), p18 expression is reduced compared to control cells (p14+/+). Cells were grown to 
confluency, lysates were prepared, and the levels of the indicated proteins analyzed by 
immunoblotting.  
 
 
	   165 
	   166 
Figure 4 
	   167 
Figure 4. The Ragulator is necessary to localize the Rag GTPases and mTORC1 to lysosomal 
membranes (A) Images of p14-null or p18-null cells or their respective controls co-
immunostained for RagC (red) and LAMP2 (green). Cells were starved of and restimulated with 
amino acids for the indicated times before processing for the immunofluorescence assay and 
imaging. (B) Images of p14-null or p18-null cells or their respective controls co-immunostained 
for mTOR (red) and LAMP2 (green). Cells were treated and processed as in (A). (C) Co-
localization of mRFP-RagB (red) with GFP-Mito (green) in cells expressing mitochondrially-
localized p18. p18-null cells (p18-/-), or p18-null cells expressing wild type p18 (p18rev) or 
mitochondrially-localized p18 (p18mito), were transiently transfected with the indicated cDNAs in 
expression plasmids and imaged. In all images, insets show selected fields that were magnified 
five times and their overlays. Scale bar is 10 µm. 
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Figure 5 
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 Figure 5. The Ragulator is required for RagC localization to lysosomal membranes and, in 
response to amino acids, association of mTOR with lysosomes and mTORC1 activation. (A) An 
MP1 knockdown displaces RagC from the lysosomal surface. Images of cells with shRNA-
mediated knockdowns of a control protein or MP1 and co-immunostained for RagC (red) and 
LAMP2 (green). HEK-293T cells expressing the indicated shRNAs were starved of and 
restimulated with amino acids for the stated times and then processed in the immunofluorescence 
assay. (B) An MP1 knockdown impairs the recruitment of mTOR to the lysosomal surface in 
response to amino acid stimulation. Images of cells with shRNA-mediated knockdowns of a 
control protein or MP1 and co-immunostained for mTOR (red) and LAMP2 (green). HEK-293T 
cells expressing the indicated shRNAs were starved of and restimulated with amino acids for the 
stated times and then processed in the immunofluorescence assay. (C) Knockdown of p18 or p14 
in HEK-293T cells impair amino acid-induced mTORC1 activation. HEK-293T cells with 
RNAi-mediated knockdown of p14 or p18, or control cells, were starved for amino acids for 50 
min or starved and restimulated with amino acid for 10 min. Cell lysates were prepared and 
analyzed by immunoblotting for the phosphorylation states and levels of indicated proteins.  (D) 
Knockdown of p18 or p14 in HEK-293T cells impairs amino acid-induced lysosomal recruitment 
of mTOR. Control cells and cells with p14 or p18 knockdown were treated as in (C) and 
immunostained for mTOR (green) and LAMP2 (red).  (E) Images of p18-/- cells stably 
expressing FLAG-p18mito and co-immunostained for FLAG-p18mito or mTOR (red) and 
Cytochrome c (Cyt c) (green). (F) The mTORC1 pathway can be activated by amino acids in 
p18-null cells expressing wild-type p18 (p18rev), but not mitochondrially-targeted p18  (p18mito). 
Cells were starved for amino acids in the presence of dialyzed serum for 50 min, or starved and 
restimulated with amino acids for 10 min. Lysates were prepared and phosphorylation states and 
levels of indicated proteins were analyzed by immunoblotting. In all images, insets show 
selected fields that were magnified five times and their overlays. Scale bar is 10 µm. 
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Figure 6. Ragulator-null and -depleted cells are highly deficient in the activation of mTORC1 
signaling by amino acids. (A) p14 is necessary for the activation of the mTORC1 pathway by 
amino acids and serum. p14-null or control cells were starved of amino acids or serum for 50 
minutes, or starved and re-stimulated with amino acids or serum for 10 minutes. Immunoblot 
analyses were used to measure the levels of the indicated proteins and phosphorylation states. 
(B) p18 is necessary for the activation of the mTORC1 pathway by amino acids and serum. p18-
null or control cells were treated and analyzed as in (A). (C) Partial knockdown of MP1 blunts 
mTORC1 pathway activation by amino acids. HEK-293T cells expressing a control shRNA or 
two distinct shRNAs targeting MP1 were starved for amino acids for 50 minutes, or starved and 
stimulated with amino acids for 10 minutes and analyzed as in (A). (D) p14 and p18 are not 
necessary for mTORC2 pathway activity. p14-null or control cells were starved for serum, or 
starved and then re-stimulated with serum as in (A). p18-null or control cells were grown in 
complete media. Cell lysates were prepared and analyzed by immunobloting for the levels of 
Akt1 and Akt phosphorylation at the S473 site phosphorylated by mTORC2.  
(E) Decreased p14 expression impairs amino acid-induced mTORC1 activation in human cells. 
Cells derived from patients with lower p14 expression or healthy individuals were treated and 
analyzed as in (A). (F) Cells lacking Ragulator are smaller than control cells. Cell size 
distributions of p14-null or p18-null cells are overlaid with those from corresponding control 
cells. (G) Ragulator function is conserved in Drosophila cells. Drosophila S2 cells were 
transfected with a control dsRNA, or dsRNAs targeting dRagC, dMP1, dp14, or dp18, starved of 
amino acids for 90 minutes, or starved and restimulated with amino acids for 30 minutes. Levels 
of indicated proteins and phosphorylation states were analyzed by immunobloting. (H) Amino 
acids fail to stimulate 4E-BP1 phosphoryation in cells lacking p14 or p18. Cells were starved for 
amino acids in the presence of dialyzed serum for 50 min, or starved and restimulated with 
amino acids for 10 min. Lysates were prepared and 4E-BP1 phosphorylation and levels analyzed 
by immunoblotting. (I) Autophagy is induced in p14-null cells. Images of cells transiently 
expressing GFP-LC3 and starved for amino acids and serum for 3 hours or growing in complete 
media. Accumulation of GFP-LC3 in large puncta in starved control cells and in the non-starved 
p14-null cells indicates increased levels of autophagy in these cells.  
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Figure 7. In cells expressing raptor variants fused to the targeting signals of Rheb1 or Rap1b, 
mTORC1 localizes to lysosomal membranes in an amino acid-independent fashion. (A) 
Schematic of raptor fusion proteins that target mTORC1 to lysosomal membranes (raptor-
Rheb15; raptor-Rap1b17) or to the plasma membrane (Raptor-HRas25) as well as proteins used 
as controls (wild-type raptor; raptor-Rheb15∆CAAX). (B) Images of amino acid starved or 
replete cells expressing lysosomally-targeted or control HA-tagged raptor proteins and co-
immunostained for the HA epitope (red) and endogenous LAMP2 (green). HEK-293T cells were 
transfected with the indicated cDNAs, starved of and restimulated with amino acids for the 
indicated times, and processed in the immunofluorescence assay. (C) Images of amino acid 
starved or replete cells co-expressing myc-mTOR and the indicated raptor fusion proteins and 
co-immunostained for the myc epitope (green) and endogenous LAMP2 (red). HEK-293T cells 
were co-transfected with the indicated cDNAs and treated and processed as in (B). In all images, 
insets show selected fields that were magnified five times and their overlays. Scale bar is 10 µm. 
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Figure 8. Constitutive association of raptor with lysosomal membranes, but not the plasma 
membrane, is sufficient to make the mTORC1 pathway insensitive to amino acid starvation. (A) 
The mTORC1 pathway is not sensitive to amino acid starvation in cells that express lysosomally-
targeted but not control raptor proteins.  HEK-293T cells were co-transfected with the indicated 
cDNA expression plasmids and starved of amino acids for 50 minutes or starved and 
restimulated with amino acids for 10 minutes. Cell lysates and anti-FLAG-S6K1 
immunoprecipitates were analyzed by immunobloting for the levels of the indicated proteins and 
phosphorylation states. (B) The mTORC1 pathway is sensitive to serum starvation and insulin 
stimulation in cells that express lysosomally-targeted as well as control raptor proteins. HEK-
293E cells were co-transfected with the indicated cDNA expression plasmids, starved of amino 
acids for 50 minutes or starved and restimulated with amino acids for 10 minutes. Duplicate 
cultures were starved of serum for 50 minutes or starved and stimulated with insulin for 10 
minutes. Cell lysates and anti-FLAG-S6K1 immunoprecipitates were analyzed by 
immunobloting for the levels of the indicated proteins and phosphorylation states.  (C) Images of 
cells stably expressing FLAG-raptor, FLAG-raptor-Rheb15, or FLAG-raptor-HRas25 and co-
immunostained for endogenous mTOR (green) and endogenous LAMP2 (red). HEK-293T cells 
stably expressing the indicated proteins were starved of and restimulated with amino acids for 
the indicated times before processing in the immunofluorescence assay. In all images, insets 
show selected fields that were magnified five times and their overlays. Scale bar is 10 µm. (D) 
Targeting of mTORC1 to the lysosomal but not the plasma membrane makes the mTORC1 
pathway insensitive to amino acid starvation. HEK-293T cells stably expressing FLAG-raptor, 
FLAG-raptor-Rheb15, or FLAG-raptor-HRas25 were starved of and restimulated with amino 
acids as in (C) and analyzed by immunoblotting for the levels of the indicated proteins and 
phosphorylation states. (E) Targeting of mTORC1 to the lysosomal membrane increases cell size 
and pathway activity in cells under normal growth conditions. Cell size distributions of cells that 
stably express FLAG-raptor or FLAG-raptor-rheb15 as well as immunoblot analyses of the 
mTORC1 pathway in the same cells. 
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Figure 9 
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Figure 9. Targeting of mTORC1 to the lysosomal surface makes the activity of the mTORC1 
pathway independent of Rag and Ragulator, but not, Rheb function. (A) In cells that express 
FLAG-raptor-Rheb15, mTORC1 pathway activity is independent of Rag GTPase function. 
Lysates of HEK-293T cells expressing FLAG-raptor or FLAG-raptor-Rheb15 were analyzed by 
immunobloting for the indicated proteins and phosphorylation states after disruption of Rag 
function by RNAi-mediated co-knockdown of RagA and RagB. Cells were starved of amino 
acids for 50 minutes or starved and restimulated with amino acids for 10 minutes before lysis. 
(B) In cells that express FLAG-raptor-Rheb15, mTORC1 pathway activity is independent of Rag 
GTPase function. Lysates of HEK-293T cells expressing FLAG-raptor or FLAG-raptor-Rheb15 
were analyzed as in (A) after disruption of Rag function by expression of the dominant negative 
RagBGDP-RagDGTP heterodimer. Cells were treated and processed as in (A). (C) Stable 
expression of FLAG-raptor-Rheb15 but not FLAG-raptor in p14-null cells is sufficient to 
reactivate the mTORC1 pathway and make it insensitive to amino acid starvation. Cells stably 
expressing the indicated proteins were treated and analyzed as in (A). (D) Stable expression of 
FLAG-raptor-Rheb15 but not FLAG-raptor in p18-null cells is sufficient to reactivate the 
mTORC1 pathway and make it insensitive to amino acid starvation. Cells stably expressing the 
indicated proteins were treated and analyzed as in (A). (E) In p18-null cells expression of raptor-
Rheb15, but not wild-type raptor, increases cell size. Cell size distributions of p18-null cells that 
stably express FLAG-raptor or FLAG-raptor-Rheb15. (F) In cells that express FLAG-raptor-
Rheb15, the activity of the mTORC1 pathway is still Rheb-dependent. Lysates of HEK-293T 
cells that stably express FLAG-raptor or FLAG-raptor-Rheb15 were analyzed by immunobloting 
for the indicated proteins and phosphorylation states after disruption of Rheb function by an 
RNAi-mediated knockdown of Rheb1. Cells were treated as in (A). (G) Co-expression of plasma 
membrane-targeted raptor and plasma membrane-targeted Rheb1 renders the mTORC1 pathway 
insensitive to amino acid starvation. HEK-293T cells stably expressing the indicated proteins 
were treated and analyzed as in (A). (H) Model for amino-acid induced mTORC1 activation. In 
the absence of amino acids, mTORC1 cannot associate with the endomembrane system, and has 
no access to its activator Rheb. In the presence of amino acids, the Rag GTPases, which are 
tethered to the lysosomal surface by the Ragulator, serve as a docking site for mTORC1, 
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allowing mTORC1 to associate with endomembranes and thus encounter and become activated 
by Rheb.  
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Figure 10 
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 Figure 10. Addition of Rheb1 and Rap1b targeting signals to raptor does not interfere with its 
binding to mTOR and raptor-HRas25 and Rheb-HRas25 localize to the plasma membrane. (A) 
HEK-293T cells were co-transfected with plasmids encoding myc-mTOR and the indicated HA-
raptor variants. Anti-myc immunoprecipitates as well as lysates were analyzed by 
immunobloting for the indicated proteins. (B) Raptor fused at its C-terminus with the localization 
signal of HRas localizes to the plasma membrane. Images of cells expressing FLAG-raptor-
HRas25 and starved of and restimulated with amino acid for the indicated times and co-
immunostained with antibodies to the FLAG epitope (red) and endogenous LAMP2 (green). (C) 
Rheb1 localizes to the plasma membrane when its localization signal is swapped for that of 
HRas. Schematic shows composition of the HA-Rheb1-HRas25 variant. Images of cells 
expressing HA-Rheb1 or HA-Rheb1-HRas25 (green).  
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Introduction 
 
 Since the discovery of mTOR sixteen years go, research on the role of the mTOR 
signaling pathway unearthed its pivotal role in cellular growth, development, and disease. In the 
work described here, we explored the biochemical mechanisms that lead to mTORC1 pathway 
activation in response to two upstream regulators: insulin and amino acids. In particular, we 
showed that PRAS40 is a negative regulator of the mTORC1 pathway, and its phosphorylation is 
a major event downstream of insulin signaling that is required for mTORC1 activation. We also 
showed that the Rheb GTPase activates mTORC1 directly, and through the coherent actions of 
PRAS40 and Rheb, the pathway is activated in response to insulin to stimulate growth. 
Identification of the Rag GTPases and the Ragulator complex illuminated how mTORC1 
activation in response to amino acids involved re-localization of mTORC1 to the lysosomal 
surface. We also showed that growth factor and amino acid regulation of mTORC1 involves 
different players, which together make sure that the pathway is active only in the presence of 
both signals. Such a control mechanism and crosstalk between the two through S6K1-mediated 
IRS downregulation ensure that activation of mTORC1 is prevented under poor growth 
conditions.  This work has also pointed to the role of lysosomes; organelles whose signaling 
function has been underappreciated, as signaling platforms where amino acid sensing might take 
place. There are several questions the work described here inspired, and some of them will be 
discussed below.  
 
What are the relative contributions of PRAS40 and Rheb in mTORC1 regulation? 
 PRAS40 and Rheb have opposite roles in mTORC1 regulation: PRAS40 is an inhibitor 
and Rheb is an activator. Insulin stimulation acts on both of them to achieve maximum activation 
of mTORC1. However, in cells that lack TSC2, due to blunted IRS function, insulin stimulation 
cannot activate Akt effectively and PRAS40 is poorly phosphorylated. Despite lack of PRAS40 
phosphorylation, mTORC1 is always active, due to presence of Rheb-GTP. If Rheb-GTP is 
sufficient to overcome PRAS40-mediated mTORC1 inhibition, what is the role of PRAS40 and 
its phosphorylation?  
  Two pieces of data that come from in vitro kinase assays may be applicable to in vivo 
situations. First, mTORC1 has basal kinase activity in vitro even though Rheb is not in the tube, 
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and this basal kinase activity negatively correlates with the amount of PRAS40. Second, the 
relative abundance of Rheb-GTP or PRAS40 determines the final degree of mTORC1 activation 
in an in vitro kinase assay.  It is tempting to speculate that this may be also the case in vivo, at 
least in some tissues. Unfortunately an analysis of relative abundances of these two proteins in 
different tissues has not been reported. It is also possible that PRAS40 is phosphorylated by 
kinases other than Akt, and this phosphorylation can contribute to mTORC1 activation, even 
though Rheb is not 100% GTP loaded. And finally, mTORC1 may not be in close contact with 
Rheb after its initial contact, and PRAS40 phosphorylation by Akt may serve to keep it active for 
an extended period of time, mimicking the in vitro situation observed in the absence of Rheb.  
 Answering these questions can be technically challenging because it requires real time 
tracking of mTORC1 activity as well as Rheb and PRAS40 phosphorylation. Nevertheless, the 
answers will provide valuable information about the dynamics of mTORC1 regulation by growth 
factors.  
 
What is upstream of Rag GTPases? 
 Amino acid starvation promotes accumulation of RagB-GDP and RagD-GTP, and 
stimulation promotes the accumulation of RagB-GTP and RagD-GDP, suggesting that there must 
be amino acid-regulated GEFs and GAPs that modulate GTPase activity and GTP/GDP 
exchange of Rag proteins. Such upstream regulators must relay the information on amino acid 
availability to Rag GTPases, and their identification may provide valuable insight about how 
amino acids are sensed and whether this “sensor” affects cellular processes other than mTORC1 
activation.  
GEF and GAP identification has been traditionally done using biochemical techniques in 
mammalian cells. Most of these techniques exploit the fact that proteins with GEF function bind 
to GTPases loaded with GDP, and proteins with GAP function bind to GTPases loaded with 
GTP. As constitutively GTP- or GDP-bound Rag mutants are already available, the most 
straightforward plan would be to identify proteins that specifically interact with Rag-GDP and 
Rag-GTP mutants, and characterize the effects of potential GEFs and GAPs on the mTORC1 
pathway. Given that there are two classes of Rag GTPases, one would expect to find two GEFs 
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and 2 GAPs, but it is possible a RagA/B GEF can function as RagC/D GAP and vice versa, and 
sorting out the details of such a regulation will certainly require in vitro assays.  
 
 
What is the role of lysosomes in amino acid sensing? 
 Lysosomes have traditionally been viewed as recycling factories of the cell where 
unwanted/old proteins and organelles are degraded by the lysosome-resident enzymes and 
building blocks are recycled for reuse. Localization of Ragulator, Rag and mTORC1 on the 
lysosomal surface revealed a previously unappreciated role of lysosomes as signaling platforms. 
It looks more than a coincidence that amino acid signaling initiates on lysosomes where amino 
acids can be generated, and are potentially stored. Despite lack of evidence so far, it is tempting 
to speculate that an amino acid sensor may be located on the lysosomes, and initiate a signaling 
cascade to communicate amino acid availability to the rest of the cell.  
 If lysosomes are where the amino acids are sensed, then perturbing lysosomal function 
pharmacologically should inhibit amino acid induced mTORC1 activation. This is indeed the 
case (Y.S. and R.Z., unpublished results), but the fact the mTORC1 pathway activity is sensitive 
to cellular stress, and inhibition of lysosomal function may have unspecific effects and cause 
cellular stress, makes it hard to interpret the results of this experiment. More specific 
perturbations of lysosomal function are need for a conclusive answer on its role in amino acid 
sensing.  
 
Are the Rag GTPases and the Ragulator complex targeted in disease? 
Whether the Rag GTPases or the Ragulator complex is deregulated in diseases is not 
known. But given their essential role in mTORC1 signaling, one can speculate that inhibiting 
their function will be useful to treat diseases where mTORC1 pathway hyper-activation is 
involved. For example, activation of S6K1 leads to IRS phosphorylation and downregulation, 
which contributes to insulin insensitivity seen in obesity and type-2 diabetes. The requirement of 
Rag GTPases for mTORC1 activation raises the obvious question: can we inhibit the Rag 
GTPase function to decrease S6K1 activation and the accompanying insulin resistance? Small 
GTPases have traditionally been targeted by inhibition of enzymes that are required for their 
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lipid modifications that are important for their proper localization. However, the Rag GTPases 
themselves do not undergo lipid modifications, but the p18 component of the Ragulator complex 
does. Since proper localization of p18 is necessary for the activation of mTORC1 pathway, 
disruption of its lipid modification and lysosomal targeting may be a way for inhibiting 
mTORC1 function. 
Currently, there are no data on the contribution of the Rag GTPases to mTOR-related 
diseases, and there are no genetically engineered mice with Rag function perturbations to help 
answer related questions. Generation of such mice is certainly of interest, and will be a useful 
tool to study the role of Rag GTPases in development and disease.  
 
Conclusion 
The role of mTOR kinase in development, homeostasis and disease is increasingly 
appreciated and understanding how it is regulated by variety upstream signals has been the 
motivation behind the work described with a focus on mTORC1. It is clear that there are many 
unidentified players upstream of mTORC1, especially in regards to amino acid signaling. The 
identification of the Rag GTPases and the Ragulator complex, and the finding that mTORC1 
changes its intracellular localization to associate with lysosomes in response to amino acids are 
the first molecular players and events described in activation of mTORC1 in response to amino 
acids. How these events are regulated by amino acid availability, and their contribution to 
physiology and disease are two of the major questions that arose ofrom he work described and 
are intensely being studied in our laboratory and others.  
 
 
 
 
 
 
 
 
 
